The role of humoral autoimmunity in gastrointestinal neuromuscular diseases by Hubball, Andrew William
The role of humoral autoimmunity in gastrointestinal neuromuscular
diseases
Hubball, Andrew William
 
 
 
 
 
The copyright of this thesis rests with the author and no quotation from it or information
derived from it may be published without the prior written consent of the author
 
 
For additional information about this publication click this link.
http://qmro.qmul.ac.uk/jspui/handle/123456789/1264
 
 
 
Information about this research object was correct at the time of download; we occasionally
make corrections to records, please therefore check the published record when citing. For
more information contact scholarlycommunications@qmul.ac.uk
  
 1 
 
 
 
 
The role of humoral autoimmunity in gastrointestinal 
neuromuscular diseases 
  
 
 
 
Andrew William Hubball 
 
A thesis submitted for the degree of Doctor of Philosophy at the University of London 
 
August 2010 
 
 
The Wingate Institute of Neurogastroenterology 
Blizard Institute of Cell and Molecular Science 
Barts and The London School of Medicine and Dentistry 
 Queen Mary, University of London 
  
 
 
 
 
 
 
 
  PhD Thesis 2010 
 
__________________________________________________________________________________ 
 
2 
 
 
 
 
 
 
 
 
 
 
 
 
 
To Carlton 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  A.W.Hubball 
 
 __________________________________________________________________________________ 
 
3 
  
 
ABSTRACT 
 
Dysfunction of the gastrointestinal neuromuscular apparatus (including interstitial cells of 
Cajal) is presumed to underlie a heterogeneous group of disorders collectively termed 
gastrointestinal neuromuscular diseases (GINMDs). Humoral (antibody)-mediated 
autoimmunity directed against ligand- or voltage-gated ion channels or associated 
proteins involved in neuromuscular transmission is associated with several acquired 
neuromuscular diseases of the periphery and is now implicated in an increasing number 
of less well-characterised diseases. Anti-channel antibodies have been reported in small 
numbers of patients with GINMD, particularly in those with GI dysfunction secondary to 
an underlying disease such as neoplasia or infection. However, little is known of humoral 
autoimmunity in primary GINMDs.  
 
This thesis investigated the association between anti-channel antibodies and GINMD, and 
the human GI tract as a potential target of anti-channel antibodies. The presence of anti-
voltage- and ligand-gated antibodies was investigated in the serum of patients with 
primary achalasia, enteric dysmotility and intestinal pseudo-obstruction, and in those with 
GINMD secondary to Chagas’ disease. The functional effect of sera from some of these 
patients on colonic smooth muscle contractility was also characterised. Finally, the 
distribution of six voltage-gated potassium channels (VGKCs), which serve essential 
roles in the peripheral and central nervous systems and are known targets of pathological 
autoantibodies, were investigated in all layers of the human GI tract.  
 
Our findings suggest that currently recognised anti-channel antibodies are not a common 
pathogenic factor in primary GINMDs. Anti-channel antibodies, in particular anti-VGKC 
antibodies, were however found in a significant number of individuals with Chagas’ 
disease. Furthermore, circulating factors in patients with chagasic GI disease altered GI 
smooth muscle contractility in vitro which may have pathological relevance to GI 
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dysfunction. VGKCs were found throughout the human GI tract, especially in enteric 
neurons and epithelial cells, which has significance for both normal function and in 
relation to the GI tract as a target organ for anti-channel autoimmunity.    
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INTRODUCTION 
 
 
 
 
 
 
1.1 GASTROINTESTINAL NEUROMUSCULAR DISEASES 
 
Gastrointestinal neuromuscular diseases (GINMDs) are a clinically heterogeneous group 
of disorders in which symptoms are presumed or proven to arise as a result of 
neuromuscular (including interstitial cell of Cajal) dysfunction (Knowles et al. 2010). 
This classification requires both symptoms of impaired motor activity and demonstrable 
abnormalities in motor function, for example manometric abnormalities with or without 
evidence of transient or persistent radiological visceral dilatation (Wingate et al. 2002). 
These disorders may be due to relatively rare congenital defects, for example 
Hirschsprung’s disease, where the pathophysiologies are to some extent elucidated 
(Heanue et al. 2007), however most GINMDs are acquired in later life and may be 
primary or secondary to another established disease. 
 
Primary GINMDs include oesophageal achalasia (Hertz 1915), gastroparesis (Shellito et 
al. 1984), enteric dysmotility (ED) (Wingate et al. 2002) and chronic idiopathic intestinal 
pseudo-obstruction (CIPO) (Dudley et al. 1958) (for the purposes of this thesis ED and 
CIPO are referred to collectively as severe intestinal dysmotility: SID), slow-transit 
constipation (STC) (Preston et al. 1986) and idiopathic megabowel (Bodian et al. 1949).. 
Some international consensus exists on the clinico-physiological diagnosis of such 
disorders (Wingate et al. 2002). Histopathological changes in nerves (Schuffler et al. 
1 
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1982), smooth muscle (Smith et al. 1997) and interstitial cells of Cajal (ICC) (Huizinga 
1998; He et al. 2000; Farrugia 2008) have been variably described in most and have 
received recent attention by an international working group (Knowles et al. 2010). 
 
Clinically similar disorders can arise in association with other diseases. Such secondary 
GINMDs include intestinal pseudo-obstruction occurring as a paraneoplastic syndrome, 
most commonly in association with small cell lung carcinoma (SCLC) (Schuffler et al. 
1983; Chinn et al. 1988; Sodhi et al. 1989; Lucchinetti et al. 1998), but also in cases of 
bronchial carcinoid (Gerl et al. 1992), thymoma (Pande et al. 1999), 
ganglioneuroblastoma and neuroblastoma (Schobinger-Clement et al. 1999; Martin et al. 
2008) and ovarian carcinoma (Lee et al. 2001). GINMDs may also occur in association 
with infective systemic diseases such as Chagas’ disease (South American 
trypanosomiasis) (Ferreira-Santos 1961), connective tissue disorders such as scleroderma 
(Treacy et al. 1963; Cohen et al. 1972; Battle et al. 1981) and some endocrine and 
metabolic disorders e.g. diabetes mellitus (Werth et al. 1992) and amyloidosis (Legge et 
al. 1970). 
 
1.2. THE GI TRACT AS A TARGET FOR AUTOIMMUNITY 
 
A significant proportion of GI diseases have an inflammatory / immune-mediated 
aetiology e.g. coeliac and inflammatory bowel disease. Although less studied, there is 
increasing experimental and clinical evidence that some GINMDs could also be immune-
mediated. Innate and adaptive immune mechanisms can both modulate neuromuscular 
function acutely, and lead to changes in sensorimotor function that are sustained after 
resolution of a discrete inflammatory stimulus including one confined to the mucosa. 
This evidence, based on extensive study of the Trichinella-infected jejunum of small 
experimental animals (Collins 1996; Barbara et al. 1997) is supported by several studies 
in IBS that demonstrate increased numbers of intra-mucosal inflammatory cells including 
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mast cells (Barbara et al. 2004; Wang et al. 2004) and T lymphocytes (Spiller et al. 2000; 
Chadwick et al. 2002), as well as increased levels of pro-inflammatory mediators 
(Gonsalkorale et al. 2003; O'Mahony et al. 2005). Inflammatory cells have also been 
shown to infiltrate deeper layers of the muscle wall or the myenteric plexus (hence the 
terms of leiomyositis and ganglionitis, respectively) and tend to be associated with more 
severe motor dysfunction. Similar findings have been made in CIPO (Ruuska et al. 2002; 
Tornblom et al. 2002; Knowles et al. 2004; Haas et al. 2005; Tornblom et al. 2007; 
Knowles et al. 2008; Lindberg et al. 2009). 
 
Humoral (antibody)-mediated autoimmunity is associated with several well-established 
acquired neuromuscular diseases (below) and is implicated in an increasing number of 
less well-characterised disorders (Newsom-Davis et al. 1991), particularly of the central 
nervous system (Lang et al. 2003). Although less studied, there is some evolving 
evidence, especially in secondary GINMDs that the enteric neuromusculature could be a 
target for autoimmune attack. Here the diversity of ion channels and other receptors, and 
in this regard, potential epitopes, is only currently being realised (Vianna-Jorge et al. 
2000; Galligan 2002; Schaufele et al. 2005).              
 
1.2.1 NEURONAL ION CHANNELS OF THE GI TRACT 
 
It is likely (based on observations of neurotransmitter heterogeneity and numbers of 
enteric neurons, akin to the spinal cord (Gershon et al. 1981; Furness 2000) that the 
profile of ion channels in the gut is similar to that of the central and peripheral nervous 
systems (CNS and PNS respectively), although less well-studied. To date, a diversity of 
voltage-gated calcium (Starodub et al. 1999), potassium (Zholos et al. 1999; Hatton et al. 
2001) and sodium channels (Franklin et al. 1993), ligand-gated ion channels (Galligan 
2002) and G-protein-coupled (North et al. 1985), neurokinin (Portbury et al. 1996), 
adrenergic (Scheibner et al. 2002) and serotinergic receptors (Pan et al. 1997) have been 
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identified in the enteric nervous system (ENS) and play important roles in gastrointestinal 
sensation and motility (Cervero et al. 2003) (Table 1.1). Of particular relevance to this 
thesis are voltage-gated potassium channels (VGKCs) which are described in more detail 
below.  
 
1.2.1.1 Group 1 voltage-gated potassium channels  
 
Amongst the major classes of K+ channels, the greatest diversity is to be found amongst 
VGKCs which activate in response to a change in membrane potential (Hille 2001). A 
large gene family encodes twelve subfamilies (KV1-12) of the principle pore-forming α-
subunit (Figure 1.1). Structurally four α-subunits, from the same subfamily, assemble into 
a tetrameric complex together with modifying auxiliary subunits, usually called β-
subunits, to form a functional channel (Christie et al. 1990; Pongs 1992). Channel 
diversity is further enhanced by the assembly of α-subunits into heteromultimeric 
channels with intermediate properties (Christie et al. 1990; Sheng et al. 1993; Scott et al. 
1994). A wide range of biophysically distinct VGKCs is thus available to cells, which 
they may selectively express to meet their functional requirements. VGKCs are involved 
in numerous processes including setting resting membrane potentials, regulation of 
cellular excitability and synaptic transmission. The most extensively studied members are 
the KV1 or Shaker-related subfamily. Numerous studies have investigated the distribution 
of these channels with a view to establishing their role in normal function and disease 
states.  
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Table 1.1: Ion channels identified in the GI tract  
 
 
Class 
 
Subclass 
 
Ion channel  
 
G-protein coupled 
 
Class A (Rhodopsin – like) 
  
 
 
 
 
 
 
 
 
Class B (Secretin – like) 
 
 
Class C (mGluR-like) 
 
M2 / M3 mAChR 
Adrenergic 
Histamine 1-4 
5HT1,2,4,6,7 
Bradykinin 1-4 
NK1-3 
Protease-activated (PAR) 1-4 
Prostaglandin 1-4 
Purinoceptors 1-11 
 
Calcitonin  
CRF 1-2 
 
Glutamate 1-8 
GABA B1-2 
Ca-sensing 
Taste T1-2R 
 
Ligand-gated  nAChR 
P2X purinergic 
5HT3 
NMDA 
AMPA 
Kainate 
Glycine 
GABAA 
 
Regulatory and sensory  TRP 
KV 
KCa 
KcsA 
NaV 
L, N, P/Q-type VGCC 
Cl- 
ASICs  
 
Growth factor  Trk-A   
RET  
ASIC, acid sensing ion channel; CRF, corticotrophin-releasing factor; KCa, calcium-activated potassium 
channel; KV, voltage-gated potassium channel; mAChR, muscarinic acetylcholine receptor; nAChR, 
nicotinic acetylcholine receptor; NK, neurokinin; TRP, transient receptor potential; Trk, tyrosine kinase 
receptor; VGCC, voltage-gated calcium channel    
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Figure 1.1: Phylogenetic tree for the voltage-gated potassium channel family. The KV1 
subfamily, studied in this thesis, are outlined. (Gutman et al. 2005).  
 
1.2.1.2 KV1 channels of the GI tract 
 
In the CNS and peripheral neuromusculature regional and cellular KV1 channel 
distribution is well characterised (Beckh et al. 1990; Veh et al. 1995; Coleman et al. 
1999; Chung et al. 2001; Glazebrook et al. 2002). In comparison, little is known of KV1 
subunit expression in neurons innervating the gut. Existing studies are described below.   
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Animal studies 
VGKC currents contribute to regulating excitability and repolarisation of action 
potentials in extrinsic sensory neurons innervating the oesophagus, stomach, ileum and 
colon. As a result, blocking these currents leads to a significant increase in action 
potential duration. Macroscopically, these currents can be divided into a rapidly 
inactivating current (IA) and a delayed rectifier or IK current. Pharmacological and 
molecular evidence points to a contribution of KV1 channels to both of these currents 
(Yoshimura et al. 1996; Glazebrook et al. 2002; Dang et al. 2004). Functionally within 
the gut, KV1 currents are associated with a number of processes including epithelial cell 
maturation and migration (Rao et al. 2002), nutrient absorption (McDaniel et al. 2001), 
modulation of enteric motor nerve excitability (Suarez-Kurtz et al. 1999; Vianna-Jorge et 
al. 2000) and generation of smooth muscle ‘slow-wave’ contractions (Thornbury et al. 
1992; Thornbury et al. 1992; Carl 1995) As such, in a similar manner channel 
characterisation in the CNS and PNS, several studies have aimed to elucidate the specific 
KV subunit expression in the gut. In the mouse, Hatton and co-workers reported KV1.1 
immunoreactivity expression in murine (as well as guinea pig and canine) myenteric 
ganglia and ICC (Hatton et al. 2001). However, others describe KV1.1 expression limited 
to enteroglial cells, with no immunoreactivity detected in neurons or ICC (Costagliola et 
al. 2009). Costagliola et al. also report KV1.2 expression in enteroglial cells and 
additionally in enteric neurons. KV channel currents contribute to the electrical slow wave 
generation of canine colonic smooth muscle cells (Thornbury et al. 1992; Thornbury et 
al. 1992; Carl 1995). Molecular studies of canine GI smooth muscle have subsequently 
identified KV1.2, KV1.4, KV1.5 and KV1.6 expression (Hart et al. 1993; Epperson et al. 
1999). However, murine colonic smooth muscle cells express transcripts encoding KV1.6, 
but lack KV1.4 suggesting inter-species variability (Koh et al. 1999).  
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Human studies 
To date, a single study has identified KV1 channel subunits in the human neuromuscular 
apparatus. Recordings from isolated human oesophageal smooth muscle cells have 
revealed voltage-gated and Ca2+-activated potassium (KCa) currents. Molecular analysis 
of the same tissue identified KV1.2 and 1.5 mRNA expression in both longitudinal and 
circular muscle layers (the expression of other KV1 channels was not investigated). 
Functionally, pharmacological blockade of the muscular voltage-gated potassium current 
caused an increase in resting tension, suggesting a role in setting resting membrane 
potentials. However, the agent used in this study (high concentration 4-aminopyridine) 
non-specifically blocks a number of potassium channel types and so the effect cannot be 
solely attributed to KV1 channels (Wade et al. 1999). 
 
1.3.  ‘CLASSICAL’ ANTIBODY-MEDIATED NEUROLOGICAL DISEASES 
 
A number of peripheral neuromuscular diseases are known to be mediated by specific 
autoantibodies and are collectively known as autoimmune neuromuscular diseases 
(AINMDs). Although they do not primarily involve the ENS, they represent models by 
which the role of autoimmunity in GINMDs can be critically discussed.  Best elucidated 
are diseases in which antibodies target peripheral ligand- or voltage-gated ion channels or 
associated proteins involved in neuromuscular transmission leading to several diseases 
e.g. myasthenia gravis, Lambert Eaton myasthenic syndrome and acquired 
neuromyotonia (Isaac’s disease) (Vincent et al. 2006). Often termed autoimmune 
channelopathies, these contrast with genetic channelopathies in which a loss or decrease 
in function is conferred by gene mutation with similar phenotypic consequences 
(Terwindt et al. 1998). 
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1.3.1 MYASTHENIA GRAVIS 
 
Myasthenia gravis (MG) is the best understood autoimmune disorder of the nervous 
system and provides a ‘bench-mark’ against which putative autoimmune disorders may 
be judged. It is characterised by clinical features of fatigable muscle weakness which may 
initially affect the ocular muscles and variously spread to facial, bulbar and respiratory 
muscles and may also involve the limbs (Adams et al. 1993). Antibodies targeting post-
synaptic nicotinic acetylcholine receptors (nAChRs) present on the surface membrane of 
muscle are detectable in greater than 85% of MG patients (Almon et al. 1974; Lindstrom 
et al. 1976; Vincent et al. 1985). 
 
Around 10% of MG patients have a thymoma, and in these cases nAChR antibodies are 
always present (Vincent et al. 2006). Muscle weakness results from the functional loss of 
post-synaptic nAChRs secondary to receptor cross-linking by divalent antibodies and 
subsequent receptor internalisation (Drachman et al. 1978; Stanley et al. 1978) and 
complement-mediated degradation of the postsynaptic membrane (Engel 1979; Engel et 
al. 1981; Richman et al. 1993). Of those in whom anti-nAChR antibodies are not 
detectable (seronegative MG), around 40% have antibodies to a muscle-specific receptor 
tyrosine kinase (MuSK) (Wolfe et al. 2008) located at the neuromuscular junction 
(Valenzuela et al. 1995). MuSK is known to be important in clustering of AChRs during 
development, and although its role in adult muscle is less clear it appears to be necessary 
for maintenance of the post-synaptic membrane (Kong et al. 2004). 
 
1.3.2 LAMBERT EATON MYASTHENIC SYNDROME 
 
The Lambert Eaton myasthenic syndrome (LEMS) is a condition of proximal muscle 
weakness with accompanying autonomic dysfunction including dry mouth, erectile 
dysfunction, constipation and urinary symptoms. Approximately 50-60% of patients have 
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an associated small cell lung carcinoma (SCLC). The underlying pathophysiology of 
LEMS is impaired calcium-dependent release of acetylcholine from motor nerve 
terminals (Elmqvist et al. 1968). Circulating antibodies against voltage-gated calcium 
channels (VGCCs) are found in around 90% of LEMS patients (Lennon et al. 1995; 
Motomura et al. 1997) and result in the down-regulation of functional VGCCs (Pinto et 
al. 1998). VGCCs are composed of a number of pharmacologically and 
electrophysiologically distinct subtypes. Although antibodies have been described that 
bind to the L-, N- and P-/Q-VGCC subtypes (Meriney et al. 1996), only those directed 
against the P-/Q-subtype, which is responsible for  pre-synaptic neurotransmitter release 
at the neuromuscular junction, have been shown to be pathogenic (Pinto et al. 1998). 
SCLCs have been shown to express functionally active P/Q-type VGCCs at the surface 
and it is thought that in these patients the neurological syndrome may result from a cross-
reactive immune response generated by tumour antigens (Viglione et al. 1995). The 
aetiology in the remaining 50% of patients without a tumour is unknown. 
 
1.3.3 ACQUIRED NEUROMYOTONIA 
 
Acquired neuromyotonia (NMT) is a disorder of spontaneous and continuous muscle 
fibre activity characterised by muscle stiffness, fasciculations, weakness and increased 
sweating (Isaacs 1961). It occurs due to motor nerve hyperexcitability and is associated 
with autoantibodies against VGKCs (Isaacs 1961; Newsom-Davis et al. 1993). Using 
current assays, antibodies to the KV1 family of VGKCs are detectable in 40% of patients 
with NMT (Hart et al. 2002). 
 
Acquired NMT is associated with thymoma or SCLC in approximately 20% of cases 
(Newsom-Davis et al. 1993). Anti-VGKCs in NMT do not appear to block channel 
function directly as short incubation times have no effect. However, prolonged incubation 
of several hours reduces K+ channel current amplitudes without altering gating kinetics 
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(Sonoda et al. 1996; Nagado et al. 1999). This effect is also independent of added 
complement, or accelerated channel turnover, and degradation may occur secondary to 
cross-linking of channels by divalent antibodies (Tomimitsu et al. 2004). 
 
1.4 EVIDENCE FOR ANTIBODY MEDIATION OF AUTOIMMUNE 
DISEASES 
 
A number of clinical and experimental findings may help indicate that a disease has an 
autoimmune aetiology and these are central to subsequent discussion of the evidence for 
antibody mediation of GINMDs. Clinical features that are suggestive include onset of 
disease in adulthood, a history of autoimmunity in the patient or their family, an 
association with specific alleles of the human leukocyte antigen (HLA) gene complex, 
association with neoplasia, and clinical improvement following plasma exchange and / or 
immunosuppressive therapy (Vincent et al. 2006) (further discussed below). Such 
findings are also supported by finding evidence of immune cells in the target tissue 
although this is not an absolute requirement (Maselli et al. 1991; Vincent et al. 1999). In 
experimental terms, proof of disease causation should meet three broad criteria (Table 
1.2). 
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Table 1.2: Proof of disease causation  
 
Detection of relevant autoantibodies • Immunohistochemistry 
• Western blot 
• ELISA 
• Radioimmunoprecipitation assays 
Specificity of autoantibodies to the disease  • Found in most cases 
• Rare in controls 
Proof of pathogenicity  • Response to immunotherapies 
• Identification of antibody in situ 
• In vitro effects 
• Induction of experimental disease by 
passive transfer and active immunisation 
 
ELISA, enzyme-linked immunoadsorbent assay 
 
1.4.1 DETECTION OF AUTOANTIBODIES 
 
Autoantibodies may be detected by a number of techniques, the choice of which is often 
limited by the availability of specific antigens. Immunohistochemistry, western blotting, 
enzyme-linked immunoadsorbent assay (ELISA), radioimmunoprecipitation as well as 
functional assays are variously employed to measure antibodies in autoimmune 
neurological disorders (Tozzoli 2007). Each varies in accuracy, sensitivity and specificity 
and, if possible, a combination of methods should be used to confirm positive results 
(Vincent 2002). Although not discussed in detail here, it should especially be noted that 
in comparison with other methods, the sole use of ELISA or immunohistochemistry 
should be viewed cautiously because of the established risks of non-specific binding 
(Vincent 2002). Radioimmunoprecipitation assays, although acceptably specific, are 
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dependent on the availability of suitable radiolabelled antigens of high specificity. The 
development of human cell lines (e.g. embryonic kidney fibroblasts) transfected to 
express channels or receptors of interest represents a means by which the binding of 
antibodies to the external surface of functionally active channels / receptors may be 
investigated (Blaes et al. 2000). This may be done by incubating cells expressing the 
target of interest with patient serum or by extracting the cells for fluorescent-labelled 
immunoprecipitation, and is perhaps now the assay of choice in detecting anti-channel 
antibodies, not only because functionality is strongly implied, but also because such 
assays may be more sensitive (Leite et al. 2008).  
 
1.4.2 SPECIFICITY FOR DISEASE 
 
Pathogenic autoantibodies would be expected to bind to the extracellular domain of a 
cell-surface antigen relevant to the disease in a significant number of affected individuals, 
and that such binding is rare in healthy and other disease controls. For instance it has 
already been noted that specific autoantibodies can now be demonstrated in almost all 
patients with MG (Chan et al. 2007), but are extremely rare in healthy controls and in 
patients with other autoimmune or neurological diseases. 
 
1.4.3 PROOF OF PATHOGENICITY 
 
The demonstration of circulating autoantibodies, even those specific for relevant cell 
surface targets does not necessarily prove a direct role in disease causation since these 
could have arisen secondary to tissue damage with exposure of host epitopes to the 
immune system (de Scheerder et al. 1989). To establish a direct pathogenic role a number 
of criteria must be fulfilled. These criteria originally established the role of nAChR 
antibodies in MG and have subsequently been applied to other putative autoimmune 
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neurological disorders (for comprehensive review see (Vincent 2002). Each is discussed 
in the following sections: 
 
1.4.3.1 Response to immunotherapies 
 
Clinical improvement to plasmapheresis (plasma separation / exchange), intravenous 
immunoglobulin treatment or immunosuppressive therapies such as steroids and 
azathioprine strongly suggests a role for humoral autoimmunity. A further requisite 
should be that clinical response corresponds with a reduction in the titre of circulating 
antibodies as is seen in MG (Newsom-Davis et al. 1978) LEMS (Newsom-Davis et al. 
1984) and acquired NMT (Shillito et al. 1995). 
 
1.4.3.2  Identification of antibody in situ 
 
Identification of autoantibodies bound at the neuromuscular junction has been 
demonstrated in MG in association with complement components and the membrane-
attack complex (Engel et al. 1977). The number of nAChRs was found to be inversely 
proportional to bound IgG confirming a role in nAChR loss (Engel et al. 1987). 
Following passive transfer to experimental animals, LEMS IgG has been identified at the 
active zones of the presynaptic motor end-plate membrane (Fukuoka et al. 1987).  
 
1.4.3.3 Modulation of antigen expression and / or functional effects in vitro 
 
Incubation with pathogenic IgG leads to altered tissue expression of the antigen and / or 
function of the antigenic target in cell lines, cell cultures and ex-vivo tissue. In LEMS, 
autoantibodies reduce the number of functional P/Q-type VGCCs on cell lines and 
cultures (Pinto et al. 1998). Similarly, muscle cells grown in the presence of MG IgG 
have a reduced number of functional nAChRs (Drachman et al. 1978). Serum or IgG 
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from MG patients also inhibits the function of nAChRs on muscle cell lines by 
preventing the binding of ACh or other agonists (Riemersma et al. 1996). Incubation with 
NMT IgG results in repetitive action potentials in dorsal root ganglion cell cultures and 
reduced potassium currents in neuronal cell lines (Shillito et al. 1995; Nagado et al. 
1999) mimicking disease electrophysiology. 
 
1.4.3.4  Passive transfer to experimental animals 
 
Injection of sera, plasma or immunoglobulins derived from affected patients into 
experimental animals results in passive transfer of the disease phenotype. Mice injected 
with MG IgG show muscle weakness and loss of muscle nAChRs (Toyka et al. 1977). 
The physiological effects on the peripheral and autonomic nervous system of LEMS can 
also be transferred to mice by injection of LEMS IgG (Prior et al. 1985; Lang et al. 1987; 
Waterman et al. 1997). Passive transfer of IgG from NMT patients results in increased 
quantal release of ACh at the neuromuscular junction and prolongation of the action 
potential (Shillito et al. 1995). 
 
1.4.3.5  Induction of experimental disease by immunisation 
 
An animal model of the disease is induced following immunisation with purified antigen. 
This confirmation of antibody pathogenicity was demonstrated at an early stage of the 
investigation of MG pathogenesis (Patrick et al. 1973). This proof has been difficult to 
achieve in other AINMDs due to an inability to produce relatively large quantities of pure 
antigen for immunisation. However, a preliminary animal model of LEMS produced by 
injecting mice and rats with synaptosomes containing (although not exclusively) L-, N- 
and P-/Q-VGCCs isolated from the electric organ of the Japanese electric ray, Narke 
japonica, has gone some way to addressing this problem (Kim et al. 1998).  
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These criteria will now be applied to primary and secondary GINMDs. From a 
perspective of hierarchy of evidence, secondary GINMDs are discussed first. 
 
1.5 EVIDENCE FOR HUMORAL AUTOIMMUNITY IN SECONDARY 
GINMDS 
 
1.5.1 PARANEOPLASIA 
 
Clinical and histological evidence suggests an autoimmune basis for GINMD-related 
motor dysfunction associated with neoplasms: (1) histological examination of GI tissue 
from patients with paraneoplastic motility disorders reveals myenteric ganglionitis / 
plexitis, suggestive of some form of immune-mediated process. These include 
lymphocytic and plasmacellular infiltration, enteroglial cell proliferation and neuronal 
degeneration and loss, progressing to aganglionosis in the most severe cases (Schuffler et 
al. 1983; Chinn et al. 1988; Schobinger-Clement et al. 1999; Lee et al. 2001); (2) patients 
with SCLC and GI dysmotility often have co-existing neurological disorders including 
peripheral neuropathies, cerebellar degeneration and limbic encephalitis, which are 
thought to have an autoimmune origin (Chinn et al. 1988; Lucchinetti et al. 1998; 
Vernino et al. 1998); (3) several potentially pathogenic ‘paraneoplastic autoantibodies’ 
reactive against antigens expressed by tumour cells and neurons have been identified, 
which in combination with neurological disorders, including GI symptoms, strongly 
suggest the presence of an underlying malignancy (Lucchinetti et al. 1998; Pande et al. 
1999; Schobinger-Clement et al. 1999; Lee et al. 2001).  
   
1.5.1.1 Detection of autoantibodies 
 
Paraneoplastic GI dysmotility, most commonly secondary to a SCLC, is associated with 
seropositivity for anti-neuronal autoantibodies. Most common in this context are type 1 
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anti-neuronal nuclear autoantibodies (ANNA-1, also known as anti-Hu), which recognise 
neuron-specific RNA binding proteins expressed by central and peripheral neurons, 
including enteric neurons, and SCLC tumour cells (Bell et al. 1976; Lucchinetti et al. 
1998; Lee et al. 2001). Antibodies targeting cell-surface channels have been detected in 
smaller numbers of cases, including anti-N-type VGCCs with SCLC, retroperitoneal B-
cell lymphoma, ovarian and breast carcinoma (Lee et al. 2001; Dhamija et al. 2008), anti-
P/Q-type VGCCs with SCLC (Pardi et al. 2002), anti-VGKCs with thymoma (Viallard et 
al. 2005) and anti-ganglionic α3 nAChR antibodies with SCLC, thymoma, bladder and 
rectal carcinoma  (Vernino et al. 2000). 
 
1.5.1.2  Specificity for disease 
 
Autoantibodies are commonly found in GI dysfunction secondary to an underlying 
malignancy. A study of patients at the Mayo clinic with confirmed paraneoplastic GI 
dysfunction found 10 of 11 patients were seropositive for one or more ‘paraneoplastic 
autoantibodies, including 8 positive for anti-Hu and one positive for anti-N-type VGCC 
(Lee et al. 2001). In a further study of various types of GI dysmotility, anti-Hu were were 
always indicative of a malignancy (Dhamija et al. 2008). It is important to note that GI 
symptoms frequently precede diagnosis of a tumour, which may remain occult despite 
intensive evaluation (Lucchinetti et al. 1998). 
 
1.5.1.3 Proof of pathogenicity 
 
Response to immunotherapies 
Paraneoplastic neurological, including gastrointestinal, symptoms may respond to 
immunomodulatory therapy. Plasmaphaeresis leading to a striking improvement in bowel 
motility and a correlating reduction in circulating antibody levels has been reported in a 
case of intestinal pseudo-obstruction associated with neuromyotonia and high titre 
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ANNA-1 and a case of slow transit constipation associated with thymoma and anti- 
VGKC antibodies (van Vuurden et al. 2005; Viallard et al. 2005). Intravenous 
immunoglobulin treatment has also achieved significant improvement in paraneoplastic 
GI dysmotility associated with anti-α3 nAChR antibodies and ANNA-1 (Dhamija et al. 
2008).     
 
Modulation of antigen expression and / or functional effects in vitro 
On the basis of their intracellular antigenic target (as discussed above), ANNA-1 are 
unlikely to be directly pathogenic although nuclear epitopes could be exposed by prior 
inflammation / cell damage. A study based on a small series of patients with 
paraneoplastic GI dysmotility has suggested that ANNA-1 positive sera are able to trigger 
neuronal apoptosis in vitro suggesting a possible role in enteric neuronal degeneration 
(De Giorgio et al. 2003) (Figure 1.2). Anti-channel antibodies are more likely to exert a 
pathogenic effect due to the accessibility of the antigenic target. It is known from the 
study of peripheral neuromuscular disease that autoantibodies against VGKC, P/Q VGCC 
and α3 nAChRs are pathogenic. However, functional effects of these autoantibodies in 
the context of paraneoplasia have not been investigated.     
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Figure 1.2: Pro-apoptotic effects of anti-Hu antibody on cultured enteric neurons. 
Representative immunofluorescent, confocal double-labelling photomicrographs of NSE-labelled cultures 
myenteric neurons (red) and three markers of cellular apoptosis: TUNEL, caspase-3 and APAF-1 (A-F). 
Exposure of myenteric neurons to commercial anti-Hu antibody (48 hrs) evoked: A: an intense TUNEL-
positivity (green) in nuclei of NSE-labelled myenteric neurons (red), B: caspase-3 immunoreactivity 
(green) and C: APAF-1 (green). In contrast, TUNEL, caspase-3 and APAF-1 were absent in NSE-positive 
myenteric neurons (red) exposed to fetal calf serum or control (blood donor) serum (D-E, respectively). 
APAF-1 = apoptotic protease activating factor 1, NSE = neuron-specific enolase, TUNEL = Terminal 
deoxynucleotidyl transferase dUTP nick end labelling. Scale bar = 20 µm. Courtesy of Prof. R De Giorgio; 
(De Giorgio et al. 2003).   
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1.5.2 CONNECTIVE TISSUE DISORDERS 
 
Severe bowel dysfunction occurs in a proportion of patients with connective tissue 
disorders and is most commonly associated with systemic sclerosis (scleroderma, SSc). 
Any region of the gut may be affected, although oesophageal dysmotility is most 
commonly recognised (Rose et al. 1998). Although in later stages of the disease smooth 
muscle atrophy and fibrosis are clearly evident, manometric studies suggest that a 
neuropathic mechanism may be the initial event (Battle et al. 1981; Rees et al. 1982).  
 
1.5.2.1 Detection of autoantibodies 
 
Scleroderma is associated with anti-nuclear autoantibodies and more recently has been 
linked with other, non-nuclear antibodies such as anti-endothelial cell, anti-fibrillin-1, 
anti-metalloproteinases and anti-platelet-derived growth factor receptor (Tan et al. 2000; 
Sato et al. 2003; Ahmed et al. 2006; Baroni et al. 2006). The sera of scleroderma patients 
has also been found to contain antibodies capable, in immunofluorescent assays, of 
binding myenteric neurons (Howe et al. 1994). Anti-muscarinic AChR (mAChR) 
autoantibodies have also been identified in patients with SSc and GI dysfunction (see 
below for further discussion) (Goldblatt et al. 2002; Kawaguchi et al. 2009).   
 
1.5.2.2 Specificity for disease 
 
Circulating anti-myenteric neuronal autoantibodies demonstrated by Howe et al., using 
indirect immunofluorescence, were found in 16 of 41 scleroderma patients and 11 of 
these had clinical or laboratory manifestations of GI dysfunction. However, 19 of 25 
patients without anti-myenteric antibodies also had GI dysfunction, casting doubt on a 
direct causative role (Howe et al. 1994). IgG against mAChRs were detected by 
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radioimmunoprecipitation in 7 of 9 scleroderma patients with gastrointestinal symptoms. 
The two negative patients had only mild or no GI symptoms (Goldblatt et al. 2002).  
 
1.5.2.3 Proof of pathogenicity 
 
Response to immunotherapies 
Plasmaphaeresis combined with immunosuppression resulted in amelioration of severe 
gastrointestinal symptoms 4 of 15 patients with gastrointestinal symptoms and 
corresponded with a decline in anti-nuclear antibody titres (Dau et al. 1981; Akesson et 
al. 1988). 
 
Modulation of antigen expression and / or functional effects in vitro 
IgG purified from scleroderma sera has been shown to inhibit muscarinic cholinergic 
smooth muscle contraction in isolated colon providing a potential mechanism for GI 
dysmotility. In this in vitro study the putative target was considered to be the M3 
mAChR, as IgG and a specific M3-receptor antagonist inhibited, in a similar manner, 
evoked colonic muscle contraction. However, from this observation alone the IgG effect 
cannot be attributed solely to M3 mAChR antagonism as the agent used to evoke the 
contractions, carbachol (a muscarinic receptor agonist) also activates the M2 receptor 
subclass. Futhermore, the authors note in their discussion that they have failed to show 
direct binding to M3 mAChRs transfected and expressed on the surface of mammalian 
cells or to virally produced recombinant receptors (Goldblatt et al. 2002) (see section 
1.5.4 for further description). Nevertheless, the presence of antibodies against the M3 
mAChR was investigated using an ELISA to screen for binding to a synthetic peptide 
corresponding to the second extraellular loop domain of the human receptor. In a study of 
14 scleroderma patients with GI involvement, sera from all were found to bind 
(Kawaguchi et al. 2009). The target autoantigen in scleroderma patients remains to be 
satisfactorily resolved and this area of study highlights the possible discrepencies 
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between peptide-based immunoassays and more complex functional or cell-based binding 
assays.    
  
Passive transfer to experimental animals  
Passive transfer of purified IgG from a patient with a specific variant of SSc (CREST 
syndrome) and anti-neuronal antibodies has successfully produced intestinal 
myoelectrical disruption in a rat model providing good evidence of pathogenic circulating 
antibodies. However, the generalisability of this to other varients of SSc is unknown 
(Eaker et al. 1999).  
 
1.5.3  TYPE 1 DIABETES 
 
Measurable disturbances in GI motility, in particular delayed gastric emptying, are a 
common feature of diabetes mellitus (Keshavarzian et al. 1987). Such changes may result 
from diabetic neuropathy affecting intinsic (enteric) and / or extrinsic (autonomic) 
neurons or from changes in intestinal smooth muscle (for review see (Chandrasekharan et 
al. 2007).  
 
1.5.3.1 Detection of autoantibodies 
 
Autoimmune mechanisms involved in diabetic neuromuscular dysfunction have rarely 
been investigated. Although autoantibodies to the neuronal and islet cell antigen glutamic 
acid decarboxylase (GAD) are detectable in around 70% of patients with recent onset 
type 1 diabetes (Seissler et al. 1993), GAD is an intracellular enzyme and would 
therefore not present a target in intact cells. The presence of functional antibodies in a 
group of patients with type 1 diabetes and gastrointestinal symptoms has been 
investigated pharmacologically and identified IgG against the L-type VGCC (Jackson et 
al. 2004). 
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1.5.3.2 Specificity for disease 
 
Using the techniques described below, 8 of 16 patients had functional anti-VGCC 
autoantibodies. Of these, 7 had reported symptomatic gastrointestinal dysfunction. Such 
findings were not found in appropriate positive and negative controls (Jackson et al. 
2004). 
 
1.5.3.3 Proof of pathogenicity 
 
Modulation of antigen expression and / or functional effects in vitro 
Diabetic IgG produced a disruption of migrating motor complexes in intact colonic 
segments which was similar to the effect produced by an L-type VGCC agonist. 
Furthermore, the IgG was shown to competitively reduce binding of the specific L-type 
channel antagonist  dihydropyridine (Jackson et al. 2004).  
 
Passive transfer to experimental animals  
Severe disruption of the migrating motor complex was demonstrated in colons isolated 
from mice injected with diabetic IgG containing the putative L-type calcium channel 
agonistic antibodies (Jackson et al. 2004). 
 
Thus, experimental evidence for anti-channel autoimmunity in diabetic patients with GI 
dysfunction exists, albeit from a single study. Whilst the microvascular and neurological 
consequences of poor glycaemic control are of course significant and account for diabetic 
complications, the finding of functional anti-channel antibodies in these patients warrants 
further investigation.    
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1.5.4 CHAGAS’ DISEASE 
 
Infection by the protozoan parasite Trypanosoma cruzi causing South American 
Trypanosomiasis (Chagas’ disease) (Chagas 1909) is a significant public health issue in 
the developing world, affecting 16-18 million of the Latin American population 
(Kirchhoff 2003). The most damaging and established sequel is that of fatal 
cardiomyopathy, however the digestive tract is also commonly affected with extensive 
destruction of ganglion cells (Ribeiro et al. 1998; da Silveira et al. 2007) leading to 
altered motility manifest as functional obstruction with eventual progression to 
hypertrophy of the smooth muscle and marked dilatation (i.e. megaoesophagus and 
megacolon) (Koberle 1968). Phenotypically, chronic disease manifestations vary 
geographically, reflecting the heterogeneity of T.cruzi strains and their pathogenic 
sequalae. Megaoesophagus and megacolon are prominent complications in southern 
countries of South America, whereas these complications are rarer in Central and 
northern regions (Miles et al. 2009).    
 
The role of antibody-mediated autoimmune pathology in Chagas’ disease is speculative 
given that there is more evidence for direct damage caused by the organism itself and by 
cell-mediated mechanisms (Kierszenbaum 2005). Nevertheless, some autoantibodies to 
both cell surface and intracellular targets have been detected (Kierszenbaum 1999).  
 
1.5.4.1 Detection of autoantibodies 
 
There is good evidence that circulating autoantibodies present in some patients with 
Chagas’ disease are capable of modifying cellular events downstream of muscarinic 
cholinergic receptor agonism. Autoantibodies modifying muscarinic cholinergic 
neuromuscular activity were first identified in Chagas’ disease patients with secondary 
dysautonomic syndrome where patient IgG caused an in vitro reduction in cardiac 
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muscular tone which could be blocked by atropine (Goin et al. 1994). Immunoblotting 
and ELISA subsequently identified the putative antigenic target as the second 
extracellular loop (the main immunogenic region) of the M2 mAChR (Goin et al. 1997).   
 
1.5.4.2 Specificity for disease 
 
The dysautonomia described in Chagasic cardiomyopathy and GI dysmotility is strongly 
associated with the presence of autoantibodies as detected by the anti-M2 peptide ELISA 
with 90% of patients with a measurable autonomic disturbance testing positive, compared 
with less than 30% with no disturbance and in no healthy controls (Goin et al. 1997; 
Ganzinelli et al. 2009). These autoantibodies have been detected in 84% of patients with 
chagasic achalasia versus 21% of those with Chagas’ disease but no oesophageal 
sequalae and 28% in idiopathic achalasia (Goin et al. 1999). Similarly, in those with 
chagasic colonic dysfunction, autoantibodies were detected in 87% compared to 24% of 
those without megacolon (Sterin-Borda et al. 2001). However, using the same ELISA, 
these antibodies have been found in a high proportion of patients with other types of heart 
disease including 62% of patients with idiopathic cardiomyopathy, 46% with 
hypertensive heart disease and 48% with rheumatic valvular disease (Fu et al. 1993; 
Zhang et al. 2002). The presence of the same autoantibodies in non-parasitic 
cardiomyopathies increases the likelihood of a secondary phenomenon arising as a result 
of tissue damage.      
 
1.5.4.3 Proof of pathogenicity  
 
Response to immunotherapies 
The chronic phase of the disease may be associated with a low parasitic load suggesting a 
further immuno-inflammatory response could contribute to disease pathology. In a rat 
model of chronic disease a short treatment with infliximab (a monoclonal antibody which 
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neutralises the activity of tumour necrosis factor-α) reduced myocarditis severity, 
indicating an immuno-pathological role for this cytokine (Perez et al. 2009). However, 
the primary role of parasite induced tissue damage in both the acute and chronic phase of 
infection, which is limited by host cellular and humoral immune responses, suggests that 
the use of immunomodulatory therapy would be counterproductive.  
 
Modulation of antigen expression and / or functional effects in vitro  
Chagasic IgG has repeatedly been shown to have in vitro effects which are mediated via 
the M2 mAChR signalling pathway. In oesophageal and colonic muscle preparations, IgG 
produced concentration-dependent increases in basal tone which were sensitive to M2 
mAChR antagonism (Goin et al. 1999; Sterin-Borda et al. 2001). It also acted as a partial 
agonist, mimicking the effect of the muscarinic agonists carbachol and pilocarpine in a 
non-competitive manner (Goin et al. 1994; Goin et al. 1997). Radioligand binding assays 
investigating the interaction of chagasic IgG with the muscarinic receptor indicated 
chagasic IgG acts as an allosteric antagonist of the muscarinic receptor. It decreased the 
number of receptors available for binding (Bmax) without an associated effect on the 
affinity constant (KD) of the radioligand (Goin et al. 1994; Sterin-Borda et al. 2001). 
Further support of receptor agonism was provided by studies examining downstream 
effects of muscarinic activation in the presence of IgG. Incubation of cardiac or GI 
smooth muscle with IgG revealed pertussis toxin-sensitive decreased tissue levels of 
cyclic adenosine monophosphate (cAMP) and an increase in cyclic guanosine 
monophosphate (cGMP). This is consistent with muscarinic receptor activation (Goin et 
al. 1997; Goin et al. 1999; Sterin-Borda et al. 2001).  
L-type voltage-gated calcium channel (VGCC) currents in isolated ventricular myocytes 
are also reduced in the presence of chagasic antibodies, in the absence of other agonists 
(Hernandez et al. 2003). An increase in inducible nitric oxide synthase (iNOS) and 
cyclooxygenase-2 (COX-2) gene transcription is observed in response to chagasic IgG 
application, increasing prostaglandin E2 (PGE2) and nitric oxide (NO) production 
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(Ganzinelli et al. 2009). This has pathological relevance to the end-organ inflammation 
seen in chronic Chagas disease.   
 
Passive transfer to experimental animals 
To date, the transfer of disease phenotype to experimental animals by injection of 
immunoglobulins from affected patients has not been demonstrated.   
 
Induction of experimental disease by immunisation  
Active immunisation of mice with M2 mAChR-derived synthetic peptides led to the 
production of functional anti-peptide antibodies. In these animals basal heart rate was 
unaffected, however carbachol induced bradycardia was significantly increased in 
comparison to controls, and atropine induced tachycardia was blunted suggesting an 
agonistic function (Peter et al. 2005).   
 
1.6 EVIDENCE FOR HUMORAL AUTOIMMUNITY IN PRIMARY GINMDS 
 
1.6.1 IDIOPATHIC ACHALASIA 
 
Idiopathic achalasia of the oesophagus is an idiopathic motility disorder characterised by 
aperistalsis of the oesophageal body and incomplete lower oesophageal sphincter (LOS) 
relaxation on swallowing leading to dysphagia, regurgitation, chest pain and weight loss 
(Willis 1674; Hertz 1915; Castell 1976). Myenteric denervation of the distal oesophagus 
extending into the stomach is characteristically seen at histological examination (Csendes 
et al. 1992) and is selective for inhibitory nitric oxide (Mearin et al. 1993; De Giorgio et 
al. 1999; Zarate et al. 2006) and vasoactive inhibitory polypeptide (Aggestrup et al. 
1983; Sigala et al. 1995) releasing motor neurons resulting in unopposed excitatory 
activity. Familial, infectious, genetic and autoimmune mechanisms have all been 
postulated to contribute to the development of achalasia (Park et al. 2005).  
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1.6.1.1 Detection of autoantibodies 
 
An autoimmune pathogenesis is suggested by lymphocytic inflammatory infiltrates in the 
myenteric plexus (Goldblum et al. 1994; Clark et al. 2000) and disease association with 
specific HLA alleles (Ruiz-de-Leon et al. 2002; Latiano et al. 2006). 
Immunohistochemical techniques have repeatedly demonstrated anti-neuronal antibodies 
binding both submucosal and myenteric ganglia in the serum of achalasia patients (Storch 
et al. 1995; Verne et al. 1997; Moses et al. 2003). Autoantibodies against specific 
neuronal, glial and muscle antigens studied using radioimmunoprecipitation assays have 
identified nAChR, VGKC and N-type VGCC antibodies in a subset of primary achalasia 
patients (Kraichely et al. 2009).    
 
1.6.1.2 Specificity to disease 
 
Indirect immunofluorescence screening puts the prevalence of anti-neuronal antibodies at 
12-64% compared with 0-9% of healthy controls (Storch et al. 1995; Verne et al. 1997; 
Ruiz-de-Leon et al. 2002; Moses et al. 2003; Bruley des Varannes et al. 2006). This 
proportion has been reported to rise significantly in patients with specific HLA 
genotypes. One hundred percent of female and 67% of male carriers of the DQA1*0103-
DQB1*0603 heterodimer with achalasia were found to have antineuronal antibodies 
(Ruiz-de-Leon et al. 2002). Significant associations between DQB1*0602, DRB1*15 
(Verne et al. 1999), DQB1*0502 and DQB1*0601 alleles (Latiano et al. 2006) and 
achalasia have also been reported, confirming an immunologic predisposition to the 
disease. However, although anti-neuronal antibodies appear specific to enteric neurons 
they bind both inhibitory and excitatory myenteric neurons and also submucosal ganglia 
with equal affinity, thus not accounting for the selective loss of inhibitory motor neurons. 
Regional specificity, which would also support a pathogenic role is lacking as antibodies 
label myenteric gangia from all regions of the GI tract (Storch et al. 1995; Verne et al. 
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1997; Moses et al. 2003). Whilst reasonably disease-specific i.e. not present in control 
groups such as megacolon, Hirschsprung’s disease, oesophageal cancer and MG (Storch 
et al. 1995), anti-neuronal antibodies have also been found in as many as 50% of patients 
with gastro-oesophageal reflux disease (GORD) casting doubt on their primary role in 
disease causation (Moses et al. 2003). Furthermore, no correlation has been found 
between patient age or clinical findings and the presence of anti-neuronal antibodies 
(Storch et al. 1995; Verne et al. 1997). A study of the prevalence of specific anti-
neuronal / muscle antibodies using radioimmunoprecipitation assays (VGKC, GAD, N-
type VGCC and muscle nAChR) found a significant proportion (26%) had one or more. 
Most strikingly, 21% of primary achalasia patients versus 2.5% of healthy controls had 
detectable anti-GAD antibodies. Only one of these had documented diabetes. The clinical 
significance of this finding remains to be ascertained (Kraichely et al. 2009).  
 
1.6.1.2  Proof of pathogenicity 
 
Modulation of antigen expression and / or functional effects in vitro 
A novel approach using pre-incubation of gastric fundal tissue with sera from patients 
with achalasia demonstrated a subsequently altered myenteric neurochemical phenotype 
relevant to current understanding of disease pathogenesis (Bruley des Varannes et al. 
2006). Specifically, inhibitory nitric oxide synthesising (NOS) neurons were reduced in 
number, whilst the proportion of excitatory choline acetyltransferase (ChAT) 
synthesising neurons increased, findings which in keeping with both incomplete LOS 
relaxation and histological findings. Achalasia sera used for both immunohistochemistry 
and in vitro motility studies revealed a correlation between the decrease in the proportion 
of NOS immunoreactive neurons and electrical field stimulation induced nitric oxide NO-
dependent relaxation in circular muscle strips. The decrease in NOS immunoreactive 
neurons may be due to an effect of the serum on neuronal NOS (nNOS) expression at 
mRNA and/or protein level as the changes occurred rapidly (after 16-18 hours of 
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incubation). Although GORD serum did not alter neuronal chemical phenotype, 
suggesting a specific effect of achalasia serum, this methodology is not yet well validated 
and no signs of neuronal degeneration were found as seen histologically in active disease. 
In addition it is unknown which serum factors are responsible for this effect 
(Boeckxstaens 2006). 
 
1.6.2 SEVERE INTESTINAL DYSMOTILITY 
 
Severe intestinal dysmotility (SID) describes a group of disorders where the bowel fails 
to propel its contents in the absence of an obstructed lumen. At the most severe end of 
this spectrum are patients with episodic or chronic signs mimicking a mechanical 
obstruction: abdominal pain, distension, nausea/vomiting, and intractable constipation. 
These are termed chronic idiopathic intestinal pseudo-obstruction (CIPO) (Dudley et al. 
1958). This diagnosis is based on a combination of the above symptoms with radiological 
evidence of gut dilatation and air-fluid levels during acute episodes (Gibbons et al. 1978; 
Hirsh et al. 1981; Gilchrist et al. 1985) and/or abnormal small bowel motility 
(Stanghellini et al. 1987; Di Lorenzo 1999). Enteric dysmotility describes patients with 
demonstrably abnormal small bowel contractility, but no history of frankly obstructive 
episodes. These patients may be at an early stage in the progression of CIPO, or perhaps  
be those in a quiescent period of a relapsing / remitting pseudo-obstriction (Wingate et al. 
2002; Lindberg et al. 2009). Whilst the pathophysiology of these disorders remains 
poorly understood, CIPO may be classified according to recognised histopathological 
abnormalities of enteric smooth muscle (myopathies), ENS (neuropathies) and of ICC 
(mesenchymopathies). Several degenerative and inflammatory myopathic and 
neuropathic phenotypes have been described in children and adults on the basis of 
histopathology (Smith et al. 1992; Ruuska et al. 2002; Knowles et al. 2004; Tornblom et 
al. 2005; Knowles et al. 2009). Cases of both myopathic and neuropathic CIPO 
secondary to presumed autoimmune processes have been reported. Histological features 
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in most cases suggest the disease may be caused by local T-cell-mediated responses 
directed against enteric neurons or smooth muscle, but there is also evidence for 
autoantibody-mediated pathogenesis.   
 
1.6.2.1 Detection of autoantibodies 
 
Serologically, CIPO has been associated with anti-nuclear, anti-neutrophil cytoplasmic 
antibody (ANCA), anti-DNA, anti-smooth muscle and anti-neuronal antibodies (ANAs) 
(Ruuska et al. 2002; Ghirardo et al. 2005). Anti-enteric neuronal antibodies have been 
described in two patients with intestinal obstruction due to acquired aganglionosis. Whilst 
these antibodies also bound CNS neurons in a pattern characteristic of ANNA-1, and 
were also indistinguishable on Western blots, immunostaining of enteric neurons 
displayed a quite different pattern, being mostly cytoplasmic with only a weak nuclear 
component. Neither patient had CNS involvement and the autoimmune injury appeared 
limited to the ENS (Smith et al. 1997).  
 
1.6.2.2 Specificity for disease 
 
Using indirect immunofluorescence techniques, the largest study to date found 6 out of 
25 (24%) patients with CIPO had anti-enteric neuronal antibodies (binding to both 
neuronal nuclei and cytoplasm) (de Giorgio et al. 2008). Other studies have identified 
specific autoantibodies in small numbers of patients, including one patient with anti-
VGKC and one with anti-ganglionic α3 nAChR antibodies. Both of these patients had 
histologically-proven inflammatory enteric neuropathy, although in these cases diarrhoea 
was the chief complaint (Tornblom et al. 2007). Using immunoprecipitation assays to 
identify antibodies against α3 nAChRs in patients with various types of dysautonomia, 
Vernino et al. identified antibodies in 3 of 34 patients with a diagnosis of idiopathic GI 
dysmotility, although at a lower titre than other seropositive patients with more severe, 
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diffuse dysautonomias, suggesting these patients may have a limited form of autoimmune 
autonomic neuropathy (AAN) (further discussion below). (Vernino et al. 2000). Low, but 
positive titres of antibodies to P/Q VGCCs were also found in 4 out of 10 patients with 
CIPO (Knowles et al. 2002). 
 
1.6.2.3 Proof pathogenicity  
 
Response to immunotherapies 
A number of case reports highlight remission of pseudo-obstructive episodes following 
immunomodulatory therapy. In these patients abdominal symptoms responded to 
immunosuppression with steroids and / or cyclosporin, which were started after failure of 
prokinetic therapy and surgical intervention and often after histological assessment 
revealed an inflammatory neuropathy or myopathy (Smith et al. 1997; De Giorgio et al. 
2002; Ruuska et al. 2002; Dewit et al. 2008). Whilst a cell-mediated immune response is 
clearly present in these cases, the humoral immune system may also be activated, as 
evidenced by a paediatric case of intestinal pseudo-obstruction associated with anti-
smooth muscle and anti-neutrophil cytoplasmic antibodies. In this instance a good 
clinical response to immunosuppressive therapy was also associated with a reduction in 
circulating autoantibody levels (Ruuska et al. 2002). Whilst not immunomodulatory, a 
patient with chronic gastropaeresis (delayed-gastric emptying) who was seropositive for 
anti-α3 nAChR antibodies reported significant improvement in GI symptoms after 
commencing acetylcholinesterase inhibitor therapy, indicating a pathogenic role for these 
antibodies. (Pasha et al. 2006).        
 
Modulation of antigen expression and / or functional effects in vitro 
A functional effect of CIPO sera containing ANAs has been suggested by de Giorgio et 
al (de Giorgio et al. 2008). They found evidence that sera containing ANAs stimulates 
neuronal autophagy (a cellular response to adverse conditions where by injured 
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organelles such as mitochondria are sequestered in autophagosomes) associated with 
neuronal stress. This effect was reduced by removal of IgG suggesting a direct role for 
immunoglobulins. However, this pathway is normally cytoprotective in limiting the 
production of reactive oxygen species and the pathophysiologic significance in CIPO is 
unclear.  
 
Passive transfer to experimental animals and induction of experimental disease by 
immunisation  
Using active immunisation and subsequent passive transfer techniques, the pathogenicity 
of anti-α3 nAChR antibodies has been investigated. Rabbits immunised with a 
recombinant fusion protein corresponding to the nAChR α3 subunit produced 
autoantibodies reactive with ganglionic nAChRs with development of a generalised AAN 
with prominent gastrointestinal dysmotility including gastroparesis and intestinal pseudo-
obstruction (Lennon et al. 2003; Vernino et al. 2003). Severity of findings correlated with 
antibody levels, and immunohistochemistry revealed reduced numbers of myenteric 
plexus neurons and reduced immunoreactivity for nAChRs at neuronal surfaces and 
synapses (Vernino et al. 2003). Passive transfer of rabbit IgG containing anti-α3 nAChR 
antibodies to mice replicated active immunisation findings, confirming the role of 
antibodies in mediating AAN (Vernino et al. 2004).  It should be noted, however, that 
passive transfer of sera of patients with severe autonomic neuropathy and anti-α3 
nAChRs, even from those with highest titres of antibodies, failed to replicate these 
findings. The reason for this discrepancy is unclear (Vernino et al. 2004). 
 
1.6.3  SLOW TRANSIT CONSTIPATION 
 
A proportion of patients with severe constipation will have a reduction in the propulsive 
capacity of all or part of the colon that on the basis of transit studies is defined as slow 
transit constipation (STC). STC includes a clinically heterogeneous group of patients, the 
  PhD Thesis 2010 
 
__________________________________________________________________________________ 
 
52 
 
majority of whom present in childhood and who are nearly always female (Preston et al. 
1986). Others present in later life with onset of symptoms de novo or often attributed to 
pelvic surgery or childbirth (Knowles et al. 1999; Knowles et al. 2000). A plethora of 
aetiologies have been proposed to underlie STC including primary neuromuscular / ICC 
dysfunction, absorptive, hormonal and psychological abnormalities, with inconclusive 
results (Knowles et al. 1999; Knowles et al. 2000). In those presenting with de novo 
adult-onset STC an autoimmune aetiology remains an under-explored possibility.  
 
1.6.3.1 Detection of autoantibodies  
 
Validated immunoprecipitation assays detected high titres of anti-VGKC antibodies in 
two of 11 sera tested suggesting anti-neuronal antibodies may be important in certain 
acquired STC patients.  
 
1.6.4 IDIOPATHIC MEGACOLON 
 
Idiopathic megacolon describes a group of patients with intractable constipation 
associated with rectal or colonic dilatation in the absence of mechanical obstruction or 
evident cause (Bodian et al. 1949). Several pathological abnormalities of nerve, ICC and 
smooth muscle have been reported including immune-mediated myenteric ganglionitis 
associated with neuronal degeneration (De Giorgio et al. 2002).  
 
1.6.4.1 Detection of autoantibodies 
 
In contrast to acquired megacolon associated with systemic diseases such as Chagas’ 
disease (see above), the possibility of a humoral immune response against enteric 
neuromuscular elements contributing to the pathogenesis of idiopathic megacolon has not 
been investigated. 
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1.7 SUMMARY AND KNOWLEDGE GAPS 
 
The recognition of autoantibody-mediated channelopathies has opened new avenues in 
the investigation and management of peripheral neuromuscular disorders, whilst in 
cancer-associated neurological syndromes the detection of antibodies to neoplastic 
antigens has increased early diagnosis and treatment of the underlying malignancy. It is 
clear that whilst there is some evidence for autoantibody-mediated GI dysfunction in 
primary and secondary GINMDs, this is not strong in comparison with AINMDs such as 
myasthenia gravis, particularly in reference to specificity of antibody detection and proof 
of pathogenicity. These data are summarised in Table 1.3. In general the evidence is 
stronger for secondary, in particular paraneoplastic, than primary GINMDs, largely due 
to a paucity of information regarding the association of anti-channel antibodies with 
primary GINMDs. In determining a role for humoral autoimmunity in GINMDs the 
original paradigms generated by the investigation of peripheral neuromuscular disorders 
such as myasthenia gravis should be applied.   
 
Of direct relevance to anti-channel autoimmunity contributing to GI dysfunction is the 
lack of data concerning channel expression in the gut. Although investigation of enteric 
channel expression points towards diversity equal to that of the CNS and PNS, in 
comparison to these systems knowledge regarding the ENS is in its infancy. This 
knowledge gap is especially true of the human ENS as initial investigations in small 
mammals are only beginning to be translated. As well as providing information regarding 
the functional biology of the gut, these studies will provide an expanding list of 
candidates for autoimmune interaction.  
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Table 1.3: Evidence for humoral autoimmunity in AINMD and GINMD 
 
Criteria Disease         
 AINMD                 GINMD    
     Secondary      Primary   
 MG LEMS NMT PN CTD DM Chagas IA CIPO STC IM 
 
Clinico-
pathological 
 
+ 
 
+ 
 
+ 
 
+ 
 
+ 
 
+/- 
 
+ 
 
+ 
 
+ 
 
+/- 
 
+/- 
Disease 
specificity * 
+ + + + +/- +/- +/- +/- - - - 
Pathogenicity 
criteria † 
           
Response to 
immunotherapy 
+ + + +/- + - - - +/- - - 
Antibody in situ + + - - - - - - - - - 
In vitro effects + + + +/- +/- +/- +/- +/- +/- - - 
Passive transfer + + + - +/- +/- - - +/- - - 
Active 
immunisation 
+ - - - - - - - +/- - - 
 
* cut off of 50% disease cases with antibodies; † defined on the basis of + good quality evidence from more 
than one study; +/- weaker evidence usually arising from only one study; - no evidence to date. MG, 
myasthenia gravis; LEMS, Lambert-Eaton myasthenic syndrome; NMT neuromyotonia; PN, 
paraneoplastic; DM, diabetes mellitus; CTD, connective tissue disorders; IA, idiopathic achalasia; CIPO, 
chronic idiopathic intestinal pseudo-obstruction; STC, slow transit constipation; IM, idiopathic megabowel. 
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1.8 AIMS  
 
The aims of this project were: 
 
1. To investigate the presence of autoantibodies directed to enteric ion channels in 
patients with neuromuscular disorders of the gut leading to severe dysmotility. 
 
2. To investigate whether autoantibodies (if present) are pathogenic. 
 
3. To further elucidate the profile of expressed ion channels in the human enteric  
neuromusculature. 
 
1.9 HYPOTHESES 
 
1.  Autoantibodies to one or more type of ion channel are present in a subset of 
patients with gastrointestinal neuromuscular disease.  
 
2. As in the CNS and PNS, these autoantibodies are pathogenic and directly 
contribute to GI neuromuscular dysfunction.   
 
3. Ion channels expressed by the CNS and PNS which are known targets of humoral 
autoimmune interaction are also present in the ENS. 
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MATERIALS AND METHODS 
 
 
 
 
 
This chapter covers all specific methods used. Details of routine techniques, such as 
standard histochemical staining, can be found in the appendices.  
 
2.1 ETHICAL APPROVAL AND COLLABORATIONS 
 
The original application established collaborations with one international and one UK 
academic institution. These were the Departamento de Clinica Medica Faculdade de 
Medicina, University of Sao Paulo, and the Neurosciences Group, John Radcliffe 
Hospital, Oxford. The former facilitated collection of sera from Brazilian patients with 
Chagas’ disease and from community controls from several clinics in Fortaleza and 
surrounding areas for anti-channel antibody analysis. Following the acquisition of Home 
Office approval, the necessary arrangements were made for the sera to be transported to 
the UK. The Neurosciences Group provided the facilities and technical support for 
screening all sera for circulating anti-channel antibodies. The collection and use of sera 
and tissue studies was approved by the Royal Free Hospital & Medical School Research 
Ethics Committee in April 2006. Following amendments to the original application, a 
further site (Homerton University Hospital, London) was added for the collection of 
human gastrointestinal tissue. 
  
 
 
2 
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The work contained within this thesis is covered by the following ethics committee 
references: 
06/Q0501/52 
06/Q0501/52/AM01        
06/Q0501/52/AM02    
 
[See Appendix 1.0 for correspondence and confirmatory documents].  
 
2.2 DETECTION OF AUTOANTIBODIES IN PATIENTS WITH GINMDS 
 
2.2.1 COLLECTION OF PATIENT SERA 
 
Venous whole blood (20 ml) was taken by antecubital fossa venepuncture and 
centrifuged for 10 min at 3,500 rpm. Serum was removed and stored at -80°C in 
Eppendorf aliquots (approximately 4 mL / patient) until use.  
 
2.2.1.1 Achalasia 
 
Twenty-one patients with achalasia (14 female, aged 26-72, median 55 years) who had 
undergone investigation at the Upper GI Unit at the Royal London Hospital were 
screened for autoantibodies. All patients had undergone manometric investigation of their 
oesophageal motility and were documented as having ‘established’ achalasia with 
manometric findings of abnormal peristalsis and incomplete lower oesophageal sphincter 
relaxation on swallowing (Figures 2.1 and 2.2) (Castell 1976; Pandolfino et al. 2005).  
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2.2.1.2 Severe intestinal dysmotility 
 
Twenty-seven patients with severe intestinal dysmotility (22 female, aged 18-62, median 
45 years) who attended the pseudo-obstruction outpatient clinic at the Royal London 
Hospital were studied. The median number of years from presentation to donation of a 
blood sample for this study was 10 (range 3-40). Chronic idiopathic intestinal pseudo-
obstruction (CIPO) was diagnosed in 7 patients (5 female) on a basis of typical 
gastrointestinal symptoms (abdominal pain, severe constipation, abdominal distension, 
nausea and vomiting, weight loss; see Table 2.1), sub-occlusive events with radiological 
signs mimicking mechanical obstruction (air/fluid levels with or without dilatation on 
plain abdominal radiograph) and abnormal small bowel manometry (Dudley et al. 1958; 
Wingate et al. 2002) (Table 2.2). Twenty patients had abnormal intestinal motility but no 
history of sub-occlusive episodes and were classified as enteric dysmotility (Wingate et 
al. 2002; Lindberg et al. 2009). Abdominal pain and bloating were the most prominent 
features in both groups. As expected and previously reported (Lindberg et al. 2009), 
nutritional support was required in a greater proportion of patients with CIPO (6/7) than 
ED (8/20). The predominant manometric abnormality in CIPO patients was a neuropathic 
motor pattern (as evidenced by abnormal qualitative and quantitative measures of the 
migrating motor complex (Stanghellini et al. 1987). The ED group had an almost equal 
frequency of neuropathic and abnormal but indeterminate manometric patterns. 
Histological reports from full-thickness biopsies were available in all CIPO and 9 ED 
patients who had undergone laparoscopic biopsy (see Table 2.3). A greater number of 
biopsy samples were reported to be normal in the ED group than the CIPO group. An 
equal number (3/7) of CIPO patients had a neuropathy as had a myopathy. Alpha-actin 
deficiency (included by convention as a myopathy (Knowles et al. 2010) was the most 
common finding in the ED group, and two patients had both an alpha-actin deficiency 
and an inflammatory neuropathy. There was a poor correlation between histological and 
manometric findings.  
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Figure 2.1: Oesophageal manometry tracing showing a normal swallow. Trace shows 
propagation of contraction following a wet swallow (black arrows) and relaxation of lower oesophageal 
sphincter (red arrow)   
 
 
 
 
 
 
 
 
 
 
 
 
 
  PhD Thesis 2010 
 
__________________________________________________________________________________ 
 
60 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.2: Oesophageal manometry tracing from a patient with achalasia. Trace 
shows simultaneous contractions following a wet swallow (black arrows) and failure of relaxation of lower 
oesophageal sphincter (red arrow)   
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Table 2.1: Clinical features of severe intestinal dysmotility  
 
 
Clinical features 
 
N 
 CIPO (n =7) ED (n=20) 
Symptoms 
   Weight loss 
    Dysphagia 
    Nausea 
    Vomiting 
    Reflux 
    Bloating  
    Abdominal pain 
    Constipation 
    Diarrhoea 
    Irregular bowel habit 
    Urgency 
    Incontinence  
    Incomplete evacuation    
 
Presentation 
6 
0 
6 
2 
0 
5 
6 
5 
0 
0 
0 
0 
0 
 
 
Current 
3 
0 
3 
1 
0 
6 
7 
2 
3 
0 
0 
0 
0 
 
 
Presentation 
8 
1 
2 
6 
1 
15 
10 
7 
0 
0 
0 
0 
0 
 
Current 
3 
2 
4 
9 
3 
13 
17 
6 
1 
4 
1 
2 
1 
 
 
Feeding requirements 
    None 
    Enteral 
    Parenteral 
    Both 
 
1 
2 
4 
0 
 
12 
2 
4 
2 
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Table 2.2: Investigation findings in patients with SID 
* One CIPO patient had radiological evidence of small and large bowel dilatation 
† Small bowel manometry failed in one patient due to retrograde propulsion 
 
 
 
 
 
 
 
Investigation findings 
 
N 
 
 
CIPO (n=7) 
 
 
ED (n=20) 
Radiography (plain radiograph +/- contrast +/- CT) 
    Normal 
    Dilated small bowel 
    Malrotated small bowel 
    Dilated large bowel 
    Delayed transit  
    Increased transit 
    Not reported 
 
Small bowel manometry 
    Neuropathic  
    Myopathic 
    Abnormal indeterminate 
    Not done 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 
7 
0 
1* 
0 
0 
0 
 
 
5 
0 
2 
0 
 
6 
0 
2 
0 
2 
1 
9 
 
 
8 
1 
10 
1† 
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Table 2.3: Histopathological findings in full-thickness jejunal biopsies from patients 
with SID 
* Two patients had both an α-actin deficiency and an inflammatory neuropathy 
 
 
 
 
 
 
 
 
 
 
 
 
Histopathological abnormalities 
 
N 
 CIPO (n=7) ED (n=20) 
 
Normal 
Visceral neuropathy 
    Degenerative neuropathy 
    Inflammatory neuropathy 
 
Visceral myopathy 
    α-actin deficiency 
    Degenerative leiomyopathy 
    Inflammatory leiomyositis     
    Vascular myopathy 
    Hollow visceral myopathy 
    Inclusion body myopathy 
     
Interstitial cell abnormalities 
Total 
 
1 
3 
1 
2 
 
3 
1 
1 
0 
0 
0 
1 
 
0 
7 
 
4 
2 
0 
2* 
 
5 
4* 
0 
0 
0 
0 
1 
 
0 
9 
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2.2.1.3 Healthy controls 
 
Ten control samples were obtained from individuals (5 female, age 18 – 70, median 59)  
attending outpatient clinics at the Royal London Hospital who had no present or past 
history of GI, connective tissue or autoimmune disorder.   
 
2.2.1.4 Chagas’ disease 
 
Sixty-one Brazilian patients with Chagas’ disease were tested, forty-five male, aged 28-
86, median 50 years. All patients were recruited from clinics in and around the city of 
Fortaleza, in north-east Brazil (Figure 2.3). Although the strain of T.cruzi was not 
identified in these cases, in this region the sequel of chronic disease is most commonly 
cardiac damage (see Chapter 1 for discussion of phenotypic variability related to T.cruzi 
strain heterogeneity). However, within this cohort, each chronic manifestation is 
represented and eight sub-groups were defined using the following criteria: those without 
organ involvement; those with achalasia, colonic disease or both; those with 
cardiomyopathy or ECG changes, and those with heart and gut manifestations. These 
patients were further divided into those that had undergone previous treatment with anti-
T.cruzi drug therapy with Benzonidazol and those that had not (see Table 2.3). It would 
have been desirable to obtain more details regarding the past medical history of these 
patients. However, despite written requests this information was not forthcoming.   
 
 
 
 
 
 
 
 
  A.W.Hubball 
 
 __________________________________________________________________________________ 
 
65 
  
 
Table 2.4: Disease-subgroups of Chagas’ disease patients 
 
2.2.1.5 Brazilian controls 
 
Twenty control sera samples were obtained from healthy subjects (11 female, aged 22 – 
76, median 39 years) from the same communities as those who provided Chagas’ disease 
samples. 
 
 
 
 
 
 
 
 
 
 
 
 
Chagas’ disease sub-groups 
 
Total 
 
Untreated 
 
Treated 
 
No sequalae 
Achalasia 
Colon disease 
Achalasia + colon disease 
Heart disease 
Heart disease + achalasia 
Heart disease + colon disease 
Heart disease + achalasia + colon disease  
 
29 
9 
4 
1 
8 
5 
3 
2 
61 
 
16 
7 
1 
0 
7 
3 
1 
1 
 
13 
2 
3 
1 
1 
2 
2 
1 
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2.2.1.6 Disease controls 
 
Disease control sera were obtained from patients attending the John Radcliffe Hospital, 
Oxford. These were from patients with: autoimmune autonomic neuropathy (n = 2), 
Lambert-Eaton myasthenic syndrome (LEMS; n = 2) and neuromyotonia (NMT; n = 2), 
containing anti-ganglionic α3 nicotinic acetylcholine receptor (α3 nAChR), anti-voltage-
gated calcium channel (VGCC) and anti-voltage-gated potassium channel (VGKC) 
antibodies respectively (see Table 2.4 for details of all subjects).  
 
 
 
 
 
 
 
 
 
Figure 2.3: Map of Brazil. All 
chagasic blood samples were obtained from 
clinics serving Fortaleza and surrounding areas 
in the north-east of the country (circled). 
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Table 2.5: Basic clinical data and demographics for patients included in assay 
studies 
AAN = autoimmune autonomic neuropathy, ED = enteric dysmotility, CIPO = chronic idiopathic intestinal 
pseudo-obstruction, LEMS = Lambert-Eaton myasthenic syndrome, nAChR = nicotinic acetylcholine 
receptor, NMT = neuromyotonia, VGCC = voltage-gated calcium channel, VGKC = voltage-gated 
potassium channel    
 
 
 
 
 
Study group 
 
Description 
 
N 
 
Sex F / M 
 
Age median 
(range) 
 
Achalasia 
 
 
 
Severe intestinal 
dysmotility 
 
 
Chagas’ disease 
 
Incomplete LOS relaxation on 
swallowing 
Abnormal peristalsis 
 
CIPO (n = 7 ) 
Enteric dysmotility  
(n = 20) 
 
No sequalae (n = 29) 
Achalasia (n = 17) 
Colon disease (n = 9) 
Heart disease (n = 18) 
 
21 
 
 
 
27 
 
 
 
61 
 
14 / 7 
 
 
 
22 / 5 
 
 
 
16 / 45 
 
55 (26 - 72) 
 
 
 
45 (18 – 62) 
 
 
 
50 (28-86) 
 
Healthy subjects 
 
 
AAN 
LEMS 
NMT 
 
UK negative controls 
Brazilian negative controls 
 
Positive controls: α3-nAChR assay 
positive controls: VGCC assay 
positive controls: VGKC assay 
 
10 
20 
 
2 
2 
2 
 
5/5 
11 / 9 
 
1/1 
1/1 
2/0 
 
59 (18-70) 
39 (22 – 76) 
 
50 (31,68) 
52 (46, 58) 
42 (34, 50) 
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2.2.2 ANTI-NEURONAL AUTOANTIBODY IMMUNOFLUORESCENT ASSAY 
 
2.2.2.1 Background to methodology 
 
Seropositivity for anti-neuronal autoantibodies (ANAs) is a diagnostic marker of occult 
malignancy in the presentation of paraneoplastic CIPO, which usually precedes the 
diagnosis of a tumour (Lennon et al. 1991; Lucchinetti et al. 1998; Lee et al. 2001). To 
confirm the absence of such autoantibodies in our cohort of patients, all those with SID 
were screened for ANAs. Three types of ANAs associated with paraneoplastic 
neurological dysfunction are commonly screened for: Anti-Hu, anti-Yo and anti-Ri. Anti-
Hu, also known as anti-neuronal nuclear antibody type 1 (ANNA-1), the most important 
with regards to paraneoplastic GI dysmotility, recognise a family of pan-neuronal RNA 
binding proteins, thus immunolabelling neuronal nuclei, and are chiefly associated with 
small-cell lung cancer (SCLC) (Bell et al. 1976; Graus et al. 1986; Altermatt et al. 1991). 
Anti-Yo, also known as anti-Purkinje cell cytoplasmic antibody (PCA) show cytoplasmic 
immunoreactivity of cerebellar Purkinje cells and are associated with gynaecological and 
breast cancer (Greenlee et al. 1983; Graus et al. 1988). Anti-Ri (ANNA-2), primarily 
associated with breast cancer, also bind neuron-specific RNA binding proteins but in 
contrast to anti-Hu, label neuronal nuclei of central neurons only (Budde-Steffen et al. 
1988; Luque et al. 1991). ANAs are detected by standard indirect immunofluorescence 
where sera are incubated with sections of nervous tissue (typically mammalian 
cerebellum) and binding detected using an anti-human secondary antibody conjugated to 
a fluorophore (see section 2.4.1 for general immunohistochemical technical description). 
The pattern of immunoreactivity (nuclear vs. cytoplasmic) suggests the type of antibody 
present, which may then be confirmed by western blotting. 
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2.2.2.2 Indirect immunofluorescence 
 
Sera samples were diluted 1 in 50 in PBS, applied to monkey cerebellar sections (Inova 
Diagnostics Inc., CA, USA) and incubated for 20 min at room temperature (RT). Anti-Hu 
and anti-Yo positive control sera (Inova Diagnostics Inc.) were also applied at this time 
for 20 min, at RT. Sera and control antibodies were rinsed off with PBS and sections 
soaked in PBS for 20 min. Fluorophore-conjugated anti-human secondary antibody was 
then applied and incubated for 20 min, at RT, followed by rinsing with PBS and further 
soaking for 20 min. Sections were mounted in glycerol and stored at 4ºC in the dark until 
reading. Reagents and detailed methodology are found in Appendix 2.0.    
  
Sections were viewed with a Nikon Eclipse 80i fluorescent microscope (Nikon 
Instruments, Amstelveen, Netherlands) and scored for anti-Hu / Ri or anti-Yo depending 
on staining pattern. Positive anti-Hu / Ri, weakly positive or equivocal results were sent 
for western blot confirmation at the Clinical Immunology Service, University of 
Birmingham, UK.   
 
2.2.3 ANTI-CHANNEL ANTIBODY RADIOIMMUNOPRECIPITATION ASSAY 
 
2.2.3.1 Background to methodology 
 
Over the past 30 years, a number of specific neurotoxins from a variety of vertebrates and 
invertebrates have been discovered and structurally characterised. In accordance with 
their amino acid sequence such toxins have differential affinities to channel types and 
subtypes (Gasparini et al. 1998). These toxins have been an invaluable tool in the 
pharmacological classification of ion channels (Moczydlowski et al. 1988; Castle et al. 
1989; Llinas et al. 1989). In autoimmune neurological disease the detection of circulating 
autoantibodies has largely depended on the availability of such target-specific 
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neurotoxins which may be radiolabelled for use in radioimmunoprecipitation assays e.g. 
∂-bungarotoxin for the labelling of nAChRs in the investigation of myasthenia gravis 
(MG) (Vincent et al. 1985), which are used in immunoprecipitation assays. The principle 
of radioimmunoprecipitation assays is shown in Figure 2.4.  
 
All serum samples were screened for the following autoantibodies: anti-α3 nAChRs, anti-
P/Q type VGCCs, anti-VGKC, and anti-glutamic acid decarboxylase (GAD). Assays 
were performed blind to the clinical diagnosis and at least twice by separate investigators.  
 
2.2.3.2 Preparation of channel extracts 
 
Rabbit brain was used for the preparation of VGKC and VGCC channels. Results have 
previously been shown to be comparable using human and rabbit cerebellar extracts as an 
antigenic source for potassium (unpublished data), and calcium channels (Motomura et 
al., 1997). For use in the assay, the membrane preparation was diluted 1:5 in 2% 
digitonin solubilisation buffer, incubated for 1 h at 4 ºC and centrifuged at 13,000 rpm for 
15 min. The supernatants were removed, stored at -70 ºC and used as the source of 
voltage-gated channels in the assay. Cultured neuroblastoma cells IMR32 were used for 
the preparation of nAChR α3 channel subunits. See appendix 3.1 for detailed 
methodology.     
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Figure 2.4: Schematic of radioimmunoprecipitation assay. Radiolabelled (125I)toxin bound 
to extracted channel preparation is precipitated by anti-human IgG in the presence of antibody (b), but 
remains in solution when autoantibodies are absent (a). IC = ion channel  
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2.2.3.3 Immunoprecipitation assays  
 
1. Sera were tested for antibodies to α3 nAChRs using immunoprecipitation of 
neuroblastoma nAChRs labelled with 125I-Epibatidine (125I-Epb) (Perkin Elmer, 
MA, USA).   
2. Sera were tested for antibodies to rabbit brain P/Q-type VGCCs using  
 immunoprecipitation of VGCCs extracted from rabbit cerebellum and labelled 
with 125I-labelled-ω-conotoxin MVIIC (125I-ω-CmTx) (New England Nuclear Ltd. 
MA, USA).  
3. Sera were tested for antibodies to rabbit brain VGKCs using immunoprecipitation 
of VGKCs extracted from rabbit cerebellum and labelled with 125I-labelled-α-
dendrotoxin (125I-α-DnTx) (Perkin Elmer). 
 4. Sera were tested for antibodies to glutamic acid decarboxylase (GAD) using a 
commercially available radioimmunoassay kit (RSR Ltd., Cardiff, UK).  
 
Detailed methodology for channel radiolabelling and immunoprecipitation assays can be 
found in Appendix 3.2. Briefly, defrosted aliquots of extract were labelled with a 
saturating (5 fM) concentration of radiolabelled toxin and incubated with diluted sera 
overnight at 4 °C. To precipitate serum antibodies excess sheep anti-human IgG serum 
was then added and incubated for 1 hour at RT. The precipitates were pelleted by 
centrifugation at 13,000 rpm for 5 min, washed in washing buffer (0.1% Triton X100 in 
20 mM phosphate buffer, pH 7.4) and counted on an automatic gamma counter (Canberra 
Packard Cobra II auto-gamma, Meriden ®, CT, USA). Results were expressed as 
picomoles of labelled toxin binding sites precipitated per litre of serum after subtraction 
of non-specific binding (calculated from control mean; see Appendix 3.3 for details).   
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2.2.4 ANTI-M2 MUSCARINIC CELL-BASED ASSAY 
 
2.2.4.1 Background to methodology 
 
This screening assay utilises cultured mammalian cells that have been transiently 
transfected to express the target autoantigen of interest (Hart et al. 1997). Sera from 
patients suspected to contain autoantibodies are incubated with transfected cells and any 
binding revealed using a fluorescently conjugated anti-human secondary antibody. 
Successful expression of the antigen is verified using a commercial antibody raised 
against the protein. This assay has a number of advantages over other techniques such as 
ELISA, immunoprecipitation and other immunohistochemical methods. Firstly, the entire 
target antigen is translated and expressed in the cell membrane which is closer to in vivo 
conditions. Secondly, this assay can be used to screen for binding to human antigens as 
opposed to rodent, which is frequently the tissue used in immunofluorescent screening 
assays. Thirdly, the antigen is specifically expressed at a high concentration, increasing 
assay sensitivity. Cell binding assays have been employed to detect autoantibodies in a 
variety of diseases and have been demonstrated to be more sensitive than traditional 
immunoprecipitation assays in screening for antibodies in well characterised disorders 
such as neuromyotonia (Kleopa et al. 2006; Leite et al. 2008).  
 
A number of studies have reported autoantibodies present in Chagas’ disease patients 
with GI disease which in ELISAs bind a synthetic peptide corresponding to a segment of 
the M2 muscarinic acetylcholine receptor (M2 mAChR). We designed and optimised a 
new cell-based assay to screen for the presence of anti-M2 mAChR autoantibodies in 
patients with Chagas’ disease using human embryonic kidney cells (HEK 293) 
transfected to express the M2 mAChR. 
 
.     
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2.2.4.2 Bacterial culture  
 
Escherichia coli (E. coli) DH5α were used for the preparation of plasmid DNA 
containing the M2 mAChR. All media components were purchased from Oxoid Ltd., 
Hampshire, UK and sterilised by autoclaving at 121°C, 15 psi for 20 min. Lysogeny 
broth (LB; 10 g/L tryptone, 5 g/L yeast extract, 5 g/L sodium chloride) and L agar were 
used for the routine growth and maintenance of bacteria. L agar was prepared by the 
addition of agar (1.5% w/v) to LB prior to autoclaving. Sterilised L agar was cooled to 55 
°C and heat labile supplements were added (Ampicillin 100 µg/ml), mixed and poured 
into 9 cm2 Sterilin® petri dishes (Sterilin Ltd., Caerphilly, UK). DH5α was maintained 
on L agar at 4 °C and subcultured every four to six weeks by overnight growth. Bacterial 
stocks were stored at –20 °C in 0.4% glucose M9 salts minimal media containing 35 % 
sterile glycerol (see Appendix 4.1 for details of media compounds and culture 
methodology).  
 
Growth conditions  
E. coli cultures were grown aerobically at 37 °C in 250 ml conical flasks, containing 50 
ml of medium with constant shaking at 250 rpm in an orbital shaker. The medium was 
inoculated with a 1:100 dilution of an overnight (~16 h) culture generated by seeding 2.5 
ml of medium with a single colony. Growth was monitored hourly by determining the 
A650 of 100 µl or 1 ml samples respectively, or dilutions thereof, using a Unicam Helios β 
UV spectrophotometer (Unicam, Cambridge, UK) (see Appendix 4.1 for details). 
 
Preparation of competent cells  
Once the culture reached an optical density (at 650 nm) of 0.4–0.5, cells were harvested 
by centrifugation at 4,000 rpm and 4 °C for 15 min. For volumes of culture less than 1.5 
ml, cells were harvested by micro-centrifugation at 13,000 rpm for 5 min at 4 °C. Cells 
were re-suspended in 4 ml of ice-cold transformation buffer-I (TFB-I). After incubation 
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on ice for 15 min, the cells were harvested and taken up in 2 ml of ice-cold TBF-II (see 
Appendix 4.1 for TFB compositions). Competent cells were either used within 3 h or 
aliquoted (0.2 ml) and stored at –80 °C. 
 
2.2.4.3 Bacterial transformation 
 
Plasmid 
cDNA for the full length human cholinergic receptor, muscarinic 2 (CHRM2, GenBank 
NM_001006630) was cloned in-frame with the mammalian cytomegalovirus promoter 
using the restriction sites EcoRI-XhoI in the polylinker region of pcDNA3 (Invitrogen 
life technologies, provided by Carl Nelson, University of Leicester). Plasmid DNA was 
stored at –20 °C in ultrapure (Promega UK Ltd., Southampton, UK). 
 
Transformation 
Various dilutions of plasmid DNA (1-50 ng in 4 µl) were added to 0.2 ml aliquots of 
competent cells, gently mixed, and incubated on ice for 40 min, followed by heat-shock 
at 42 °C for 1 min to facilitate uptake of the DNA. After cooling on ice for 5 min, 0.7 ml 
of pre-warmed LB was added to the mixture and incubated at 37 °C for 30–60 min to 
allow the expression of the antibiotic resistance genes. Finally the cells were harvested by 
centrifugation at 13,000 rpm for 5 min and 0.7 ml of supernatant removed. The cells were 
re-suspended in the remaining supernatant and plated out on L agar plates containing 
ampicillin and incubated at 37 °C overnight (see Appendix 4.2 for detailed 
methodology).  
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2.2.4.4 Plasmid DNA isolation 
 
Plasmid DNA Miniprep preparations 
The QIAprep® Minipreps DNA Purification Kit (Qiagen Ltd., West Sussex, UK) was 
used according to the centrifugation protocol supplied by the manufacturer for plasmid 
DNA yields of less than 10 µg. Depending on the copy number of the plasmid, 1-5 ml 
(high-copy number plasmids) or 10 ml (low-copy number plasmids) overnight cultures 
were used (see Appendix 4.3 for detailed methodology). 
 
Plasmid DNA Maxiprep preparations 
For up to 850 µg plasmid DNA, a 200 ml overnight culture was manipulated using the 
PureLink™ HiPure Plasmid (Maxi) Filter Purification Kit (Invitrogen Ltd., Paisley, UK) 
according to the manufacturer’s instructions. The DNA pellet was re-suspended in 200-
500 µl TE Buffer (in kit) and used in downstream applications or stored at -20 °C (see 
Appendix 4.3 for detailed methodology). 
 
2.2.4.5 DNA sequencing 
 
DNA digestion with restriction endonucleases 
To confirm the presence and check the correct orientation of the CHRM2 insert, the 
purified plasmid was analysed by DNA digestion. DNA digestion was performed using 
restriction enzymes (EcoR1 and Xho1) according to the manufacturer’s instructions (New 
England BioLabs UK Ltd., Hertfordshire, UK). Approximately 5 units of enzyme per µg 
of DNA were incubated at 37 ºC for 1–3 h (see Appendix 4.3 for detailed methodology).  
 
Agarose gel electrophoresis 
Agarose gel electrophoresis was used to separate and visualise DNA fragments, and was 
performed in a Bio-Rad Mini/Wide-Sub cell (Bio-Rad Labs. Ltd. Hertfordshire, UK). 
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Agarose gels were 0.7-1.5 %, depending on the size of the DNA fragments, in 0.5x TBE 
buffer (see Appendix 4.3 for composition), containing 0.5 µg/ml ethidium bromide. 
Samples were prepared by the addition of 6x loading buffer (Appendix 4.3) and 
electrophoresed in gels submerged in 0.5x TBE buffer for 45-120 min at 70-100 V 
(constant). The size marker, Hyperladder I (Bioline, London, UK) was loaded alongside 
samples for estimating both the size and quantity of DNA following gel electrophoresis. 
After electrophoresis the DNA bands were visualised using a 2011 Macrovue UV 
transilluminator (LKB Instruments, Victoria, Australia) (see Appendix 4.3 for solutions 
and detailed methodology). 
 
DNA sequencing 
Final validation was achieved by sequencing the CHRM2 insert from the purified 
plasmid DNA to confirm that the gene was in frame. DNA sequencing was performed by 
the in-house service at the Weatherall Institute of Molecular Medicine (WIMM) (John 
Radcliffe Hospital, Oxford, UK) on a 48 capillary ABI-3730 DNA cycle sequencer 
(Applied Biosystems, California, USA). Template plasmid DNA (>10 ng depending on 
the size of the insert being sequenced) was provided in solution to the WIMM sequencing 
service. Sequencing reactions were performed by using the T7 forward primer: 5'-TAA 
TAC GAC TCA CTA TAG GG-3' (3.2 pmol/µl) and for the reverse sequence the Sp6 
reverse primer: 5'-ATT-TAG-GTG-ACA-CTA-TAG-3' (3.2 pmol/µl). 
 
2.2.4.6 Mammalian cell culture 
 
Human embryonic kidney (HEK293) cells 
HEK 293 cells were grown in cell culture flasks containing Dulbecco’s modified Eagles 
Medium (DMEM) (Sigma-Aldrich, Dorset, UK) containing fetal calf serum (FCS) 
(Sigma-Aldrich) and antibiotics (PSA: penicillin, amphotericin and streptomycin) 
(Invitrogen, Paisley, UK)  (see Appendix 4.4 for compositions) and split at a ratio of 1:8 
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every three days. On day 3 cells were harvested following removal of DMEM by 
aspiration, washing in PBS and trypsinising for 1 min at 37 ºC. Cells were re-suspended 
in DMEM containing FCS and PSA, 10 µl extracted, added to an equal amount of Trypan 
Blue (Sigma-Aldrich) and counted on a haemocytometer. The remaining cell suspension 
was centrifuged at 1000 rpm for 6 min. After removing the supernatant the remaining cell 
pellet was re-suspended in DMEM containing FCS and PSA. A volume containing 1.8 x 
106 cells was added to DMEM containing FCS and PSA to make a final volume of 12 ml. 
The remaining suspension was split 1:8 and placed in a new flask for further growth.  
 
Transfection 
Cells were seeded onto poly-L-lysine coated cover-slips in 6-well tissue culture plates (3 
coverslips / well). 2 ml (3 x 105 cells) of cell suspension were added to each well. Cells 
were maintained in growth medium overnight at 37 ºC. Medium was changed to 
antibiotic-free DMEM and cells were transfected with the CHRM2-containing plasmid 
using the transfection agent polyethylenimine (PEI) (Sigma-Aldrich). This was 
subsequently changed to lipofectamine (Invitrogen) to reduce background staining in the 
immunofluorescence assay. Cells were incubated for 24 h at 37 ºC with antibiotic-free 
DMEM containing per well: 4 µg DNA and 10 µl lipofectamine. Some cells were 
transfected with plasmids containing green fluorescent protein (GFP) (AB Vector, San 
Diego, CA, USA) as a transfection control (see Appendix 4.4 for detailed methodology). 
   
Indirect immunofluorescence 
The following day the medium was changed and cells were maintained for a further 24 h 
at 37 ºC. Cover-slips were then transferred to 24-well culture plates washed with PBS and 
incubated with Chagas’ disease or community control serum diluted 1:20 in DMEM 
containing HEPES and 1% BSA for 1 h at RT. Cells stained with a monoclonal antibody 
against M2 mAChR (1:200) (Abcam, Cambridgeshire, UK) served as a positive control. 
As this antibody is raised against an intracellular epitope, these cells were first fixed with 
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4% formaldehyde for 10 min and permeabilised with 1% Triton X.  Cells were washed 
three times in DMEM containing HEPES (DMEM wash) and incubated with a 
fluorescently-conjugated secondary antibody (anti-human for cells stained with serum, 
anti-mouse for control cells) (Invitrogen Ltd. Paisley, UK) diluted 1:700 for 45 min in the 
dark at RT. Cells were washed again in several changes of DMEM wash and PBS and 
mounted on microscope slides using fluorescent mounting medium (Dako, 
Cambridgeshire, UK) containing the fluorescent DNA stain 4’,6-diamidino-2-
phenylindole (DAPI; Roche Diagnostics Ltd. Burgess Hill, West Sussex, UK). Slides 
were refrigerated at 4ºC in the dark and allowed to dry over night before reading (see 
Appendix 4.4 for detailed methodology).     
 
2.3 FUNCTIONAL IN VITRO EFFECTS OF CHAGASIC SERA 
 
2.3.1 IN VITRO CONTRACTILITY EXPERIMENTS 
 
Background to methodology 
Evoking changes in smooth muscle contractility by electrical field stimulation (EFS) is an 
established tool for the study of contractility (Bulbring et al. 1967; Kosterlitz et al. 1970). 
This technique involves maintaining tissue in a physiological solution between platinum 
ring electrodes and applying pulses of electricity across the muscle to induce a response. 
Relaxations and contractions are measured by way of an isometric force-transducer to 
which the muscle is attached and kept under a baseline muscle tension. The muscle is 
also kept at a constant resting, baseline tension (Figure 2.5). The initial response to EFS 
may be a contraction or relaxation, depending on whether excitatory or inhibitory 
neurons form the majority of neurons stimulated. This initial response is usually followed 
by an after contraction. The pharmacology of the smooth muscle responses may be 
investigated by adding compounds to the organ bath solution and measuring changes to 
contractility. The advantages of EFS over simple contractility studies using only a resting 
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tension is that EFS enables neurogenic responses (which occur during EFS) and 
myogenic responses to be distinguished.           
 
Chagas’ disease and control sera 
The effect of sera from three patients with chagasic colonic dysfunction, three with 
Chagas’ disease and no GI sequalae and three healthy community controls on human 
colonic smooth muscle responses to EFS were investigated as previous studies have 
shown that chagasic sera may increase the tone of resting smooth muscle.  
 
Human tissue 
Resection margin segments of human colon (ascending, transverse or sigmoid) were 
obtained from patients undergoing surgery for cancer at the Royal London Hospital. The 
segments were transferred to the research laboratories within 2 h after resection in ice-
cold Kreb’s solution (containing in mmol L): NaCl 121.5, CaCl2 2.5, KH2PO4 1.2, KCl 
4.7, MgSO4 1.2, NaHCO3 25, glucose 5.6) equilibrated with 5 % CO2 and 95 % O2. The 
segments were opened and the mucosa removed by blunt dissection and discarded. Strips 
(3–5 x 15 mm) from the inter-taenial parts of the segment were cut parallel to the circular 
muscle fibres. These strips were used immediately or stored overnight at 4 °C in fresh, 
oxygenated Kreb’s solution before use.  
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Figure 2.5:  Organ bath for electrical field stimulation and measurement of smooth 
muscle contractility. Strips of human colonic smooth muscle maintained in a physiological solution 
were placed between platinum ring electrodes and electrically stimulated. Smooth muscle contractions were 
measured by an isometric force transducer (Courtesy of Dr J Broad, Wingate Inst. of 
Neurogastroenterology, London).      
 
In vitro contractility studies 
The strips (n = 4–16 from each patient) were mounted in tissue baths containing 5 ml 
Kreb’s solution at 37 °C and gassed with 5 % CO2 in O2. The change in the tension was 
recorded using isometric force transducers (AD Instruments, Chalgrove, UK) on a data 
acquisition system (Biopac Systems Inc., Goleta, CA, USA). The strips were given 2 g 
tensions and allowed to equilibrate for 45 min during which time the bath solutions were 
changed every 15 min. At the end of the equilibration period the strips were stimulated 
via two parallel platinum ring electrodes connected to a stimulator (STG2008, 
Scientifica, Uckfield, UK). The stimulation parameters were 50 V (200 mA), 5 Hz, 0.5 
ms bipolar pulse duration, for 10 s, every 1 min. These EFS parameters in preliminary 
experiments were shown to elicit sub-maximal contractions. The effects of sera from 
patients with Chagas’ disease were investigated by adding serum direct to the organ bath, 
using a single concentration (1%). The effects of control sera from healthy community 
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controls were also measured in each experiment. The effect of the serum in a single strip 
was determined from at least three EFS-induced responses. The effect of chagasic sera on 
cholinergic and nitrergic pathways were investigated by pre-incubating strips with 
atropine (a cholinergic antagonist) or N-ω-nitro-L-arginine methyl ester (L-NAME; a 
nitric oxide synthase inhibitor) respectively. Serum effects were also determined 
following tissue pre-incubation with the voltage-gated sodium channel blocker 
tetrodotoxin (TTX). Minimum contact time for pharmacological agent was 30 min.  
 
2.4 EXPRESSION AND LOCALISATION OF ENTERIC KV1 CHANNELS IN 
THE HUMAN GI TRACT 
  
2.4.1 INDIRECT IMMUNOHISTOCHEMISTRY 
 
Background to methodology 
Immunohistochemistry utilises labelled antibodies as reagents for the optical detection 
and localisation of antigenic material (usually proteins) in cells and tissues (Coons et al. 
1950). As such, this method is dependent on the specificity of antibody binding to the 
chosen epitope. Immunohistochemistry involves a number of steps beginning with the 
‘unmasking’ of antigens which may be hidden by the fixation process (e.g. formalin 
cross-links) with antigen retrieval. A number of techniques such as pressure cooking, 
protease treatment, and microwaving in an appropriate buffer may be employed, although 
the molecular mechanisms underlying the process are poorly understood (Shi et al. 2001). 
Following antigen retrieval, the specific primary antibody is applied and incubated with 
the tissue before washing to remove excess. A species-specific secondary antibody which 
is conjugated to a tag such as biotin or a fluorophore is applied which binds to the 
primary antibody. Finally, if required, a detection reagent containing a chromagen is 
applied that binds to the secondary conjugate and allows visualisation of the antibody 
complex (e.g. avidin-biotin). Primary antibody specificity should be checked using 
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control tissue that is known to contain the antigen, and ideally by immunoblot. Negative 
controls, where the primary antibody is omitted, should also be included in each 
experiment (Burry 2000).          
 
The composition of all solutions and reagents are detailed in Appendix 5.1.  
 
Clinical material 
Sections from formalin-fixed, paraffin wax-embedded tissue samples of disease-free, full 
thickness human oesophagus, stomach, jejunum, ileum and colon were used in this study. 
Stomach, small intestinal and colonic tissues were identified and retrieved from the 
Archive of Pathology at the Royal London Hospital (London, UK). Due to a lack of 
archived specimens, oesophageal tissue was obtained prospectively (full thickness 
surplus tissue at oesophageal cancer resections) and processed in the same manner as 
archived tissue (see Appendix 5.2 for routine tissue processing and section preparation). 
Prior to immunostaining, a 3 µm section from each tissue block was cut, collected on 
coated slides (VWR International, Leicestershire, UK) and stained with haematoxylin and 
eosin (H&E) (Appendix 5.3). These sections were then inspected using light microscopy 
to confirm that there were no inflammatory or other histological abnormalities. For each 
anatomical location studied, anti-channel immunostaining was performed on a minimum 
of five tissue samples, from different patients. 
 
Control tissue 
Formalin-fixed, paraffin wax-embedded murine (strain: C57 black 6) cerebella were 
obtained from the Blizzard Institute of Cell and Molecular Science (ICMS) Pathology 
Group, (Queen Mary University, London, UK) control tissue bank. KV1 channel 
distribution has been previously well-described in this brain region (Veh et al. 1995; 
Chung et al. 2001)      
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Indirect immunohistochemistry 
Indirect immunohistochemical staining was performed using a kit-based (Vectastain 
Universal Elite ABC: Vector Laboratories, Burlingame, CA, USA) avidin-biotin-
peroxidase complex method (see Appendix 5.4 for detailed methodology) with 
commercially available antibodies raised against KV1 channel α-subunits (Santa Cruz 
Biotechnology Inc, CA, USA). Tissue sections were de-waxed in two changes of xylene 
for 2 min and dehydrated in two changes of industrial methylated spirit (IMS) for 2 min. 
After washing in running tap water for 5 min thermal antigen retrieval was carried out by 
microwaving sections in a citrate buffer (Vector Laboratories, Burlingame, CA, USA) for 
25 min. Sections were allowed to cool for 5 min and washed again in running tap water 
for 5 min. Endogenous peroxidase activity was blocked by placing sections in methanol 
containing 3% H2O2 for 15 min. After further washing in running tap water for 5 min and 
soaking in wash buffer (WB; Dako, Cambs, UK) for 2 min, sections were then incubated 
in normal horse serum (in kit) for 20 min at RT. Excess blocking serum was tipped off 
and sections were incubated with primary anti-human KV1 antibodies raised in goat 
diluted in antibody diluent (Dako, Cambs, UK) for 60 min at RT (see Table 2.5 for 
dilutions). Sections incubated with antibody diluent only served as negative controls. 
Primary antibodies were washed off with WB and sections incubated with secondary 
anti-goat biotinylated antibodies raised in horse (Vector Laboratories, Burlingame, CA, 
USA) diluted 1:250 in WB, for 30 min at RT. Secondary antibody was washed off with 
WB and sections incubated in avidin complex solution (in kit) for 30 min at RT, washed 
again with WB and incubated in diaminobenzidine solution (Bio-Genex-Laboratories, 
San Ramon, CA, USA) for 5 min. After further washing in running tap water for 5 min, 
sections were counter-stained in Gill’s haematoxylin for 2 min, washed in running tap 
water for 5 min, dehydrated twice in IMS for 2 min, cleared twice in xylene for 2 min and 
mounted in Canada balsam (VWR International, Leicestershire, UK).   
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Light microscopy and qualitative analysis 
Sections were analysed at magnifications of x10, x20 and x40 using a light microscope 
(Leitz Dialux 20, Leica Microsystems UK Ltd., Milton Keynes, UK). The presence and 
distribution of anti-channel immunostaining was noted and a representative area for each 
gut region was photographed with a digital camera using the Leica IM50 Image Manager 
software (Leica Microsystems, UK).  
 
Table 2.6: Anti-KV1 channel antibody dilutions used for indirect 
immunohistochemistry 
 
 
 
 
 
 
 
 
All antibodies incubated for one hour at room temperature, except KV1.3* which was incubated overnight 
at 4ºC 
 
2.4.2 CHARACTERISATION OF ENTERIC NEURONAL KV1.4 LOCALISATION 
 
The distribution of KV1.4 immunostaining in enteric ganglia was distinct from other 
subunits (see Results sections 3.12-3.14). A similar distribution of KV1.4 containing 
channels has previously been demonstrated in excitatory neurons of the hippocampal 
formation in the brain and was localised to axonal segments and pre-synaptic termini 
(Cooper et al. 1998). We therefore investigated whether KV1.4 is specifically localised to 
these areas in enteric neurons with indirect immunofluorescent double-staining 
employing antibodies raised against two corresponding neuronal peptides: neurofilament 
 
Primary antibody 
 
Dilution 
 
KV1.1 
 
1:150 
KV1.2 1:75 
KV1.3 1:75 * 
KV1.4 1:75 
KV1.5 1:75 
KV1.6 1:75 
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(NF) (Diepholder et al. 1991; Luider et al. 1992) and synaptophysin (Wiedenmann et al. 
1986; Stefaneanu et al. 1988). Neurofilaments belong to the intermediate filament family 
of proteins and are found specifically in neurons where they form a key component of the 
axonal and dendritic cytoskeleton (Davison et al. 1960; Schlaepfer 1987). Synaptophysin 
is a glycoprotein present in the membrane of pre-synaptic vesicles (Wiedenmann et al. 
1985). 
 
Clinical material 
Sections from formalin-fixed, paraffin wax-embedded tissue samples of disease-free, full 
thickness stomach were used in this study. As in the previous immunohistochemical 
study, tissue was obtained from the Archive of Pathology at the Royal London Hospital 
(Whitechapel, London, UK). This region was chosen due to tissue availability and high 
levels of KV1.4 subunits exhibiting this distribution.   
 
Indirect immunofluorescence 
Tissue sections were de-waxed in two changes of xylene for 2 min and dehydrated in two 
changes of IMS for 2 min. After washing in running tap water for 2 min, thermal antigen 
retrieval was carried out by microwaving sections in a citrate buffer (Vector Laboratories, 
Peterborough, UK) for 18 min. Sections were allowed to cool for 5 min, were washed 
again in running tap water for 2 min and then incubated with a serum-free protein block 
(Dako, Cambs, UK) for 10 min at RT. Excess protein block was tipped off and sections 
were incubated with a mixture of anti-KV1.4 and an anti-neuronal primary antibody 
diluted in PBS for 24 h at 4 ºC (see Table 2.6 for primary antibody details and dilutions). 
After allowing sections to reach room temperature primary antibodies were washed off 
by soaking in two changes of PBS for 4 min and incubated with a mixture of appropriate 
Alexa Fluor® fluorescently-conjugated secondary antibodies (Invitrogen Ltd. Paisley, 
UK) in the dark for 45 min at RT. Secondary antibodies were washed off in two changes 
of PBS for 4 min and sections were mounted in fluorescence mounting medium (Dako, 
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Ely, Cambridgeshire, UK) containing DAPI (1:1000) for nuclear visualisation (see 
Appendix 5.5 for detailed methodology). 
 
Table 2.7: Antibodies used in indirect immunofluorescence 
 
Primary antibodies were incubated for 1 h at RT. All secondary antibodies were used at dilution of 1:200 
and incubated for 45 min at RT. NF-2F11 = neurofilament, clone 2F11. 
 
Fluorescent microscopy and qualitative analysis 
Sections were viewed with a multi-channel fluorescence microscope (Olympus BX61-
UCB, Olympus UK Ltd., Essex, UK). Sequential images were captured (Cell* imaging 
software, Soft Imaging Solutions GmbH, Münster, Germany) and overlaid using Adobe 
Photoshop (Version 7.0, Adobe Systems Inc., San Jose, CA, USA).   
 
 
 
 
 
 
 
 
 
 
 
 
Primary antibody 
 
Source 
 
Dilution  
 
Secondary antibody 
 
KV1.4 
 
 
Goat polyclonal against internal 
region of human peptide 
 
1:25   
 
Alexa fluor (568) 
donkey anti-goat 
Synaptophysin Mouse monoclonal against coated 
vesicles from bovine brain 
1:100 Alexa fluor (488) 
donkey anti-mouse  
NF-2F11 Mouse monoclonal against 
isolated neurofilament from 
human brain  
1:100 Alexa fluor (488) 
donkey anti-mouse 
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RESULTS 
 
 
 
 
 
 
 
3.1 DETECTION OF AUTOANTIBODIES  
 
3.1.1 ANTI-NEURONAL ANTIBODY ASSAY 
 
Twenty seven samples from patients with severe intestinal dysmotility (SID) were 
screened for the presence of anti-neuronal antibodies, the presence of which may be 
indicative of a paraneoplastic process. An indirect immunofluorescence assay using 
monkey cerebellum as substrate was employed to determine the presence of anti-neuronal 
nuclear (anti-Hu / Ri), or anti-Purkinje cell cytoplasm antibodies (anti-Yo). Commercial 
anti-Hu and anti-Yo antibodies were used as positive staining controls. Pooled normal 
serum was used as negative control. Samples which produced positive nuclear staining 
were sent for western blot confirmation of antigen specificity, as this assay cannot 
distinguish between anti-Hu and Ri antibodies.  
 
Anti-Hu antibodies produced strong nuclear staining of cells from all three cerebellar 
layers (granular, purkinje and molecular). Anti-Yo staining was clearly distinguishable 
from anti-Hu, revealing punctate staining of Purkinje cell cytoplasm only. PNS failed to 
stain any cerebellar structures. Three samples from patients with SID (1 chronic intestinal 
pseudo-obstruction and 2 enteric dysmotility) moderately stained cell nuclei of the 
granular, purkinje and molecular layers and were sent for western blot confirmation. The 
3 
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remaining 24 samples produced no staining. The three samples sent for confirmation 
were found to be negative (Figure 3.1). These negative findings minimise the likelihood 
that these cases of SID had a paraneoplastic basis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Cerebellar anti-neuronal immunostaining. Sections of cerebellum were used as 
substrate to screen for the presence of anti-neuronal autoantibodies. Anti-Hu positive staining control 
stained nuclei of granular layer cells, Purkinje cells (arrow) and cells of the molecular layer. Anti-Yo 
positive staining control specifically stained puncta in Purkinje cell cytoplasm only. Pooled normal serum 
served as the negative control and failed to stain any cerebellar cells. Sera from two patients with chronic 
intestinal pseudo-obstruction and 1 with enteric dysmotility moderately stained cells of all three layers and 
required western blot confirmation. An example from one of these cases is shown in the lower right panel. 
All three cases were subsequently found to be negative. G = granular layer, P = Purkinje cell, M = 
molecular layer, CIPO = chronic intestinal pseudo-obstruction. Scale bar = 30 µm.    
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3.1.2 ANTI-CHANNEL ANTIBODY RADIOIMMUNOPRECIPITATION ASSAYS 
 
Sera from all patient groups (21 achalasia, 27 SID and 61 Chagas’ disease, 20 Brazilian 
healthy control and 10 UK healthy controls) were screened for the presence of anti-
channel antibodies using radioimmunoprecipitation assays. In each assay, with the 
exception of the glutamic acid decarboxylase assay, where it is considered only necessary 
to repeat positive results (Powell et al. 1996) each sample was tested twice by different 
investigators blinded to the diagnosis, to confirm the result. Due to limited quantities of 
chagasic serum samples, it was not possible to screen the full complement of 61 samples 
in every assay.  
 
3.1.2.1 Ganglionic nicotinic acetylcholine receptor: alpha 3 subunit 
 
Assays performed twice showed good agreement between results: mean difference 
between assays = 4 pM (95% CI -2 to 9), p = 0.0007. All positive and negative control 
sera were positive and negative in the expected titre ranges. None of the GINMD, 
Chagas’ disease or control sera were found to be positive (Figure 3.2).  
 
3.1.2.2 Glutamic acid decarboxylase 
 
Three sera from Brazil showed precipitation of the complex which was comparable to the 
‘low positive’ calibration control. Two such low positive samples were from patients 
with Chagas’ disease, one with cardiac complications the other with colonic disease, and 
the third from a healthy community control. A low positive result would suggest that 
these individuals are predisposed to or have Type I diabetes mellitus. However, these 
titres are not considered high enough to have a neurological impact (Saiz et al. 2008; 
Liimatainen et al. 2010). None of the GINMD or UK healthy control sera were positive 
Figure 3.3).        
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Figure 3.2:   Scatter plot of results from anti-α3 nAChR immunoprecipitation assay. 
None of the samples from any patient group were positive for anti-α3 antibodies. UK.HC = UK healthy 
controls, SID = severe intestinal dysmotility, B.HC = Brazilian healthy controls, AAN = autoimmune 
autonomic neuropathy. Dotted line indicates 100pM, above which samples were regarded as positive.  
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Figure 3.3: Scatter plot of results from anti-GAD immunoprecipitation assay. Two 
Chagas’ disease samples and one Brazilian healthy control were weakly positive for anti-GAD antibodies. 
UK.HC = UK healthy controls, SID = severe intestinal dysmotility B.HC = Brazilian healthy controls.   
 
3.1.2.3 Voltage-gated calcium channels (VGCCs) 
 
One of 57 Chagas’ disease patients showed strong precipitation of the labelled channel 
complex in a range comparable to LEMS positive controls (246 pM of MVIIC binding 
sites per litre of serum). [LEMS median: 194, range 131 to 256 pM]. At the time of 
venepuncture this patient had not received anti-T.cruzi therapy and did not have 
secondary manifestations of Chagas’ disease. No GINMD patient sample or control 
sample was positive (Figure 3.4). 
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Figure 3.4: Scatter plot of results from anti-VGCC immunoprecipitation assay. One 
Chagas’ disease serum sample was strongly positive for anti-P/Q type VGCC antibodies. All other samples 
were negative. LEMS positive controls were positive in the expected titre ranges. UK.HC = UK healthy 
controls, SID = severe intestinal dysmotility, B.HC = Brazilian healthy controls, LEMS = Lambert-Eaton 
myasthenic syndrome.  
 
3.1.2.4 Voltage-gated potassium channels (VGKCs) 
 
Assay repeats showed very high agreement: mean difference between assays = 12 pM 
(95% CI -4 to 28), p < 0.0001. Eight of 59 sera from patients with Chagas’ disease 
showed precipitation of the labelled complex that was greater than 100 pM of binding 
sites per litre of serum. The eight positives did not however define a specific clinical 
phenotype: 5 were female, 5 had no heart or gut manifestations, one had achalasia and 
heart disease, one had achalasia only and another had colonic dysfunction only. [Whole 
Chagas’ disease group: median 34, range -16 to 282]. Although consistently positive, 
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none of the eight were in a range comparable to NMT positive controls [Chagas’ disease 
positive median: NMT median: 1199, range 776 to 1622 pM). All of the samples from 
patients with primary GINMD were found to be negative as were all UK and Brazilian 
healthy controls (Figure 3.5).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.5: Scatter plot of results from anti-VGKC immunoprecipitation assay. Eight 
Chagas’ disease sera were weak to moderately positive for anti-VGKC antibodies. None, however, were in 
the same range as the NMT positive controls. UK.HC = UK healthy controls, SID = severe intestinal 
dysmotility, B.HC = Brazilian healthy controls, NMT = neuromyotonia. 
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3.1.3 ANTI-M2 MUSCARINIC ACETYLCHOLINE RECEPTOR CELL-BASED 
ASSAY 
 
3.1.3.1 Anti-M2 muscarinic acetylcholine receptor assay optimisation 
 
Cell transfection efficiency was measured by green fluorescent protein (GFP) transfection 
where protein expression results in cells fluorescing green. This was performed in several 
assays and was judged as good by the fact the majority of cells in several microscopy 
views were positive (Figure 3.6). The success of M2 muscarinic acetylcholine receptor 
(M2 mAChR) transfection was confirmed using a commercially available monoclonal 
antibody raised against the M2 mAChR in indirect immunofluorescence assays. Only 
antibodies raised against an internal region of the receptor peptide were available at the 
time of assay development. It was therefore necessary to first permeabilise transfected 
cells prior to antibody application in order for the antibodies to gain access to the epitope. 
Whilst it would have been preferable for cells to have remained intact, cells 
permeabilised and stained with the monoclonal anti-M2 mAChR antibody had clearly 
circumscribed borders suggesting that the cells were not severely disrupted and the 
receptor was expressed in the cell membrane (Figure 3.6). This procedure was 
subsequently used as a positive control in every assay. Negative controls consisted of 
cells incubated with antibody diluent only, and gave only a low background signal.  
 
3.1.3.2 Screening of chagasic sera for anti-M2 mAChR autoantibodies 
 
None of 57 sera samples from patients with Chagas’ disease stained the membranes of 
M2 mAChR transfected cells. Similarly, Brazilian healthy community control samples 
failed to produce positive staining (Figure 3.7).   
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Figure 3.6: Indirect immunofluorescent staining of transfected HEK293 cells with 
anti-M2 mAChR antibody. GFP-transfected cells auto-fluoresced green demonstrating successful 
transfection. Cells transfected with M2 mAChR-containing plasmids and incubated with a monoclonal anti-
M2 antibody served as the positive control and revealed membranous immunostaining. Transfected cells 
incubated with antibody diluent only served as the negative control and produced no staining. Scale bar = 
10µm.    
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Figure 3.7: Indirect immunofluorescent staining of transfected HEK293 cells with 
chagasic sera. Chagasic serum samples failed to bind M2 mAChR-transfected cells as demonstrated by 
indirect immunofluorescence using an anti-human fluorescently-conjugated secondary antibody. Similarly, 
control serum taken from healthy individuals showed no binding. Scale bar = 10µm.     
 
3.2 FUNCTIONAL IN VITRO EFFECTS OF CHAGASIC SERA   
 
Following the negativity of the M2 mAChR cell-based assay we investigated the effects 
of chagasic sera on human colonic smooth muscle contractions. Due to time constraints 
the work presented here is preliminary. The effects of sera from three patients with 
chagasic colonic disease on colonic smooth muscle contractility were investigated. These 
effects were compared with those of three samples from patients with Chagas’ disease 
and no GI disease and from three healthy community controls.      
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Table 3.1: Subjects investigated for sera effects on colonic smooth muscle 
contractility  
 
3.2.1.1 Characterisation of responses of human colonic smooth muscle to electrical 
field stimulation, atropine and L-NAME 
 
Responses to electrical field stimulation (EFS) in muscle strips from the same patient 
were heterogeneous and consisted of contractions (55 %; 21 / 38 strips; n = 9 colons), 
relaxations (32 %) or no response (13 %) and were usually followed by a large after-
contraction (Figure 3.8A). Responses could be blocked by the sodium channel blocker 
tetrodotoxin, 1 µM (n = 3 colons), indicating that they were neuronally mediated (Figure 
3.8B). The addition of atropine 1 µM, a mAChR antagonist, prevented contractions 
during EFS (n = 3 colons) revealing, or facilitating muscle relaxation, and strongly 
attenuated after-contractions. L-NAME 0.3 mM, the nitric oxide synthase inhibitor, 
prevented muscle relaxation during EFS (n = 4 colons) (Figure 3.8B).       
 
 
 
Subject Age / sex Details 
1 57 F Chagasic colonic disease 
2 53 M Chagasic colonic disease 
3 46 M Chagasic colonic disease 
4 39 M Chagas’ disease, no sequalae 
5 37 F Chagas’ disease, no sequalae 
6 35 M Chagas’ disease, no sequalae 
7 40 M Healthy community control 
8 45 F Healthy community control 
9 33 M Healthy community control 
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Figure 3.8: Human colonic smooth muscle responses to EFS and pharmacological 
modulation of responses. A: The initial response to EFS was a contraction mediated by 
acetylcholine, or a relaxation mediated by nitric oxide. Each response was usually followed by a spike 
representing a large after-contraction. These are mediated by acetylcholine or a neurokinin. (Horizontal bar 
beneath traces represents the duration of EFS). B: Application of tetrodotoxin prevented EFS responses 
indicating that they were neuronally mediated. Atropine prevented muscle contraction during EFS, 
revealing a relaxation, and strongly reduced the magnitude of the after-contraction. L-NAME prevented 
muscle relaxation during EFS and increased basal muscle tension. ACh = acetylcholine, NK = neurokinin. 
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3.2.1.2 Effect of sera on human colonic smooth muscle responses to EFS 
 
The only consistent, measurable effect caused by addition of serum to colonic muscle 
stimulated by EFS was a change in baseline muscle tension. Application of 100 µl (bath 
concentration 1%) of serum from three patients with chagasic colonic disease caused a 
consistent reduction in baseline muscle tension (n = 4 colons / patient; 12/12 relaxations) 
without a corresponding effect on the magnitude of responses to EFS (Figure 3.9). The 
overall reduction in muscle tension (mean ± SEM) was 36 ± 6 mg (p < 0.05, one sample t 
test; Figure 3.12).  Contractions during EFS were 104 ± 13 % of magnitude of 
contractions before addition of serum; Figure 3.9, which persisted for at least 30 min.   
 
Application of 100 µl of serum from three Chagas’ disease control patients (with no GI 
sequalae) produced variable responses in baseline muscle tension. The mean effect on 
baseline muscle tension was not significant (2 ± 15 mg; n = 4 colons / patient; 7/12 
relaxations; Figures 3.10 and 3.12). The addition of three serum samples from healthy 
community controls also produced mixed responses, the mean of which was not 
significant (-7 ± 32 mg; 4 colons / patient; 7/12 relaxations; Figures 3.10 and 3.12).      
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Figure 3.9: Effects of serum from patients with Chagas’ colon disease on human 
colonic smooth muscle responses to EFS. Following addition of serum from patients with 
Chagas’ colon disease, baseline muscle tension always decreased, although to varying degrees. The 
magnitude of the response during EFS was unchanged.  
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Figure 3.10: Effects of serum from Chagas’ disease and healthy controls patients 
on human colonic smooth muscle responses to EFS. Following addition of serum from 
patients with Chagas’ disease and no GI sequalae or from healthy community controls EFS responses were 
unchanged. Changes in baseline muscle tension varied, but overall were not significant.   
 
3.2.1.3 Effect of chagasic sera on EFS-induced human colonic smooth muscle 
contractions in the presence of atropine or L-NAME 
 
To investigate whether the effect of serum from Chagas’ colon disease involved a 
mechanism dependent on mAChR activation, as reported in previous studies, the effects 
of these sera were tested in the presence of the mAChR antagonist atropine. Atropine (1 
µM) was applied to organ baths and allowed 30 min contact time with muscle strips. 
Serum was then applied as before. In the presence of atropine, serum continued to cause a 
reduction in baseline muscle tone. Although the relaxation was slightly attenuated, it was 
consistent, as before (-31 ± 11 mg; n = 3 colons / patient; 9/9 relaxations; Figures 3.11A 
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and 3.12), demonstrating that the observed effect is not dependent on mAChR activation. 
The response was further examined by application of the nitric oxide synthase inhibitor 
L-NAME 0.3 mM, to investigate whether the effect was dependent on nitric oxide 
production. Following 30 min compound contact time, addition of serum reduced muscle 
tension by 54 ± 11 mg (n = 3 colons / patient; 9/9 relaxations) showing that the response 
is independent of nitric oxide production (Figures 3.11B and 3.12). In further 
experiments, Tetrodotoxin (TTX), which blocks voltage-gated sodium channels essential 
for neuronal action potential generation, was applied to muscle to block neuronal activity. 
Following pre-incubation with 1µM TTX, all three Chagas’ colon disease serum samples 
produced a reduction in basal muscle tension (-20 ± 6 mg; n = 3 colons / patient, 7/9 
relaxations) which although attenuated compared to toxin free preparations, were not 
significantly different. This demonstrates that although the effect may perhaps in part 
involve neuronal mechanisms, it is not dependent on neuronal activity.  
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Figure 3.11: Serum effects on human colonic smooth muscle EFS responses in the 
presence of atropine and L-NAME. The decrease in baseline tension following the addition of 
serum from a patient with chagasic colonic dysfunction was maintained in the presence of atropine (A) and 
L-NAME (B) suggesting that circulating factors were not exerting their effects via  muscarinic cholinergic 
receptor activation or via facilitation of nitric oxide synthesis. Red dashed line represents baseline muscle 
tension prior to addition of serum.     
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Figure 3.12: Serum effects on human colonic baseline muscle tension in the 
presence of atropine and L-NAME. Serum from three patients with Chagas’ colon disease 
produced a significant reduction in colonic smooth muscle tone. Serum from three patients with Chagas’ 
disease but no sequalae variably changed basal muscle tone, however these changes were not significant. 
Responses to serum from three healthy individuals from the same community were more variable, overall 
producing a reduction in smooth muscle tone. This effect however was not significant. In the presence of 1 
µM atropine the relaxant effect on baseline muscle tension was preserved, although slightly attenuated, 
demonstrating the effect is not dependent on muscarinic cholinergic receptor activation. Relaxations 
continued in the presence of 300 µM L-NAME, and appeared to be slightly facilitated, revealing that they 
were not the result of nitric oxide production. Tetrodotoxin (TTX; 1 µM) slightly attenuated but did not 
abolish the relaxant effect of serum, demonstrating that although this effect may involve neuronal 
pathways, it is not dependent on neuronal action potentials. 
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3.3 KV1 CHANNEL DISTRIBUTION  
 
The distribution of six members of the KV1 VGKC subfamily was investigated 
immunohistochemically in the human GI tract. Antibody specificity and optimal working 
dilutions were first determined by immunostaining murine cerebellum.  
 
3.3.1 MURINE CEREBELLUM 
 
The distribution of KV1 channels has been previously established in rodent cerebellum 
and allowed us to confirm the specificity of our antibodies and determine optimal 
working dilutions. No staining was seen in the negative control sections where the 
primary anti-KV1 antibodies were omitted but the secondary detection system was used 
as normal, indicating areas of staining seen in test sections were not due to non-specific 
secondary antibody binding (Figure 3.13). The staining patterns we observed in mouse 
cerebellum with the anti-KV1 antibodies (Figure 3.14) were the same as those described 
in previous reports (Veh et al. 1995; Chung et al. 2001). KV1.1 was found in basket cell 
axon terminals around Purkinje cells and also weakly in the neuropil within the granule 
cell layer. KV1.2 immunoreactivity also appeared in basket cell axon terminals, in greater 
abundance to KV1.1. Immunoreactivity for KV1.3 was found in Purkinje cells, Golgi-type 
II cells of the granular layer and basket cells of the molecular layer. Purkinje cell bodies 
were stained with anti-KV1.4, 1.5 and 1.6. KV1.6 immunoreactivity was also found in 
basket cells of the molecular layer and Golgi type II cells of the granular layer. No 
staining was seen in the negative control sections. Human and mouse KV1 channels are 
homologous. Therefore, having confirmed that the anti-KV1 antibodies bound as expected 
in murine cerebellum, we proceeded to immunohistochemically investigate KV1 
distribution in the human GI tract. For the purposes of this thesis and considering the 
questionable value of quantitative immunohistochemistry (Polak et al. 2003), this is a 
descriptive study only.  
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Figure 3.13: Negative immunostaining control of mouse cerebellum. Sections of mouse 
cerebellum incubated with antibody diluent in the absence of anti-KV1 antibodies showed no staining 
confirming that the secondary detection system, which was used as normal, was not responsible for any 
staining subsequently observed. G = granule cell layer, M = molecular layer, P = Purkinje cell. Scale bar = 
25 µm.  
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Figure 3.14: Anti-KV1 immunostaining of mouse cerebellum. KV1.1 and 1.2 localised 
specifically to basket cell axon terminals around Purkinje cells (arrow and inset, respectively). KV1.3 was 
found in Purkinje cell bodies, Golgi type II cells of the granular layer (arrow) and basket cells of the 
molecular layer (star). KV1.4 immunoreactivity was also found in Purkinje cell bodies. KV1.5 strongly 
stained Purkinje cell bodies. KV1.6 localised to Purkinje cell bodies, basket cells (star) and Golgi type II 
cells of the granular layer (arrow). M = molecular layer, P = Purkinje cell layer, G = granular layer; WM, 
white matter. Scale bar = 25 µm.  
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3.3.2 OESOPHAGUS 
 
Oesophageal epithelium 
The oesophageal epithelium did not show immunopositivity for any of the six KV1 
channel subunits (Figure 3.15).     
 
Oesophageal neurons 
Anti-KV1.1 strongly immunostained cell bodies of the myenteric plexus. Cell bodies also 
exhibited moderate cytoplasmic immunoreactivity for KV1.5. Anti-KV1.2 and KV1.4 
weakly stained myenteric cell bodies, KV1.2 exhibited a cytoplasmic distribution and 
KV1.4 staining cell nuclei. Anti-KV1.3 and KV1.6 immunostaining was not above 
background levels (Figure 3.16).   
 
Oesophageal smooth muscle 
KV1.5 was found to be localised myocytes of the oesophageal muscularis propria and 
arterioles. Anti-KV1.5 immunostaining identified discrete patches of punctate staining, 
which often appeared to be intracellular, specifically peri-nuclear, in distribution (Figure 
3.17). No other channel subunit was identified in smooth muscle cells.      
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Figure 3.15: Anti-KV1 immunostaining of oesophageal epithelium. All cells of the 
squamous epithelium were negative for KV1.1-1.6 immunoreactivity. E, epithelium; SM, submucosa. Scale 
bar = 50 µm.    
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Figure 3.16: Anti-KV1 immunostaining of human oesophageal myenteric ganglia. 
KV1.1 was found in neuronal cell bodies in a cytoplasmic distribution. KV1.2 immunostaining was weak in 
neuronal cell bodies. KV1.3 was not detected in oesophageal myenteric ganglia. Neuronal nuclei were 
weakly immunopositive for KV1.4 (arrow). KV1.5 was distributed in the cytoplasm of cell bodies and KV1.6 
was not found to be present. Scale bar = 10 µm.     
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Figure 3.17: Anti-KV1.5 immunostaining of human oesophageal smooth muscle. 
KV1.5 containing puncta were abundant throughout muscularis propria and in arteriolar myocytes. These 
puncta were often observed to be intracellular, and often peri-nuclear (inset). Scale bar = 10 µm.    
 
3.3.3 STOMACH 
  
Gastric mucosa 
KV1 immunostaining of the gastric epithelium labelled Chief cells (as identified by H&E 
appearance) where intracellular granular staining was present. Immunostaining for KV1.1, 
KV1.2, KV1.3 and KV1.4 was strong compared with KV1.5 and KV1.6 which were 
moderate. Parietal cells and surface epithelial cell staining was not above background 
levels (Figure 3.18). The muscularis mucosa was also negative (data not shown).   
 
Gastric neurons  
KV1 subunits exhibited a selective distribution in gastric submucosal and myenteric 
ganglia (Figures 3.19 and 3.20, respectively). Cell bodies and the neuropil of submucosal 
and myenteric ganglia were weakly immunopositive for KV1.1. Cell bodies of both plexi 
intensely stained for KV1.2. Anti-KV1.3 immunostaining also localised to cell bodies with 
the additional observation of nuclear immunostaining. Anti-KV1.4 failed to stain 
submucosal cells bodies, however immunostaining of KV1.4 was scattered around the 
periphery of myenteric ganglion in a punctate distribution. At light microscopic 
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magnifications it was not possible to identify these channel-rich structures. Certain 
myenteric cell bodies were also strongly immunopositive for KV1.4. KV1.5 
immunostaining was moderate to strong in submucosal and myenteric cell bodies with. 
KV1.6 immunostaining was not consistently above background levels. Antibodies to KV1 
subunits did not label circular or longitudinal layers of muscularis externae.    
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Figure 3.18: KV1 immunostaining of human gastric epithelium. Cells located towards the 
base of gastric glands identified as Chief cells were strongly stained with anti-KV1.1 (inset; dark brown), 
KV1.2, KV1.3 and KV1.4 antibodies. Chief cells were moderately stained with antibodies against KV1.5 and 
KV1.6. Surface epithelial cells and parietal cells were negative (membranous staining of surface epithelial 
cells seen in KV1.6 slide was considered to be artefact). Scale bar = 50 µm.    
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Figure 3.19: KV1 immunostaining of human gastric submucosal neurons. Anti-KV1.1 
weakly stained neuronal cell bodies (arrow) whereas KV1.2 and 1.3 were strong. KV1.4 and 1.6 were not 
found to be expressed by gastric submucosal ganglia (arrow). Anti-KV1.5 moderately stained cell bodies. 
Scale bar = 10 µm. 
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Figure 3.20: KV1 immunostaining of human gastric myenteric ganglia. Gastric 
myenteric neurons were immunopositive for KV1.1 – 1.5. Anti-KV1.2, 1.3 and 1.5 antibodies selectively 
labelled neuronal cell bodies. KV1.1 was also present in the surrounding neuropil. KV1.4 exhibited a unique 
punctuate distribution at the periphery of ganglia and certain neuronal cell bodies (inset). KV1.6 
immunostaining was not above background. Scale bar = 10 µm.    
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3.3.4 JEJUNUM  
 
Jejunal mucosa 
As in the stomach, KV1 immunostaining was localised to jejunal epithelial cells (Figure 
3.21). Both absorptive enterocytes and goblet cells were immunopositive for both 
cytoplasm and surface membranes, albeit moderately. Epithelial cells towards the villi 
tips were more strongly stained than those of the crypts. KV1.2 was the most abundant 
subunit in jejunal epithelium. KV1.1 and KV1.3 immunostains were moderately positive 
whereas anti-KV1.4 and KV1.5 were weak. KV1.6 failed to stain above background levels. 
Anti-KV1.1, 1.3, 1.4 and 1.6 antibodies specifically immunolabelled a subset of cells, 
presumed to be enteroendocrine cells (based on their morphology) of jejunal epithelium, 
particularly in crypts (Figure 3.21, arrows). The muscularis mucosa was negative for all 
six channel subunits.   
 
Jejunal neurons 
KV1.1 immunostaining was strong in selected ganglion cell bodies of the submucosal 
plexus and stained the neuropil of myenteric ganglia. KV1.2 localised specifically to 
certain cell bodies of both plexuses, with little staining of the neuropil. Submucosal and 
myenteric cells, including cell nuclei, were strongly positive for KV1.3. No specific 
pattern regarding positivity of large vs. small neurons was discernable. As in the stomach, 
immunoreactivity for KV1.4 was scattered throughout enteric ganglia in a peripheral 
punctate distribution with very little staining of cell bodies. KV1.5 appeared very specific 
for cell bodies of both ganglia with no staining of the neuropil.  Submucosal and 
myenteric neuronal cell bodies were negative for KV1.6 (Figure 3.22 and 3.23). Smooth 
muscle cells of the jejunum appeared negative for all KV1 immunostaining (not shown).  
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Figure 3.21: KV1 immunostaining of human jejunal mucosa. KV1 subunits were 
specifically observed in surface epithelial cells, KV1.2 appearing to be most abundant. Crypt epithelial cells 
were also stained, although at a lower intensity. KV1.1 and 1.3 immunostaining were moderate, KV1.4 and 
KV1.5 were weak and KV1.6 was not above background staining. A subset of cells, presumed by 
appearance to be enteroendocrine, were strongly stained at their basal aspect by anti-KV1.1 (inset), 1.3, 1.4 
and 1.6 (arrows). Scale bar = 50 µm.      
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Figure 3.22: KV1 immunostaining of human jejunal submucosal ganglia. Jejunal 
submucosal neurons were moderate-strongly stained with anti-KV1 antibodies. KV1.1, 1.2, 1.3 and 1.5 were 
localised to a subset of neuronal cells bodies. In addition to cytoplasmic staining, KV1.3 also exhibited 
nuclear staining. KV1.4 uniquely immunostained discrete structures around ganglion cells bodies and 
ganglia periphery, in a punctate distribution (inset). KV1.6 failed to stain above background. Scale bar = 10 
µm. 
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Figure 3.23: KV1 immunostaining of jejunal myenteric ganglia. Anti-KV1.1 
immunostained the neuropil of myenteric ganglia, KV1.2 and 1.5 localised to neuronal cell bodies and 
KV1.3 immunostained both, including neuronal nuclei. KV1.4 stained discrete fine punctate patches 
scattered around the periphery of ganglia and certain cell bodies (inset). KV1.6 failed to stain ganglia. Scale 
bar = 10 µm.      
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3.3.5 ILEUM 
 
Ileal mucosa 
The transition between immunopositive and immunonegative cells from villi to crypts 
was more pronounced in the ileum (Figure 3.24). Ileal enterocytes and goblet cells were 
strongly immunopositive for KV1.2 and KV1.3. KV1.1 and KV1.5 also localised to surface 
epithelial cells although at a lower intensity. As in the jejunum, anti-KV1.4 and KV1.6 
antibodies only weakly stained epithelial cells. Presumed enteroendocrine cells expressed 
a high density of KV1.1, 1.2, 1.3, 1.4 and 1.6 in their basal regions. Cells of the lamina 
propria and muscularis mucosa were negative.   
 
Ileal neurons 
Immunostaining for KV1.1 was largely confined to the neuropil of myenteric and 
submucosal ganglia. KV1.2 was selectively present in high density in ganglion cell 
bodies. KV1.3 exhibited nuclear localisation, appearing highly expressed in submucosal 
ganglion cell bodies and moderately in myenteric neurons. As in the stomach and 
jejunum, KV1.4 immunostaining was scattered throughout ganglia of both plexi in a 
punctate distribution, which appears unique to this subunit. Certain ileal ganglion cell 
bodies also appeared weakly KV1.4 positive. A high density of KV1.5 subunits was 
observed in submucosal ganglion cell bodies and a moderate concentration in myenteric 
ganglion cells. KV1.6 immunostaining was only weakly positive in submucosal cell 
bodies and was not present in myenteric cell bodies (Figure 3.25 and 3.26). As in the 
stomach and jejunum, ileal smooth muscle cells were not immunostained with anti-KV1 
antibodies (not shown).     
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Figure 3.24: KV1 immunostaining of human ileal mucosa. KV1 subunits were localised to 
ileal enterocytes. Anti-KV1.2 and 1.3 antibodies strongly stained surface enterocytes and moderately 
stained crypt cells. KV1.1 and 1.5 appeared moderately expressed by ileal enterocytes. KV1.4 and KV1.6 
appeared only weakly expressed in enterocytes. Enteroendocrine cells were intensely stained at their basal 
aspect by anti-KV1.1 (inset), 1.2, 1.3, 1.4 and 1.6 (arrows). Lamina propria and muscularis mucosa were 
negative. Scale bar = 50 µm.     
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Figure 3.25: KV1 immunostaining of ileal submucosal ganglia. KV1.1 was localised to the 
myenteric neuropil, whereas KV1.2 was limited to cell bodies only. KV1.3 exhibited strong nuclear (arrows) 
and cell body cytoplasmic staining. KV1.4 was present in fine puncta adjacent to certain cell bodies (inset) 
and towards ganglia periphery and weakly in cell bodies. Cell bodies strongly stained for KV1.5 whereas 
KV1.6 was only weakly present. Scale bar = 10 µm.  
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Figure 3.26: KV1 immunostaining of ileal myenteric ganglia. The neuropil was moderately 
positive for KV1.1. KV1.2 appeared highly expressed by some myenteric cells bodies and moderately by 
others. KV1.3 exhibited nuclear staining with moderate staining of cell body cytoplasm. KV1.4 expression 
appeared restricted to discrete puncta (inset) with occasional weak cell body staining. KV1.5 moderately 
stained cell bodies. Ganglia were negative for KV1.6. Scale bar = 10 µm.     
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3.3.6 COLON 
 
Colonic mucosa 
The gradient of KV1 expression in surface compared with deep epithelial cells was most 
pronounced in the colon (Figure 3.27). Surface enterocytes and goblet cells appeared 
moderately to strongly positive for all six subunits. Crypt enterocytes appeared largely 
negative except for enteroendocrine cells which displayed immunoreactivity for KV1.1, 
1.4 and 1.6 (Figure 3.27). Lamina propria and muscularis mucosa were negative.  
    
Colonic neurons 
Submucosal ganglion cell bodies and neuropil were moderately immunostained with anti-
KV1.1. In myenteric ganglia this appeared largely restricted to the neuropil where only 
selected cell bodies appeared positive. KV1.2 immunostaining was selectively localised to 
cell bodies which were moderately immunopositive in submucosal ganglia. Selected 
myenteric ganglion cell bodies were strongly KV1.2 immunopositive whereas others 
appeared negative. KV1.3 localised to neuronal cell bodies of both plexuses, more 
strongly in the submucosal, with the additional observation of nuclear staining. 
Submucosal cell bodies were moderately positive for KV1.4 whereas myenteric cells 
displayed only weak immunostaining. Punctate staining of KV1.4 containing structures 
observed in gastric, jejunal and ileal ganglia were not seen in the colon. In both plexuses 
KV1.4 was localised to cell bodies, moderately in submucosal and weakly in myenteric. 
KV1.5 immunostaining was strongly present in submucosal and selected myenteric cell 
bodies. KV1.6 appeared to be moderately expressed by submucosal cell bodies but only 
weakly expressed in myenteric cell bodies and neuropil (Figures 3.28.and 3.29, 
respectively). Colonic smooth muscle appeared negative for KV1 subunit expression (not 
shown).  
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Figure 3.27: KV1 immunostaining of colonic mucosa. Surface enterocytes appeared positive 
for KV1.1-1.6 channel expression, whereas deep epithelial cells appeared negative. KV1.1, 1.4 and 1.6 were 
also present in the basolateral membrane of a subset of cells (presumed enteroendocrine, inset and arrows). 
Muscularis mucosa immunostaining was not above background levels. Scale bar = 50 µm.    
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Figure 3.28: KV1 immunostaining of colonic submucosal ganglia. KV1.1 immunostaining 
was present in both neuronal cell bodies and the surrounding neuropil whereas KV1.2 appeared restricted to 
cell bodies. Neuronal cell bodies appeared to strongly stain for KV1.3, both cytoplasmic and nuclear. 
Immunostaining for KV1.4 and 1.6 was moderately strong in cell bodies. KV1.5 immunostaining was 
strong. Scale bar = 10 µm.  
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Figure 3.29: KV1 immunostaining of colonic myenteric ganglia. KV1.1 was largely 
confined to the neuropil. Selected neuronal cell bodies appeared to strongly stain for KV1.2, 1.3 and 1.5 
KV1.1 was also present in the neuropil. KV1.3 stained both cytoplasm and cell nuclei. KV1.4 and KV1.6 
weakly immunostained the neuropil and cell bodies. Scale bar = 10 µm.      
 
 
 
 
  A.W.Hubball 
 
 __________________________________________________________________________________ 
 
129 
  
 
3.3.7 KV1.4 LOCALISATION IN HUMAN GASTRIC MYENTERIC PLEXUS 
 
Following the identification of a unique punctate distribution of KV1.4 in enteric ganglia, 
the distribution of this subunit was further investigated using double-labelling 
immunofluorescent staining in the gastric myenteric plexus.    
 
KV1.4 immunofluorescent staining 
In the same manner as that observed with DAB immunohistochemistry, tissue 
immunofluorescently stained for KV1.4 exhibited multiple fine puncta throughout 
ganglia, often clustered around the ganglion cell bodies and ganglia periphery. 
Immunofluorescent staining revealed more KV1.4 containing structures than the DAB 
method, which, in addition to simple puncta also defined small vesicular structures 
(Figure 3.30).  
 
Neurofilament and KV1.4 
Neurofilament immunostaining was dense throughout the myenteric plexus, identifying 
axons and some cell bodies of myenteric ganglia. Where axons were cut transversely, NF 
staining appeared punctuate, although as larger patches than KV1.4 puncta. KV1.4 
immunoreactivity was often closely associated with NF and occasionally localised to the 
periphery of NF-positive structures suggesting this subunit may be localised to a 
subpopulation of axons (Figure 3.30).  
 
Synaptophysin and KV1.4 
Synaptophysin immunoreactivity was present throughout ganglia, concentrated at ganglia 
peripheries and surrounding cell bodies. Double-labelling with anti-KV1.4 revealed 
frequent but not universal overlap with KV1.4 puncta, suggesting channels are located at a 
subpopulation of synaptic terminals (Figure 3.30).  
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Figure 3.30: Co-localisation of KV1.4 and neuronal markers in the gastric myenteric 
plexus. KV1.4 exhibited punctate distribution throughout myenteric ganglia and also occasional structures 
which appeared vesicular. Left column: NF immunostaining revealed multiple large puncta within ganglia. 
Occasional overlap was seen between KV1.4 and NF puncta (inset), suggesting localisation to a 
subpopulation of axons and / or dendrites. Right column: Synaptophysin immunoreactivity was also 
punctate, surrounding cell bodies, and also defined larger, branching areas, presumably representing the 
divergence of axonal terminals. KV1.4 and synaptophysin immunostaining frequently overlapped (inset), 
suggesting localisation to a subpopulation of synaptic terminals. Syp = synaptophysin, NF = neurofilament. 
Scale bar = 20 µm.  
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DISCUSSION 
 
 
 
 
 
 
4.1 ORIGINAL PROJECT AIMS 
 
4. To investigate the presence of autoantibodies directed to enteric ion channels in 
patients with neuromuscular disorders of the gut leading to severe dysmotility. 
 
5. To investigate whether autoantibodies (if present) are pathogenic. 
 
6. To further elucidate the profile of expressed ion channels in the human enteric  
neuromusculature. 
 
4.2 SUMMARY OF MAIN RESULTS 
 
The main results of each section of this thesis will be highlighted and discussed in 
relation to existing studies relevant to this field.  
  
Finding 1: Humoral autoimmunity against currently recognised neuronal antigens 
is not a common cause of primary GINMD  
 
The presence of circulating autoantibodies against a number of neuronal antigens was 
determined in 21 patients with primary achalasia and 27 patients with severe intestinal 
dysmotility (SID) using well validated radioimmunoprecipitation assays. The targets of 
interest were voltage- and ligand-gated ion channels and a neuronal enzyme which are 
4 
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known antigens of pathogenic autoantibodies in autoimmune peripheral and central 
neurological diseases. These were group 1 voltage-gated potassium channels (VGKC / 
KV1; acquired neuromyotonia, and limbic encephalitis), voltage-gated calcium channels 
(VGCC; Lambert-Eaton myasthenic syndrome), ganglionic α3 nicotinic acetylcholine 
receptors (α3 nAChR; autoimmune autonomic neuropathy) and glutamic acid 
decarboxylase (GAD; epilepsy and cerebellar ataxia). Sera from patients with SID were 
also screened for the presence of anti-neuronal antibodies (ANAs) which are frequently 
present in dysmotility secondary to neoplasia. All patients were negative for anti-channel 
and anti-neuronal antibodies.    
 
Study limitations 
It is possible the negativity of our screening could be due to inadequate assay sensitivity 
or specificity. This is unlikely as the radioimmunoprecipitation assays employed are well-
validated (Apiwattanakul et al. 2010) and are routinely used in clinical diagnosis. 
Methodological error is also an unlikely cause of our negative findings as disease control 
samples included in each assay were consistently positive in the expected titre ranges and 
each assay was repeated at least twice to confirm results. It is more likely that the 
converse is true, i.e. the approach taken was too specific and that we might, with 
hindsight, have used a broader although less specific screening method before embarking 
on the detailed assays used (see below). Thus, a limitation of our study was the small 
number of targets screened for. We included antigens which are proven pathogenic 
targets in peripheral neuromuscular and central nervous system (CNS) diseases, 
autoantibodies against which have also been previously identified in patients with a 
secondary GINMD, particularly in association with cancer, and in small numbers of 
patients with a primary GINMD. Although we included almost all of these antigens, due 
to time constraints, some autoantibodies were not screened. These included N-type 
VGCCs, which have been found in primary achalasia, delayed gastric emptying and slow 
transit constipation (Dhamija et al. 2008; Kraichely et al. 2009). It is important to point 
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out that the number of targets for autoantibodies is continually growing, an example 
being previously ‘seronegative’ cases of myasthenia gravis now recognised as positive 
for autoantibodies against a muscle-specific receptor tyrosine kinase (MuSK) (Hoch et al. 
2001; Wolfe et al. 2008). The number of assays available is far behind the number of 
potential targets, being limited, in the case of radioimmunoprecipitation assays, by the 
availability of specific toxins to label the channel of interest.  
 
A screening tool which has been used extensively in the investigation of humoral 
autoimmunity in achalasia is indirect immunofluorescent staining of the target tissue 
using patient serum (Storch et al. 1995; Verne et al. 1997; Moses et al. 2003). Whilst a 
positive result does not provide limited information regarding the specific autoantigen, it 
is a simple means by which evidence for or against ‘anti-gut’ autoantibodies can be 
gathered before proceeding to more complex assays to determine the antigen identity. An 
advantage of this method is that the specificity of the IgG for the gut and gut region may 
be determined. However, caution should be applied in interpreting results. False-positive 
results could arise due to non-specific binding, which without a specific antigen in mind 
is difficult to control for. False-negative results may occur as consequence variable 
antigen availability following tissue processing and due to temporal or sub-regional 
variation in antigen expression. There is also a precedent in the study of achalasia for 
HLA-typing. Certain alleles have been shown to be significantly associated with 
achalasia and also in this regard with the presence of anti-neuronal antibodies (Ruiz-de-
Leon et al. 2002), although a correlation with antibodies may not be true for every 
population (Latiano et al. 2006). Nevertheless, HLA-typing of our achalasia patients may 
have allowed us to better select those in whom the presence of anti-neuronal antibodies is 
more likely. Identification of a specific HLA allelic association in pseudo-obstruction and 
enteric dysmotility would lend further support to an autoimmune mechanism, but to date 
there is no precedent for this.    
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Significance and interpretations 
Primary GINMD are relatively rare disorders and findings of anti-neuronal or anti-
channel autoantibodies have previously been restricted to case-reports or small cohorts. 
The number of cases screened in our study (21 achalasia and 27 SID) represents one of 
the largest cohorts of primary GINMD studied in this manner to date. A similar study 
(Dhamija et al. 2008) screened 29 patients with GINMD affecting one or more levels of 
the gut. This study was designed to investigate the profile of autoantibodies useful in the 
diagnosis of suspected ‘autoimmune gastrointestinal dysmotility’ (AGID) as all patients 
had been selected due to the proven existence of one or more autoantibody. AGID 
represents a group of patients who have a limited form of dysautonomia with prominent 
GI symptoms of hyper- or hypo-motility and one or more autoantibodies against cell-
surface cation channels and includes GI dysmotility secondary to neoplasia, diabetes 
mellitus and hypothyroidism. It may also occur idiopathically as a manifestation of 
autoimmune autonomic neuropathies (Lennon et al. 1991; Smith et al. 1997; Vernino et 
al. 2000). Although the study by Dhamija et al.  screened 29 cases, only 8 of these could 
be considered as primary GINMD, the others having neoplasia and / or other disease. 
Anti-P/Q-type VGCC antibodies were found in a case of primary achalasia, anti-N-type 
VGCC in a patient with slow small intestinal transit, anti-muscle nAChR in another case 
of primary achalasia, anti-ganglionic α3 nAChR in two patients with delayed gastric 
emptying and in a patient with delayed small intestinal and colonic transit, who also had 
anti-VGKC antibodies, and finally anti-VGKC antibodies in a patient with delayed 
colonic transit. Whilst useful in defining which autoantibodies are indicative of AGID, 
the selectivity bias and heterogeneity of findings means that the results of this study 
cannot be generalised to unexplained GINMD. All of our patients were selected on the 
basis of a confirmed primary GINMD and had not previously been investigated for anti-
channel autoimmunity. All patients with SID were subsequently confirmed to be negative 
for anti-neuronal antibodies (ANAs) commonly associated with neoplasia (anti-Hu, Yo 
and Ri). In light of the results of Dhamija et al. it is surprising that none of our patients 
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had detectable autoantibodies. An important reason for this could be the chronicity of the 
disorders in our patient groups. Dhamija et al. do not provide information regarding 
symptom duration in their patients, however the median duration of follow-up was only 
25 months (range 2-127). Two studies have previously screened unselected patients with 
primary GI dysmotility. The first of these detected high titres of anti-VGKC antibodies in 
two of eleven patients with colonic slow transit constipation, one gave a 6 year history, 
the other had had symptoms for only 1 year (Knowles et al. 2002). The second study 
screened 33 patients. The median duration of dysmotility symptoms for this group was 18 
years (range 5-60). Two patients with a 9 and 12 year history of diarrhoea-predominant 
IBS were seropositive for anti-VGKC and anti- α3 nAChR antibodies respectively. In 
both of these cases a full-thickness jejuna biopsy revealed an inflammatory neuropathic 
process.  Interestingly, none of 4 patients with enteric dysmotility, 8 patients with 
intestinal pseudo-obstruction and 9 patients with slow transit constipation had detectable 
autoantibodies (Tornblom et al. 2007). The median duration of symptoms of the SID 
patients of our study, 10 years (range 3-40 years) was similar to that of Tornblom et al.  It 
is possible then that autoantibodies in primary GINMD are an early phenomenon which 
subsequently resolve but lead to chronic disease due to activation of lymphocytes, 
macrophages/killer cells producing permanent damage. In practise this is difficult to 
study as the best characterised autoimmune disorders are treated by immunomodulation. 
However, there is further evidence in support of this. Anti-VGKC antibodies have 
retrospectively been observed to be monophasic with levels falling over time without 
immunomodulatory therapy (Buckley et al. 2001). Anti-VGKC, -GAD and - N-methyl-
D-aspartate receptor (NMDAR) antibodies associated with non-paraneoplastic limbic 
encephalitis appear to be highest during the early stage of disease and early treatments 
appear to produce optimal clinical outcomes (Irani et al. 2010) Rassmussen’s encephalitis 
which has been associated with anti-glutamate receptor antibodies also responds well to 
immunotherapy in the early course of the disease, but as the disease progresses this is less 
effective (Bethan Lang, personal correspondence). Furthermore, in anti-GAD antibody 
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associated epilepsy, antibody titres are much higher at presentation than seen in chronic 
disease (Bethan Lang, unpublished observation).       
Regarding primary achalasia, a study of a large group (70) of unselected patients revealed 
a remarkably high prevalence of anti-neuronal antibodies, 25.7% having one or more of 
anti-skeletal muscle AChR or striational, neuronal voltage-gated cation channel 
(potassium channel or N-type calcium channel) or GAD antibodies. In addition, 21% had 
anti-GAD antibodies. The mean number of years from diagnosis to sera collection in this 
group was only 5 years (Kraichely et al. 2009). The mean number of years from 
diagnosis to sera collection in our achalasia group was 6 years. However, this does not 
necessarily correlate with disease duration as some of our patients, even at first 
investigation, were noted to have a manometric pattern characteristic of established 
achalasia. Data regarding stage of disease at diagnosis in the study of Kraichely et al. are 
not provided. It should be mentioned that none of the positive anti-GAD sera, which were 
detected using an indirect immunofluorescence assay, were confirmed using the 
radioimmunoprecipitation assay to confirm specificity (Saiz et al. 2008).  
 
Interpreting our results in the light of these previous studies we may tentatively speculate 
that the failure to detect anti-channel autoantibodies in our GINMD patients may be due 
to chronicity where antibodies which may present in early disease ‘burn-out’, leaving a 
more chronic, cell-mediated immune process. To test this hypothesis it would be 
desirable to study patients in the early stages of disease and follow-up with a longitudinal 
study. Dhamija et al. report a moderate to dramatic improvement in gastrointestinal 
symptoms in 4 out of 4 seropositive patients treated with immunotherapy.  
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Finding 2: Autoantibodies which directly bind the M2 muscarinic acetylcholine 
receptor were not detected in chagasic patients.  
 
A large body of data from in vitro pharmacological experiments supports the existence of 
circulating autoantibodies in the sera of patients with Chagas’ disease and GI 
involvement, which, in GI smooth muscle, produce effects mediated by activation of M2 
mAChRs. However, the only evidence for direct binding to the receptor previously came 
from ELISA assays which employ a synthetic peptide representing only a part of the 
receptor. We designed a cell-based assay to screen for the presence of anti-M2 mAChR 
autoantibodies to clarify whether such autoantibodies are able to directly bind to the 
receptor. We did not detect IgG in the sera of 57 chagasic patients capable of directly 
binding the M2 mAChR. Thus anti-M2 mAChR autoantibodies, if present in this cohort of 
patients, do not exert their effects by direct receptor binding.    
 
 
Summary box: Humoral autoimmunity in primary GINMD 
 
Previous knowledge 
• Non-specific anti-neuronal autoantibodies present in significant number 
• Anti-channel (VGKC, VGCC, nAChR) antibodies detected in a few cases and may represent a 
limited form of dysautonomia (AGID) 
• Anti-GAD present in significant number of primary achalasia 
 
This study 
• Anti-channel antibodies not associated with chronic primary GINMD 
• Anti-GAD antibodies not detected in neurologically significant titres in primary achalasia 
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Study limitations 
The negativity of our assay could be explained by the fact it was a newly designed assay 
and was not sufficiently optimised to detect autoantibodies. Control measures were taken 
however to ensure viability. These controls have previously been employed in the 
successful optimisation of other cell-based assays used for this purpose. Firstly, 
transfection efficiency was checked using the well validated method of GFP transfection 
to produce auto-fluorescent cells (Modarressi et al. 2004). This confirmed our method of 
transfection was robust. Secondly, successful expression of M2 mAChR was confirmed 
by immunofluorescently staining transfected cells with a commercial anti-M2 mAChR 
monoclonal antibody (Leite et al. 2008). It should be noted that only commercial 
antibodies raised against intracellular epitopes of the receptor were available at this time 
and as such it was necessary to permeabilise the transfected cells prior to antibody 
incubation. Whilst not directly comparable to subsequent staining using patient serum on 
intact cell membranes, this control demonstrated that the receptor protein was 
successfully expressed by transfected cells and the pattern of staining, despite the 
permeabilisation process appeared to delineate a circumscribed cell border, suggesting 
the receptor was reaching the cell membrane. With these conditions satisfied one may 
feel confident in using the assay to screen sera for antibodies against the target in 
question. Indeed, this assay is increasingly becoming the assay of choice in detecting 
autoantibodies as it has been shown to be more sensitive than traditional 
radioimmunoprecipitation assays and is closer to the in vivo conditions where 
autoantibodies meet membrane bound, fully processed channels and receptors (Leite et 
al. 2008).   
 
Significance and interpretations 
The sufficiency of ELISA using a short, linear portion of a receptor to detect 
autoantibodies has been called into question (Vincent et al. 2010). Indeed this issue is 
highlighted by a similar study of GI dysmotility secondary to scleroderma (Goldblatt et 
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al. 2002). Circulating autoantibodies which modify in vitro events associated with 
muscarinic antagonism have been detected in such patients, and have been postulated, as 
a result of indirect pharmacological evidence, to exert a functional effect, via the M3 
mAChR. Furthermore, autoantibodies in the sera of patients with scleroderma and GI 
involvement have been shown to bind a synthetic M3 mAChR peptide in ELISA. 
However, the authors of the in vitro study note in their discussion that functional these 
autoantibodies failed to bind mammalian cells transfected with the M3 mAChR calling 
into question direct interaction with the receptor itself. Whilst the pharmacological 
evidence for M2 mAChR activation in the presence of chagasic autoantibodies is stronger 
than for M3 mAChR antagonism in scleroderma, the results of our cell-based assay 
suggest that anti-muscarinic autoantibodies capable of directly binding the M2 mAChR 
are not always present in a significant number of patients with Chagas’ disease and GI 
involvement, as currently claimed. 
 
An important consideration in interpreting our results is the origin of our cohort of serum 
samples which came from individuals living in the north-east of Brazil. All previous 
studies relevant to this subject have examined the effects of sera collected from patients 
residing in Argentina (specifically in the Beunos Aires area). This is significant as 
clinical manifestations of chronic Chagas’ disease are distinct in different geographical 
regions, megaviscera being more prominent in the southern countries of South America. 
It is now known that Trypanosoma cruzi (T.cruzi) is a heterogeneous organism, 
consisting of several strains (Miles et al. 2009), and whilst host factors must also play a 
role, differences in infecting genotypes appear to govern chronic disease sequalae (Figure 
4.1). It is then likely that the patients in the present cohort were infected by a 
genotypically different organism to those studied previously, and although patients 
studied here and previously had GI involvement, the failure to detect anti-M2 mAChR 
autoantibodies in our cohort may be due to a different immune response which is 
consequent of a dissimilar infective event. To help answer the question of whether the 
  PhD Thesis 2010 
 
__________________________________________________________________________________ 
 
140 
 
present cohort have autoantibodies which activate muscarinic pathways without binding 
receptors directly or have another mechanism of action, we proceeded to investigate the 
functional effects of the sera from our cohort on GI smooth muscle.     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.1: Geographical distributions of T.cruzi lineages (Tc I – VI). Sera analysed in 
this thesis were taken from patients residing in and around the city of Fortaleza, in the north-east of Brazil 
(indicated in the upper left panel). It is possible that individuals in this cohort were infected with any of 
four strains of T.cruzi (Tc I – IV), which may be transmitted via domestic or sylvatic triatomines 
(haematophagous insect vectors, a subfamily of the genus Reduvius). Adapted by permission from 
Macmillan Publishers Ltd: Nature (465, S8-9), copyright (2010).          
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Finding 3: Circulating factors present in patients with Chagas’ disease modulate 
colonic smooth muscle contractility through non-cholinergic / non-nitrergic 
pathways 
 
A number of studies have implicated chagasic IgG in activation of the M2 muscarinic 
cholinergic signalling pathway with subsequent end organ effects (Goin et al. 1994; Goin 
et al. 1994; Goin et al. 1997; Sterin-Borda et al. 1997; Hernandez et al. 2008; Ganzinelli 
et al. 2009) including an increase in GI smooth muscle tone (Goin et al. 1999; Sterin-
Borda et al. 2001). It should be noted that the majority of these studies originate from a 
single research group, and all studies have used the same ELISA to detect anti-M2 
mAChR autoantibodies. Regarding the investigation of serum effects on colonic smooth 
muscle tone, in vitro experiments have used muscle taken from either normal rat colon or 
human chagasic megacolon samples, reporting very similar responses to incubation with 
chagasic serum in both tissues. This result is curious as inter-species variability in colonic 
muscarinic receptor profile appears to exist (Gomez et al. 1992) and chagasic megacolon 
is characterised by extensive damage to the neuromuscular apparatus including 
 
Summary box: Anti-muscarinic humoral autoimmunity in Chagas’ disease 
 
Previous knowledge 
• Autoantibodies present in high proportion of individuals with Chagas’ disease are capable of 
modulating muscarinic GI neuromuscular activity 
• Autoantibodies bind synthetic M2 peptide in ELISA suggesting direct receptor modulation 
 
This study 
• Autoantibodies capable of directly binding M2 mAChR expressed by mammalian cells were not 
detected in patients with Chagas’ disease suggesting an alternative mechanism of receptor 
activation or absence of anti-M2 mAChR antibodies 
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significant inflammatory enteric neuronal degeneration, muscular inflammatory cell 
infiltration and muscular fibrosis (Corbett et al. 2001; da Silveira et al. 2007). Our cell-
based assay designed to detect anti-M2 mAChR IgG failed to detect these autoantibodies 
in a cohort of Chagas’ disease patients. We therefore undertook the investigation of the 
effect of chagasic serum on colonic smooth muscle taken from patients without Chagas’ 
disease.  
 
The overall observed effect was a decrease in baseline smooth muscle tension. This effect 
was maintained in the presence of the muscarinic antagonist atropine and the nitric oxide 
synthase inhibitor L-NAME, demonstrating that it was not dependent on muscarinic 
cholinergic receptor activation or nitric oxide production. This finding represents a novel 
chagasic serum effect on colonic smooth muscle contractility.  
 
Study limitations 
The most important limitation of our findings is the fact that we have investigated the 
effect of serum from only three patients with chagasic GI disease. For this reason we 
cannot generalise this finding. Work is on-going to characterise more samples. We did 
however investigate the effects of disease control serum (from patients with Chagas’ 
disease but no GI involvement) and community healthy control serum (from other 
individuals living in north-eastern Brazil without Chagas’ disease), neither of which 
showed a comparable effect on smooth muscle tone. It would have also been desirable to 
purify IgG from the sera to determine if this effect was antibody mediated or due to other 
circulating factors. However, previous work has shown almost identical effects of whole 
serum and purified IgG on cholinergic muscle responses (Goin et al. 1994). As this was 
only a preliminary study, we used a single concentration of sera. Work is also on-going to 
determine a concentration-dependent response which would add weight to the evidence 
for a direct pathogenic role.      
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Significance and interpretations 
Previous studies reported that the addition of IgG autoantibodies from patients with 
Chagas’ disease to in vitro preparations of GI smooth muscle resulted in M2 mAChR 
agonism. Initially the IgG were found to non-competitively replace the binding of the 
cholinergic agonist carbachol, producing partial receptor agonism in an allosteric manner 
(resulting from binding at a site other than the primary, orthosteric binding site). This 
effect was also blocked by the muscarinic antagonist atropine. More recent studies report 
that the same autoantibodies may mediate their effect by positive modulation of 
acetylcholine activity at the M2 mAChR (Hernandez et al. 2008). Whatever the proposed 
mechanism of action, with the exception of the dominant excitatory activity in the lower 
oesophageal sphincter in achalasia, the pathologic relevance of this effect in chagasic GI 
disease, which is characterised by inflammatory neuro-degeneration and pathological 
dilatation, remains unclear.      
 
Our findings are novel in three respects. Firstly, we have shown an effect of chagasic sera 
on non-infected human colon. Secondly, we have identified a relaxant effect of chagasic 
sera on colonic smooth muscle which may represent early stages in the development of a 
megacolon. Thirdly, we have shown that this effect is not dependent on muscarinic 
cholinergic receptor activation.  
 
Previous studies only looked at smooth muscle under a resting tension which does not 
provide information regarding whether activity is mediated by an alteration in neuronal or 
muscular activity. We examined the effect of chagasic sera on GI smooth muscle under 
electrical field stimulation (EFS) which allows neuronally mediated changes in muscle 
tension to be observed whilst also monitoring the changes in baseline muscle tone. We 
found that muscle responses during EFS were unchanged following addition of chagasic 
sera suggesting that the reduction in tone was not secondary to an alteration in neuronal 
activity. This evidence was strengthened by the observation that the effect was not 
  PhD Thesis 2010 
 
__________________________________________________________________________________ 
 
144 
 
prevented by pre-incubation of muscle preparations with the voltage-gated sodium 
channel blocker tetrodotoxin, which prevents action potential generation (Narahashi et al. 
1960; Kao 1964). Furthermore, we found that the effect was not dependent on production 
of nitric oxide, the principle neurotransmitter of inhibitory motor neurons, or mAChR 
activation. The decrease in baseline muscle tension is therefore likely to be the result of a 
direct effect on the muscle. A candidate target for mediation of such an effect is the L-
type voltage-gated calcium channel (VGCC), which is the predominant channel 
responsible for calcium entry into intestinal smooth muscle cells necessary for 
contraction (Farrugia et al. 1995; Liu et al. 2001). The L-type VGCC antagonist, 
nifedipine, has been shown to reduce the basal tone of human colonic circular muscle in 
vitro (Ghia et al. 2004). Furthermore, in isolated cardiac muscle cells, L-type Ca2+ 
current inhibition was observed in the presence of chagasic antibodies (Hernandez et al. 
2003). Smooth muscle relaxation in response to serum factors may represent an early 
stage in the development of dysmotility which may progress to megacolon.  
 
Finding 4: Humoral anti-neuronal autoimmunity is present in some individuals with 
Chagas’ disease 
 
Anti-channel autoantibodies were identified in patients with Chagas’ disease. Anti-
VGCC antibodies were identified in one of 57 patients, although this patient had no 
secondary disease manifestations, antibody titre was comparable to LEMS disease 
control. Eight chagasic patients were found to have moderate titres of circulating anti-
VGKC antibodies. Of these, five had no chronic disease sequalae, one had achalasia and 
heart disease, one had achalasia only and one had colonic dysfunction. Low titre anti-
GAD antibodies were found in one patient with cardiac complications, although as 
previously stated, these are unlikely to have neurological significance  
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Significance and interpretations 
The finding of anti-VGCC and VGKC antibodies in Chagas’ disease was unexpected and 
is the first time this has been described. Whilst the presence of these autoantibodies may 
occasionally be found in individuals with no overt neurological disease, the presence of 
anti-VGKC antibodies in 8 (13.6%) of chagasic individuals is notable. The majority of 
these cases (5/8) at the time of venepuncture had no sequalae of their infection. Of 
interest to this thesis the remaining three patients had GI diseae of oesophagus and / or 
colon. In the classical anti-VGKC-mediated diseases, such as neuromyotonia, GI features 
have not been especially reported (Isaacs 1961; Benatar 2000). However, anti-VGKC 
disorders are being increasingly recognised and three previous studies have described 
VGKC antibodies in relation to gut dysfunction. The first associated anti-VGKC 
autoantibodies with slow transit constipation arising de novo in adults (an uncommon 
presentation of a disorder which usually presents in childhood) (Knowles et al. 2002). 
Another describes VGKC antibodies occurring in a case of paraneoplastic (thymoma) 
associated intestinal pseudo-obstruction. Importantly, improvement in gastrointestinal 
symptoms following plasma exchange correlated with a decrease in VGKC antibody 
levels, suggesting for the first time a real pathological significance (Viallard et al. 2005). 
A study of 80 patients who were VGKC autoantibody positive found gastrointestinal 
symptoms in at least 12 (17%) (the true figure may have been higher because some 
medical records studied retrospectively were incomplete) (Rueff et al. 2008). All patients 
included were identified on the basis of previous investigation for a suspected 
autoimmune neurological disorder, possibly paraneoplastic. It is not known whether any 
of these patients were initially referred because of isolated GI symptoms and what 
proportion were subsequently found to have an underlying neoplasm. However, this 
study further establishes an association between VGKC antibodies and GI symptoms.  
 
Damage to the enteric nervous system is an established feature of chagasic GI disorders, 
and is characterised by neuronal degeneration and loss, connective tissue fibrosis, 
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inflammatory cell infiltration, decreased numbers of interstial cells of Cajal and 
decreased enteric glia (Koberle 1968; Hagger et al. 2000; Iantorno et al. 2007). The 
production of autoantibodies in Chagas’ disease has previously been attributed to 
molecular mimicry, where a cross-reactive immune response to a parasitic epitope and 
native antigen occurs, or due to a secondary immune response to tissue damage where 
‘cryptic’ antigens which are normally hidden from the immune system are revealed 
(Kierszenbaum 2005). Our findings of anti-VGKC autoantibodies in patients with 
Chagas’ disease, which is known to specifically lead to enteric neuronal pathology, 
together with our findings of KV1 channel expression in the gut would fit the hypothesis 
that these autoantibodies may occur as a result of tissue damage exposing antigens that 
are normally hidden to the immune system. In support of this was the identification of 
anti-VGKC antibodies in a patient with diarrhoea-predominant irritable bowel syndrome 
(D-IBS) which had begun after infectious enteritis. This patient was also found to have 
inflammatory cell infiltration (lymphocytic ganglionitis) and signs of enteric neuropathy 
(Tornblom et al. 2007). Against this is the fact that the majority of the patients in which 
we detected anti-KV1 channel antibodies had no disease sequalae, and others had only 
heart disease. However, even those without overt secondary disease would almost 
certainly have some parasite induced tissue damage that was perhaps at that time sub 
clinical (see Finding 5 for further discussion).  
 
 
Summary box: Anti-channel humoral autoimmunity in Chagas’ disease 
 
Previous knowledge 
• No previous description of anti-channel autoantibodies in Chagas’ disease  
 
This study 
• 8/59 (13.6%) patients positive for anti-VGKC autoantibodies but variable clinical phenotype  
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Finding 5: Shaker-related voltage-gated potassium channels are expressed by the 
human gastrointestinal neuromuscular apparatus. 
 
Due to the increasing evidence of anti-VGKC autoimmunity in certain types of GI 
dysfunction we set out to investigate the presence of these channels in the GI 
neuromuscular apparatus. The confirmation of their expression in the human GI tract has 
potential physiological significance and in the context of this and other studies, 
pathogenic implications.    
 
Due to the specificity of α-dendrotoxin, anti-VGKC radioimmunoprecipitation assays 
screen for autoantibodies against KV1.1, 1.2 and 1.6 channel subunits (Stuhmer et al. 
1989; Grissmer et al. 1994). However, due to the assembly of heteromultimeric channels 
(MacKinnon 1991; Parcej et al. 1992)  and the heterogeny of diseases associated with 
anti-VGKC autoimmunity (Rueff et al. 2008), it is likely that other members of this 
subfamily also have pathogenic importance. Therefore, we investigated the expression of 
six members of the KV1 subfamily (KV1.1-1.6) in all layers of the human oesophagus and 
gastrointestinal tract immunohistochemically. The results showed that KV1 channels are 
abundant throughout the human gastrointestinal tract and are expressed by epithelial cells 
and enteric neurons of the myenteric and submucosal plexi in a regionally specific 
pattern.     
 
Epithelial KV1 channel subunit expression varied according to the region studied. 
Oesophageal squamous epithelial cells were not immunopositive for any of the six KV1 
channel subunit. In gastric epithelium KV1 expression was restricted to chief cells which 
are responsible for production and secretion of pepsinogen. Jejunal, ileal and colonic 
enterocytes expressed KV1 subunits to varying degrees, the concentration of channels 
appearing to be greatest in mature enterocytes towards villi tips and colonic surface 
epithelium with relatively little expression in the crypts. In addition, cells identified by 
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H&E appearance as enteroendocrine expressed a high abundance of channels in their 
basal aspect.  
 
Within the enteric nervous system each KV1 channel subunit exhibited a stereotypical 
pattern of distribution, localising specifically to neuronal cell bodies and / or ganglia 
neuropil, and these patterns were largely consistent throughout the gut. Of the six 
subunits studied, KV1.4 was especially notable for its distinctive punctate distribution 
within enteric ganglia and this was further investigated using double-labelled 
immunofluorescent staining (see Finding 6).      
 
Study limitations 
This study was dependent on antibody specificity and, as with any immunohistochemical 
investigation, results could be due to non-specific tissue binding. This possibility is 
unlikely as we first confirmed that our antibodies stained cerebellar tissue in previously 
described patterns (Veh et al. 1995; Chung et al. 2001). These measures confirmed that 
the antibodies used were specific for these channels. The expression of cell surface 
proteins may be temporal, altering according to internal or external circumstances, and 
may also differ between individuals. It is therefore necessary to confirm findings in a 
number of different cases in order to describe ‘normality’. For each gut region we studied 
KV1 channel distribution in at least five different individuals and found our results to be 
consistent. A limitation of this however was the source of tissue samples. The availability 
of disease-free tissue is, for obvious reasons, limited. The majority of tissue was obtained 
from cancer resection margins. Whilst all sections were histologically normal, with no 
evidence of cancer or inflammation, the possibility that channel expression is altered 
secondary to such disease processes cannot be ruled out. However, the difficulties 
inherent in studying normal human microanatomy mean that these results represent a 
significant step forward in mapping ion channel distribution in the human gut.   
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Significance and interpretations 
VGKC channels are involved in numerous processes in both excitable and non-excitable 
cells, but are best known in relation to setting resting membrane potentials, regulating 
cellular excitability and synaptic transmission. The KV1 or Shaker-related subfamily is 
the most extensively studied and the distribution of these channels in the CNS and 
periphery in relation to their role in normal function and disease states is fairly well 
elucidated (Beckh et al. 1990; Veh et al. 1995; Coleman et al. 1999; Chung et al. 2001; 
Glazebrook et al. 2002). In comparison, knowledge regarding KV1 channel expression in 
the GI tract was limited. Studies of small mammals had begun to identify KV (including 
KV1) currents associated with epithelial cell maturation, migration and nutrient 
absorption (McDaniel et al. 2001; Rao et al. 2002). Cells from the IEC-6 cell line derived 
from rat intestinal enterocytes express KV1.1, 1.2, 1.4, 1.5 and 1.6 mRNA (McDaniel et 
al. 2001). Furthermore, as these cells migrate and differentiate towards a mature 
phenotype the expression of KV1.1 and 1.5 increases (Rao et al. 2002). Our finding of 
KV1 channel expression in mature, differentiated enterocytes of the human GI tract is in 
agreement with these findings and further suggests that increased KV1 channel expression 
occurs with human enterocyte maturation. 
 
Modulation of enteric motor nerve excitability (Suarez-Kurtz et al. 1999; Vianna-Jorge et 
al. 2000) and generation of smooth muscle ‘slow-wave’ contractions (Thornbury et al. 
1992; Thornbury et al. 1992; Carl 1995) have been suggested to involve KV1 channel 
activity. Previous work has also elucidated KV current contributions in extrinsic sensory 
neurons innervating the oesophagus, stomach, ileum and colon (Yoshimura et al. 1996; 
Glazebrook et al. 2002; Dang et al. 2004). Examining the intrinsic innervation of the gut, 
Hatton and co-workers reported KV1.1 expression in murine, guinea pig and canine 
myenteric ganglia and ICC (Hatton et al. 2001). However, others describe murine KV1.1 
expression limited to enteroglial cells, with no expression detected in neurons or ICC 
(Costagliola et al. 2009). Enteroglial cells and enteric neurons may also express KV1.2 
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channel subunits (Costagliola et al. 2009). These points have yet to be resolved. In the 
human gut we did not find evidence of KV1 channel protein expression in enteroglial 
cells or cells resembling ICC. Other currents have been shown to contribute to the 
activity of these cells, for example ether-a-go-go-related (ERG) K channel and VGCCs in 
ICC (Huizinga et al. 2004). Our study suggests that KV1 channels are widely expressed 
by enteric neurons of both the myenteric and submucosal plexi and that they have an 
overlapping yet differential subcellular distribution. This would be expected from 
heteromultimeric assembly and has been previously shown in the CNS, where KV1 
channel subunits have overlapping but also unique patterns of subcellular distribution, 
depending on the region and also neuronal subtype studied. This produces a highly 
complex arrangement, presumably mirroring functional diversity (Wang et al. 1994; Veh 
et al. 1995). In contrast to the CNS, KV1 subunits in the human ENS appear to be 
stereotypically directed to subcellular locations and this was consistent between 
submucosal and myenteric neurons and throughout the gut (with the exception of some 
subunits in the oesophagus and colon). As the specific expression of KV1 subunits in 
subcellular compartments would help determine the unique firing pattern and thus 
function of a neuron it is perhaps not surprising that CNS neurons, which are highly 
diverse, do not exhibit stereotypical patterns of channel expression. Whilst the gut has a 
large population of neurons (comparable to that of the spinal cord) (Furness 2000), the 
number of functions and thus complexity is considerably less than that of the CNS. 
Whilst further studies of KV1 expression by specific neuronal subtypes are required, the 
stereotypical distribution of KV1 channel subunits in the human ENS is at least 
suggestive of specific functionality.  
 
In canine colonic smooth muscle molecular studies have identified KV1.2, KV1.4, KV1.5 
and KV1.6 mRNA (Hart et al. 1993; Epperson et al. 1999). Murine colonic smooth 
muscle cells express transcripts encoding KV1.6, but lack KV1.4 suggesting there may be 
inter-species variability (Koh et al. 1999). A single study has previously identified KV1 
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channel subunits in the human neuromuscular apparatus. Recordings from isolated 
human oesophageal smooth muscle cells have revealed a voltage-dependent potassium 
current and KV1.2 and 1.5 mRNA expression in both longitudinal and circular muscle 
layers were detected (the expression of other KV channels was not investigated). 
Functionally, pharmacological blockade of the muscular voltage-gated potassium current 
caused an increase in resting tension, suggesting a role in regulation of muscular 
contraction. However, the agent used in this study (high concentration 4-aminopyridine) 
non-specifically blocks a number of potassium channel types and so the effect cannot be 
attributed to KV1 channels alone (Wade et al. 1999). Our results demonstrate human GI 
smooth muscle to be largely devoid of KV1 channel expression further suggesting inter-
species variability in GI KV1 channel expression. The exception to this and in agreement 
with the findings of Wade et al. was the finding of KV1.5 expression in oesophageal 
myocytes. The expression of KV1.5 in GI smooth muscle was peculiar to the oesophagus. 
Here, channel expression was mainly, although not exclusively, perinuclear in 
distribution. In some myocytes, KV1.5 was also present in the cell cytoplasm. 
 
The observation that KV1.5 is expressed by oesophageal smooth muscle is interesting in 
relation to our finding of anti-VGKC autoantibodies in patients with Chagas’ disease (see 
Finding 4). Chronic Chagas’ disease primarily affects the heart and the gut, specifically 
regarding the latter, the oesophagus and colon. Why these organs are specifically the 
focus of disease pathology remains unknown. It is known however, that KV1.5 is also 
expressed by human cardiac muscle (Snyders et al. 1993; Wang et al. 1993), where it is 
responsible for the ultra-rapid delayed-rectifier current essential for atrial repolarisation 
(Feng et al. 1997). KV1.5 is therefore a channel subunit common to both the heart and the 
oesophagus. One may tentatively speculate that circulating anti-VGKC autoantibodies, 
which were present in 14% of our cohort and are known to impair KV1 channel function, 
may contribute to chagasic oesophageal and heart disease by impairing KV1.5 channel 
function. In support of this hypothesis is the fact that down-regulation of expression of 
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this channel has been found to be associated with arrhythmia (Van Wagoner et al. 1997; 
Lai et al. 1999; Brundel et al. 2001) which is a common feature of chagasic heart disease 
(Elizari 2002). Due to their function of regulating cellular excitability, impairment of 
KV1.5 oesophageal smooth muscle would be expected to interfere with oesophageal 
contractility, and this may be relevant to the loss of normal peristalsis and failure of 
smooth muscle relaxation characteristic of oesophageal achalasia. We did not observe 
KV1.5 immunostaining in colonic smooth muscle. We did however observe KV1.5 in 
colonic submucosal and myenteric neurons. Whilst these findings are interesting and 
deserve further investigation, the inflammatory fibrotic reaction which damages the 
cardiac muscle and conduction network and the enteric nervous system remains the most 
striking feature of this disease. Not all infected individuals, progress to the chronic, 
symptomatic stage of the disease. About two-thirds of patients remain in an 
asymptomatic ‘indeterminate’ phase and no determinants of progression to the 
symptomatic phase have been identified (Lescure et al. 2010)  As discussed in Finding 4, 
five of the eight patients in which we detected anti-VGKC autoantibodies were 
asymptomatic. It would be of interest to follow these patients to see if they go on to 
develop symptomatic disease, as perhaps in some individuals anti-VGKC autoantibodies 
represent a marker of disease progression, either as a pathological factor, or as a marker 
of more severe tissue damage which reveals these antigens to the immune system. In 
either case, the finding would be of significance in guiding a treatment regime which 
currently lacks definition (Lescure et al. 2010). 
  
Having now demonstrated the presence of KV1 channels throughout the human enteric 
nervous system, the finding of anti-VGKC autoantibodies in patients with primary and 
secondary GINMD (Knowles et al. 2002; Viallard et al. 2005; Tornblom et al. 2007; 
Dhamija et al. 2008) takes on new relevance. Whilst not common, the detection of these 
potentially pathogenic antibodies in patients with GI dysmotility coupled with the 
knowledge that the human enteric nervous system possesses the antigenic targets could in 
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future help guide treatment, particularly in the direction of immunomodulation. The 
reason for GI involvement in a minority of individuals with anti-VGKC antibodies is 
unclear, but as discussed in relation to their detection in patients with Chagas’ disease 
(Finding 4), it is likely that an accompanying event such as infection, or neoplasia 
(Viallard et al. 2005) is necessary. Further investigation of pathogenesis should include a 
comparative study of enteric KV1 channels in disease.       
 
 
 
 
 
 
Summary Box: Enteric KV1 channel protein expression 
 
Previous knowledge 
• KV1.1 identified in murine*, guinea pig and canine myenteric neurons and ICC 
• KV1.1 expressed by murine enteroglia* 
• KV1.2 expressed by murine myenteric neurons and enteroglia 
• KV1 subunits expressed by murine (KV1.6), canine (1.2, 1.4, 1.5, 1.6) and human GI smooth 
muscle (1.2 and 1.5)  
 
This study 
• KV1.1-1.6 expressed in epithelial cells and/or enteric neurons in all gut regions in humans  
• Epithelial expression limited to gastric chief cells, surface enterocytes and enteroendocrine cells 
• Each subunit exhibits a stereotypical subcellular distribution in enteric neurons  
• KV1.4 exhibited a unique punctate distribution in gastric and small bowel ganglia 
• No expression evident in ICC or enteroglia 
• Oesophageal exclusively expresses KV1 channels: KV1.5 
 
*conflicting results regarding KV1.1 distribution in murine myenteric plexus  
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Finding 6: KV1.4 is specifically localised to synaptic and axonal locations in enteric 
ganglia  
 
Of particular interest was the finding of discrete puncta of KV1.4 immunoreactivity in 
ganglia neuropil. KV1.4 containing channels are unique amongst KV1 channels due to 
properties of fast-inactivation followed by a slow recovery from inactivation which 
enable the integration of brief depolarisations over tens of seconds (Pardo et al. 1992; 
Rasmusson et al. 1995). It is therefore of interest to determine the subcellular distribution 
of these channels in relation to neuronal functioning. In the central nervous system, 
particularly the hippocampus, KV1.4 has been localised to axons and nerve terminals 
(Sheng et al. 1993; Cooper et al. 1998). We investigated KV1.4 localisation to enteric 
synapses and axonal segments using double-labeling immunofluorescent staining for 
synaptophysin (a synaptic vesicle glycoprotein) and neurofilament (an intermediate 
filament which is a major component of the axonal cytoskeleton) respectively. In 
common with hippocampal findings we observed areas of KV1.4 and synaptophysin co-
localisation. We also saw occasional overlap of KV1.4 and neurofilament. Taken together 
these findings demonstrate that in the human enteric nervous system KV1.4 is located at 
some pre-synatic termini and a subset of axons, consistent with the hippocampal findings 
(Cooper et al. 1998). The finding of KV1.4 immunoreactivity at synaptic termini suggests 
that KV1.4 may contribute to the process of neurotransmitter release (Sheng et al. 1993). 
Axonal KV1 channels located at or near para-nodal regions are responsible for action 
potential repolarisation (Hodgkin et al. 1952; Stolinski et al. 1981; Chiu et al. 1982; 
Wang et al. 1993). As KV1.4-containing channels inactivate quickly and are slow to 
recover, action potentials propagated along axons bearing KV1.4 broaden (Bean 2007). A 
phenomenon known as activity-dependent spike broadening occurs during high 
frequency stimulation (Berry 1972; Carew et al. 1977) due to cumulative inactivation of 
these channels. When this occurs the number of Ca2+ ions entering the pre-synaptic 
terminal per action potential rises, increasing neurotransmitter release with consequent 
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post-synaptic effects (Ma et al. 1995; Geiger et al. 2000; Bischofberger et al. 2002). The 
finding of this channel in human enteric neurons has potentially important implications 
regarding the temporal coding of enteric neurotransmission and merits further 
investigation.  
 
 
4.3 CONCLUDING REMARKS 
 
Despite increased knowledge regarding the pathophysiology of GINMD, the underlying 
aetiology of these disorders remains largely unknown. Due to phenotypic similarities 
between GINMD and certain neuromuscular disorders of the periphery which are known 
to occur as a result of pathogenic autoantibodies against ion channels, and the previous 
identification of anti-channel autoantibodies in small numbers of patients with GINMD, 
this thesis investigated ion channel expression in the gut and the presence of anti-channel 
autoantibodies in idiopathic and infective examples of GI dysfunction.  
 
 
 
 
 
 
Summary box: Enteric neuronal KV1.4 expression in humans 
 
Previous knowledge 
• KV1.4 expression not previously investigated in enteric nervous system 
 
This study 
• KV1.4 exhibits discrete punctate distribution in enteric ganglia of stomach and small bowel  
• Located at synapses and axonal processes 
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The headline findings are: 
1. Humoral autoimmunity against currently recognised neuronal antigens is not 
commonly associated with chronic primary gastrointestinal neuromuscular 
diseases.  
2. Circulating factors present in patients with Chagas’ disease modulate colonic 
smooth muscle contractility through non-cholinergic / non-nitrergic-dependent 
pathways. 
3. Humoral anti-neuronal autoimmunity, particularly in the form of anti-voltage-
gated potassium channel antibodies, is present in some individuals with Chagas’ 
disease 
4. Shaker-related voltage-gated potassium channels are expressed by the human 
gastrointestinal neuromuscular apparatus 
5. KV1.4 is located in pre-synaptic termini and axons of a subset of enteric neurons  
 
The results presented in this thesis demonstrate that the human enteric neuromusculature 
expresses some of the same ion channels that are targets for autoantibodies in the 
peripheral neuromusculature, but suggest that autoantibodies against these and other 
channels are not commonly detectable in chronic primary GINMDs. To what extent anti-
channel antibodies are present in early GINMD remains to be elucidated but is an 
important question, as if present, early detection and immunomodulatory therapy could in 
theory prevent or limit deterioration in gut function. Certain phenotypes may increase the 
likelihood of finding anti-channel antibodies. Dhamija et al., in their investigation of 
autoimmune gastrointestinal dysmotility conclude: ‘Factors that raise the clinical 
suspicion of AGID were noted in several patients of this report: an antecedent event, 
subacute onset, evidence of multi-level GI dysmotility, co-existing organ-specific 
autoimmune disorder (including subtle autonomic/neurological abnormalities, such as 
postural orthostatism or somatic neuropathy) (Dhamija et al. 2008). A relevant 
antedecent event could provide an antigenic stimulus. This is clear in paraneoplastic 
  A.W.Hubball 
 
 __________________________________________________________________________________ 
 
157 
  
 
cases where a cross-reactive immune response to neural antigens expressed by a tumour 
leads to neuronal dysfunction. In idiopathic cases it is possible that an occult tumour may 
have been eliminated by immune surveillance mechanisms that subsequently generate a 
neurological syndrome (Irani et al. 2010) or even that a tumour may not be detectable 
until much later: anti-NMDAR encephalitis may precede by years the detection of an 
ovarian teratoma ((Iizuka et al. 2008). A preceding infection may also provoke an 
antibody-mediated autoimmune response as demonstrated in patients with Guillain Barré 
syndrome (Willison et al. 2002). Post-infectious IBS associated with altered cell-
mediated immunity is now a commonly recognised phenotype (Gwee 2010) and it is 
interesting that the two patients in whom antibodies (anti-VGKC and – α3 nAChR) were 
detected in the study of Tornblom et al. had onset of disease after probable acute 
infectious enteritis. Our finding of anti-VGKC antibodies in patients with Chagas’ 
disease lends further support to the hypothesis that these antibodies can often be a post-
infectious phenomenon.     
 
Autoimmune channelopathies are being increasingly identified, a pertinent example being 
the recent identification of autoantibodies binding aquaporin 4 (a water channel) in 
patients with neuromyelitis optica (Lennon et al. 2005), a severe inflammatory 
demyelinating disease of the optic nerves and spinal cord. This discovery has caused a 
dramatic paradigm shift in the identification and early treatment of this previously poorly 
understood condition. Further identification of autoimmune channelopathies may open 
new avenues in the study of gut dysfunction. For now careful selection of GINMD 
patients in whom to look for autoantibodies based on the conclusions of Dhamija et al. 
and following the findings of this study, will help to clarify whether or not AGID is a 
significant aetiological entity. 
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 Appendices 
 
1.0 CONFIRMATORY DOCUMENTS 
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2.0 ANTI-NEURONAL IMMUNOFLUORESCENT ASSAY 
 
SOLUTIONS AND REAGENTS 
Solutions and reagents were supplied by Instrumentation Laboratory (UK) Ltd., 
Warrington, Cheshire, UK (IL), VWR International, Leicestershire, UK (VWR) or 
Binding Site, Birmingham, UK (Binding Site).  
 
Phosphate buffered saline (PBS) (VWR): 
 
Mounting media (prepared weekly):   12.5ml PBS filtered through 0.2mm 
      37.5 glycerol (VWR) 
 
SUBSTRATE 
Monkey cerebellum, 5 well slides (IL)  
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INDIRECT-IMMUNOFLUORESCENT STAINING PROTOCOL  
 
1. Apply 30µl of sera diluted 1:50 to slide well and incubate for 20 min RT 
2. Apply ready-to-use positive controls (Hu/Ri and Yo) and incubate as above 
3. Rinse off sera with PBS, and soak in PBS for 20 min 
4. Dilute FITC-conjugated secondary antibody 1:40 in PBS and microcentrifuge at 
13,000 rpm for 5 min. 
5. Wipe around sections and apply secondary antibody for 20 min at RT 
6. Rinse secondary antibody off with PBS and soak in PBS for 20 min 
7. Blot off excess PBS and mount with mounting media 
8. Store at 4ºC until reading   
 
3.0 RADIOIMMUNOPRECIPITATION ASSAYS 
 
SOLUTIONS AND REAGENTS 
 
Solutions and reagents were supplied by Sigma-Aldrich, Poole, Dorset, UK (not stated), 
Calbiochem-Novabiochem, San Diago, CA, USA (Calbiochem), Binding Site, 
Birmingham, UK (Binding Site), RSR, Cardiff, UK (RSR), New England Nuclear, 
Boston, MA, USA (New England) or Perkin Elmer, Waltham, MA, USA (Perkin Elmer)  
 
3.1 PREPARATION OF CHANNEL EXTRACTS  
 
Solubilisation buffer (SB), 1 litre:  25mM Tris-HCl  2.15g 
(pH 7.4, stored at -20°C until use) 5mM HEPES   1.19g   
0.32M Sucrose  0.32g 
Protease inhibitors: 
Pepstatin A       final concentration 1µM 
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Leupeptin       final concentration 2µM 
Phenylmethylsulphonylflouride (PMSF)   final concentration 0.1µM 
 
Digitonin (50% pure) (Calbiochem)  
 
2% Digitonin in solubilisation buffer for VGKC extraction only (DTX): 
20mM Tris 
100mM NaCl 
5mM KCl 
 
Natural pH ≅ 10.0, therefore add HCl to pH 7.12 
 
1. To 2ml (will be 2.5 ml when 500µl membranes added), add digitonin 0.05g (50%) 
to give final concentration of 2% (active concentration: 1%). 
2. Incubate in water bath at 37°C for 15 min. 
3. Just before use, add protease inhibitor: PMSF: 5µl of 0.1M in propan-2-ol (final 
concentration 0.2mM). 
 
Preparation of brain membranes 
 
1. Remove tissue as soon as possible post-mortem, cut into small pieces and drop 
into liquid nitrogen. Store at -70°C until use. 
2. Take ‘x’ gram of cerebellum, and make up with ice cold SB (with protease 
inhibitors added immediately before use) to 6-8 x volume of ‘x’. 
3. Homogenise using a Polytron Homogeniser (PT10-35, Kinematica GmbH, Littau, 
Switzerland), full speed 3 x 10 sec, resting on ice in-between. 
4. Spin 1000rpm for 10 min  
5. Harvest supernatant 
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6. Spin 13,000rpm for 10 min  
7. Re-suspend pellet in a volume of SB equivalent to original brain tissue weight 
8. Aliquot in 500µl amounts and store at -70°C until use 
 
Voltage-gated potassium channel (VGKC) extract preparation 
 
(made fresh for immediate use) 
 
1M NaCl in SB:  5.84g NaCl in 100ml SB 
 
1. Defrost aliquots of rabbit brain cortex-membrane preparation. 
2. Add stepwise (2 x 250µl) to 2ml DTX (with fresh protease inhibitor), mix gently 
with pipette (1 : 5 dilution) (total volume 2.5ml: see above). 
3. Incubate 37°C for 15 min. 
4. Spin 13,000rpm for 15 min (bench-top Eppendorf centrifuge). 
5. Harvest the supernatant (VGKC extract) and store on wet ice until use. 
 
Voltage-gated calcium channel (VGCC) extract preparation 
 
(made in batches for storage before subsequent use) 
 
4% digitonin in SB: 
Digitonin purchased is 50% pure. Therefore the solution is made up to 8%: 1.6g digitonin 
in 20ml SB, heated to 60oC, until dissolved and stored at 4°C before use. There is a lot of 
insoluble material remaining; before use in the assay an aliquot must be centrifuged: 
13,000rpm for 5 min and clear supernatant removed for subsequent use. 
 
1. Defrost aliquots of rabbit cerebellum membrane preparation 
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2. Add 700µl SB (with fresh protease inhibitors), vortex, spin 13,000rpm for 5min 
(bench-top Eppendorf centrifuge), discard supernatant. 
3. Add 1 ml SB, vortex, spin 13,000rpm for 5 min, discard supernatant. 
To the pellet (approx. 200µl), add: 100µl 1M NaCl in SB   
200µl SB     
500µl 4% digitonin in SB   
 
(therefore the final solution will be 2% digitonin, 0.1M NaCl) 
 
4. Rotate 1h, 4°C. 
5. Spin 13,000rpm for 15 min 
6. Remove supernatant, aliquot and store at -70°C as source of VGCCs. 
 
Ganglionic α3 nAChR extract preparation 
 
1. Grow neuroblastoma cells IMR32 to confluence (5% CO2, 37 ºC). 
2. Trypsinise cells from three flasks and spin 1000rpm for 5 min 
3. Combine the pellets and re-spin 13,000rpm for 5 min 
4. Remove the supernatant and freeze at -80ºC until use 
 
Detergents 
 
Triton X100 (t-octylphenoxypolyethoxyethanol)  
 
Radiolabelled toxins and ligands 
 
The toxins are received as lyophilised powder and are reconstituted with distilled 
water at a concentration of 0.1µCi/10µl, aliquotted into 10µCi amounts and 
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stored 70°c until use. 
 
Potassium channels 
125I-α-dendrotoxin (125I-α-DnTx) (Perkin Elmer), 
 
Calcium channels 
125I-ω-conotoxin MVIIC (125I-ω-CmTx), 5µCi, S.A. > 2000 Ci/mmol (New England)  
 
Ganglionic AChR-α-3 channels 
125I-Epibatidine (125I-Epi) (Perkin Elmer) 
 
Glutamic acid decarboxylase tracer 
125I-recombinant GAD65 radioimmunoassay kit (RSR)  
 
3.2 RADIOIMMUNOPRECIPITATION ASSAYS 
 
Sheep anti-human IgG (Binding Site) 
 
Washing buffer (PTX):  0.1% Triton X100 in 20mM phosphate buffer  
(pH 7.4, stored at 4°C) 
 
VGKC assay 
 
Radio-labelling using 125I-α-dendrotoxin (125I-α-DNTX)   
1. Defrost 1µCi of 125I-DNTX and add 3.5-4ml of VGKC extract 
2. Count on automatic gamma counter (Canberra Packard Cobra II auto-gamma, 
Meriden ®, CT, USA) and adjust to 50,000cpm / 50µl  
3. Incubate at 4ºC until use  
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4. Calculate total amount of labelled extract required (50µl x number of samples), 
and mix gently with pipette:  x µl VGKC extract 
x µl PTX 
x / 10 125I-α-DnTx 
 
5. Transfer to Eppendorfs, and microcentrifuge 13,000rpm for 5 min before use to 
remove particulate matter. 
 
Anti-VGKC radioimmunoprecipitation assay 
1. Dilute 10µl patient sera 1:10 with PTX, vortex, spin 13,000rpm for 5 min. 
2. Add 50µl of supernatant from each sample of diluted serum to 50µl of labelled 
extract, vortex, and incubate overnight at 4°C. 
3. Add 50µl sheep anti-human IgG to each sample (not microcentrifuged) 
4. Incubate 1h at room temp. 
5. Add 500µl PTX, vortex, spin at 13,000rpm for 5 min  
6. Remove supernatant by suction, wash pellet twice in 500µl PTX.  
 
[N.B if large number of samples, perform steps 12 and 13 stepwise in sets to prevent 
time dependent dissociation of 125I-DNTX-complexes] 
 
7. Remove excess liquid. Count pellet on automatic gamma counter (Canberra 
Packard Cobra II auto-gamma, Meriden ®, CT, USA). 
 
VGCC assay  
 
Radio-labelling using 1251-ω-conotoxin MVIIC (125I-ω-CmTx)  
Incubation buffer (IB) pH 7.4, stored at 4°C:  500µl digitonin 4% 
17.5 ml dH20 
2ml 0.2M phosphate 
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1. Defrost extracts on wet ice 
2. In a 7ml bijou, add 25µl IB to 5µl cerebellar extract, i.e. up to a total of 30µl per 
sample, multiplied by the total number of samples to be tested in assay. 
e.g. cerebellar extract for 50 samples = 250µl extract + 1.25ml IB 
3. Defrost 1.0µCi aliquots of 125I-ω-conotoxin, make up each aliquot with 500µl IB, 
spin 13,000rpm for 5 min. 
4. Add 5 fmol of 125I-ω-conotoxin per sample, usually 6-10 µl / sample: see 
Appendix 3.3 for calculation. 
5. Make up total volume / sample to 50µl with IB. i.e. 30µl + 6-10µl (above) + 20-
(6-10)µl. This is the labelled extract preparation. 
6. Incubate 2h at 4°C on wet ice. 
 
Anti-VGCC radioimmunoprecipitation assay 
1. Dilute 10µl test sera diluted 1:10 with IB, vortex, spin 13,000rpm for 5 min. 
2. Add 25µl of supernatant from each sample of diluted serum (equivalent to 2.5ul 
serum) to 50µl of labelled extract, vortex, and incubate overnight at 4°C. 
3. Add 25µl sheep anti-human IgG  to each sample (not microfuged) 
4. Incubate 1h at 4°C. 
5. Add 1ml PTX, vortex, spin at 13,000rpm for 5 min  
6. Remove supernatant by suction, wash pellet twice in 1ml PTX. 
[N.B if large number of samples, perform steps 12 and 13 stepwise in sets to prevent 
time dependent dissociation of 125I-ω-conotoxin-complexes]. 
7. Remove excess liquid. Count pellet on automatic gamma counter (Canberra 
Packard Cobra II auto-gamma, Meriden ®, CT, USA). 
8. Calculate final binding of labelled extract in pM / l using algorithm (Appendix 
3.3) 
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Ganglionic α3-AChR assay 
 
Radio-labelling using 125I-Epibatidine  
1. Defrost IMR32 pellets and wash once in 0.05M Tris pH 7.2 
2. Spin 13,000rpm for 5 min and remove the supernatant 
3. Re-suspend the pellet in 400µl 0.05M Tris pH7.2 and add 400µl 4% Triton X in 
0.05M Tris pH7.2 and 10µl PMFS 
4. Vortex the pellet until homogenous and rotate at 4ºC for 1 h 
5. Spin 13,000rpm for 15 min and remove the supernatant 
6. Determine the amount of extract required by titration by setting out 0, 5, 10, 20, 
30µl made up to 50µl with PTX 
7. Defrost 1.0µCi aliquots of 125I-Epibatidine, make up each aliquot with 500µl 
PTX, spin 13,000rpm for 5 min 
8. Aliquot 10µl and count on automatic gamma counter (Canberra Packard Cobra II 
auto-gamma, Meriden ®, CT, USA). 
9. Add 50,000cpm to each titration tube and incubate for 2h at 4ºC 
 
Anti-α3nAChR radioimmunoprecipitation assay 
1. Dilute 10µl patient sera 1:10 with PTX, vortex, centrifuge 13,000rpm for 5 min. 
2. Add 50µl of supernatant from each sample of diluted serum to 50µl of labelled 
extract, vortex, and incubate overnight at 4°C. 
3. Add 50µl sheep anti-human IgG to each sample (not microcentrifuged) 
4. Incubate 1h at room temp. 
5. Add 500µl PTX, vortex, spin at 13,000rpm for 5 min  
6. Remove supernatant by suction, wash pellet twice in 500µl PTX.  
7. Remove excess liquid. Count pellet on automatic gamma counter (Canberra 
Packard Cobra II auto-gamma, Meriden ®, CT, USA). 
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Glutamic acid decarboxylase assay using 125I-GAD 65 
 
1. Dilute 10µl patient sera 1 / 10 with PTX, vortex, spin 13,000rpm for 5 min. 
2. Add 50µl of supernatant from each sample of diluted serum to 50µl 125I-labelled 
human recombinant GAD 65 tracer, vortex, and incubate overnight at 4°C. 
3. Add 50µl sheep anti-human IgG to each sample (not microcentrifuged) 
4. Incubate 1h at room temp. 
5. Add 500µl PTX, vortex, spin at 13,000rpm for 5 min  
6. Remove supernatant by suction, wash pellet twice in 500µl PTX.  
 
[N.B if large number of samples, perform steps 12 and 13 stepwise in sets to prevent 
time dependent dissociation of complexes of 125I-labelled human recombinant GAD 
65 tracer ] 
 
7. Remove excess liquid. Count pellet on automatic gamma counter (Canberra 
Packard Cobra II auto-gamma, Meriden ®, CT, USA). 
 
3.3 CONVERSION OF OBSERVED COUNTS TO CONCENTRATIONS  
 
Final concentrations of antibody are expressed as pmol / litre of serum (i.e. pM).  
 
VGKC and AChR assays 
 
Conversion factor = 0.1 (not isotope date dependent). Therefore final concentration = 
(observed cpm – mean control cpm) .0.1 
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VGCC assays 
 
Conversion is dependent on isotope decay. The conversion factor (κ) may be calculated 
from a further variable (λ) which is date dependent, and taken from the decay table 
(below), and the volume of serum used (2.5µl for all assays), where: 
κ = λ (fmol cpm) / 2.5µl 
 
The final concentrations of antibody are then calculated, where: 
 
[ab] = (observed cpm – mean control cpm) . κ 
 
e.g. on day –15 
κ = 0.000243 (fmol cpm-1) / 2.5µl 
κ = 0. 243 (pmol cpm-1) / 2.5 l 
κ = 0.0972 (pmol cpm-1 l-1 ) 
and: [ab] = (observed cpm – mean control cpm) . 0.0972 
 
Total and non-specific binding curves (perform this every 2 months): 
Calculate a quantitative precipitation curve for known strongly positive (LEMS) and 
known negative (healthy control) sera. Total binding is calculated by using increasing 
serum concentrations in the presence of labelled toxin only, and non-specific binding, by 
repeating the assay at each serum concentration in the presence of excess unlabelled 
toxin. The specific binding is calculated at each point by subtracting the non-specific 
binding from the total binding.  
 
Calculation of volume equivalent of  5fmol 125I-ω-conotoxin 
 
Count 10µl of diluted 125I-ω-conotoxin (cpm). 
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Find “expected count” using decay table (see below) and knowledge of the time period 
since preparation by the manufacturer. N.B “minus” days are a nuance of the decay curve 
and manufacture. 
Calculate the volume (x) equal to 5fmol by using the equation: 
 
actual cpm / 10 µl  = expected cpm / x 
i.e. on day – 23, if the observed count for 10µl is 37,000 cpm, then: 
37,000 / 10 = 21,960 / x 
and x = 6 µl (1 s.f) 
 
GAD assay 
 
The GAD kit contains a calibration kit containing sera with known levels of GAD 
antibodies (0-300 international units (IU) /ml). All test samples were assessed in an assay 
containing GAD standards. 
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125I-ω-conotoxin decay table 
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4.0 CELL-BASED ASSAY 
 
4.1 BACTERIAL CULTURE 
 
All media components were purchased from Oxoid Ltd., Hampshire, UK 
 
Bacteria:  Escherichia coli, strain DH5α 
Lysogeny broth (LB): 10 g Tryptone  
   5 g Yeasy extract  
   5 g NaCl  
   1 L dH2O  
 
Transformation buffer-I (TF-I):/L 12 g RbCl 
     30ml 1M (pH7.5) K acetate 
     1.5 g calcium chloride dihydrate 
     150 g glycerol 
 
Make up TF-I to a final volume of 950 ml, adjust to pH 6.4 with 0.2 M acetic acid, and 
divide into 95 ml aliquots. Autoclave, allow to cool, and then add 5 ml of 1 M manganese 
chloride tetrahydrate. 
 
Transformation buffer-II (TF-II): /L 1.2g RbCl 
     11g calcium chloride dihydrate 
     150g glycerol 
 
Make up TF-II to a final volume of 980 ml and divide into 98 ml aliquots. Autoclave, 
allow to cool, and then add 0.5 M 3-[N-morpholino]propanesulfonic acid.   
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Culture growth and collection 
 
1. Set up overnight pre-culture(s) by inoculating 2.5ml LB in 15 ml test tube 
2. In 250 ml conical flask, inoculate 50 ml LB with 0.5 ml pre-culture 
3. Measure optical density (OD) at 650 nm of culture every hour using a Unicam 
Helios β UV spectrophotometer (Unicam, Cambridge, UK) 
4. Plot log OD650nm vs. time  
5. When OD is predicted to rise above 0.1, remove 7 ml and place in ice cold bottle 
6. Measure OD of 1 ml and transfer exactly 0.5 OD units (0.5/OD observed) into 
fresh chilled tube 
7. Centrifuge 13,000 rpm, 4ºC for 5 min and remove supernatant by aspiration 
8. Continue to collect 0.5OD units every hour until growth is complete 
 
OD = 0.5-1.0  remove 2.5 ml, use 1 ml for OD measurement and rest to take  
   sample 
1.0-2.0 remove 1 ml and mix with 1 ml ice cold saline, use 0.9 ml for OD  
measurement and rest to take sample 
2.0-3.0 remove 1 ml and mix with 2 ml ice cold saline, use 1 ml for OD 
measurement and rest to take sample 
3.0-4.0 remove 1 ml and mix with 3 ml ice cold saline, use 1 ml for OD 
measurement and rest to take sample  
 
Preparation of competent cells 
 
Use sterile technique throughout 
 
1. Inoculate 2.5 ml of LB and grow overnight at 37ºC with moderate agitation (250 
rpm) 
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2. Inoculate 50 ml LB with 0.5 ml of overnight culture 
3. Grow at 37 ºC, 250 rpm until OD is 0.4-0.5 
4. Centrifuge 4000 rpm for 15 min at 4ºC 
5. Remove supernatant and re-suspend in 4 ml of TF-I  
6. Place on ice for 15 min 
7. Centrifuge 2,500 rpm for 15 min at 4ºC 
8. Resuspend in 2 ml TF-2 
9. Keep cells on ice until use, or aliquot into 0.2 ml and store at -80ºC  
 
4.2 BACTERIAL TRANSFORMATION 
 
Plasmid: cDNA encoding full length muscarinic 2 human cholinergic receptor (GenBank 
NM_001006630) cloned in- frame using the restriction sites EcoRI-XhoI in the 
polylinker region of pcDNA3 (Invitrogen Ltd., Paisley, UK). Provided by Dr Carl 
Nelson, University of Leicester, UK.    
 
 
 
 
 
 
 
 
 
 
1. Add various dilutions of plasmid DNA (1-50 ng in 4 µl) to 0.2 ml aliquots of 
competent cells 
2. Mix gently and incubate on ice for 40 min 
3. Heat shock at 42 ºC for 1 min 
4. Place on ice for 5 min 
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5. Add 0.7 ml of pre-warmed LB and incubate at 37 ºC for 30 -60 min 
6. Centrifuge 13,000 rpm for 5 min and remove 0.7 ml of supernatant  
7. Resuspend cells in remainder of supernatant and plate out onto plates containing 
L agar and ampicillin 
8. Allow to dry, cover and incubate overnight at 37 ºC 
 
4.3 DNA ISOLATION AND SEQUENCING 
 
DNA purification 
 
Miniprep: for plasmid yields of less than 10 µg 
QIAprep® Spin Miniprep kit (Qiagen Ltd., West Sussex, UK) 
 
1. Centrifuge overnight cultre at 4,000 rpm, 4 ºC for 5 min 
2. Re-suspend pelleted cells in 250 μl Buffer P1 (in kit) and transfer to a 
microcentrifuge tube 
3. Add 250 μl Buffer P2 (in kit) and gently invert the tube 4–6 times to mix 
4. continue inverting the tube until the solution becomes viscous and slightly clear. 
Do not allow the lysis reaction to proceed for more than 5 min 
5. Add 350 μl Buffer N3 (in kit) and invert the tube immediately but gently 4–6 
times 
6. Centrifuge for 10 min at 13,000 rpm 
7. Remove supernatant and apply to the QIAprep spin column (in kit) by decanting 
or pipetting 
8. Centrifuge for 30–60 s. Discard the flow-through 
9. (Optional): Wash the QIAprep spin column by adding 0.5 ml Buffer PB (in kit) 
and centrifuging for 30–60 s. Discard the flow-through. 
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10. Wash QIAprep spin column by adding 0.75 ml Buffer PE and centrifuging for 
30–60 s 
 
Maxiprep: for plasmid yields greater than 10 µg  
Purelink™ HiPure Plasmid (Maxi) Filter Purification Kit (Invitrogen Ltd., Paisley, UK) 
 
1. Place the Maxi Column on the PureLink™  Nucleic Acid Purification Rack (in kit) 
2. Apply 30 mL EQ1 buffer (in kit) directly into the Filtration Cartridge, which is 
inserted into the Maxi Column 
3. Allow the solution in the HiPure Filter Maxi Column to drain by gravity flow 
4. Prepare the cell lysate (see below) while the HiPure Filter Maxi Column is 
equilibrating. 
5. For high copy number plasmids, use 100– 200 mL of an overnight LB culture per 
sample. 
6. For low copy number plasmids, harvest 250– 500 mL of an overnight LB culture 
per sample. 
7. Harvest the cells by centrifuging the overnight LB culture at 4,000 rpm for 10 
minutes. Remove supernatant 
8. Add 10 mL R3 buffer (in kit) with RNase A to the pellet and resuspend the cells 
until homogeneous 
9. Add 10 mL L7 buffer (in kit) and mix gently by inverting the capped tube until 
the lysate mixture is thoroughly homogeneous. Do not vortex.  
10. Incubate at room temperature for 5 minutes 
11. Add 10 mL N3 buffer (in kit) and mix immediately by inverting the tube until the 
mixture is thoroughly homogeneous. Do not vortex. 
12. Transfer the precipitated lysate including all the precipitated material into the 
equilibrated HiPure Filter Maxi Column  
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13. Let the lysate run through the filter by gravity flow until the flow stops (10– 15 
minutes) or becomes very slow (<1 drop per 10 seconds)  
14. Discard the flow through 
15. Optional: The final DNA yield may be increased by washing the residual bacterial 
lysate in the HiPure Filter Maxi Column with 10 mL W8 buffer (in kit). 
16. Let the buffer flow through the HiPure Filter Maxi Column by gravity flow until 
the flow stops or dripping becomes very slow 
17. Immediately after the HiPure Filter Maxi Column has stopped dripping, remove 
the inner Filtration Cartridge from the column and discard. 
18. Wash the Maxi column with 50 mL of W8 buffer. Allow the solution in the 
column to drain by gravity flow and discard the flow-through. 
 
Eluting DNA 
1. Place a sterile 50-mL centrifuge tube (elution tube) under the HiPure Filter Maxi 
column. 
2. Add 15 mL E4 buffer (in kit) to the Maxi column and allow the solution to drain 
by gravity 
3. Discard the HiPure Filter Maxi column. 
 
DNA precipitation 
1. Add 10.5 mL isopropanol to the DNA to the elution tube and mix well. 
2. Centrifuge the tube at 10,000 rpm for 30 min at 4°C 
3. Remove and discard the supernatant 
4. Add 5 mL 70% ethanol to resuspend the DNA pellet. 
5. Centrifuge the tube at 10,000 rpm for 5 min at 4°C 
6. Remove and discard the supernatant. 
7. Air-dry the pellet for 10 min 
8. Resuspend the DNA pellet in 500 μL TE Buffer (in kit) 
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9. For low copy number plasmids, use 200 μL TE 
10. Transfer the supernatant (DNA sample) into a fresh tube. 
11. Store the purified DNA at – 20 ºC, or store at 4 ºC and proceed to desired 
downstream application. 
 
DNA digestion 
Restrictions enzymes (New England BioLabs UK Ltd., Hertfordshire, UK): 
EcoR1. Recognition site: 5’…GAATTC…3’ 
    3’…CTTAAG…5’ 
NEBuffer EcoR1 (supplied with enzyme): 
100 mM Tris-HCl 
50 mM NaCl 
10 mM MgCl2 
0.025 % Triton X-100 
 
Reaction conditions: 
Incubate 5 units of enzyme per µg of DNA for 1 h at 37ºC 
 
Xho1. Recognition site: 5’…CTCGAG…3’ 
    3’…GAGCTC…5’ 
NEBuffer 4 (suuplied with enzyme): 
20 mM Tris-acetate  
50 mM potassium acetate 
10 mM magnesium acetate 
1 mM dithiothreitol 
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Reaction conditions: 
Incubate 5 units of enzyme supplemented with 100 µg/ml bovine serum albumin for 1 h 
at 37 ºC 
 
DNA sequencing 
 
Agarose gel electrophoresis 
 
5x TBE buffer: 54 g Tris 
   27.5 g Borate (orthoboric acid) 
   20 ml 0.5 M EDTA (pH8) 
   980 ml dH2O 
Mix Tris, Borate and dH2O, then add EDTA. Make to final volume of 1 L. 
 
0.5 M EDTA (pH8): 18.6 g EDTA 
   175 ml dH2O 
   2 g NaOH 
Increase final volume to 200 ml, check pH and autoclave.  
 
1% agarose gel: 1g agarose 
   10ml 5x TBE 
   90 ml H2O 
Melt in microwave, cool under tap and add ethidium bromide to final concentration of 25 
µg/ml. 
 
6x gel loading buffer: 2.5 ml bromophenol blue 
   2.5 ml xylene cyanol FF 
   4.0 ml Ficoll in H2O 
Store at room temperature 
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4.4 MAMMALIAN CELL CULTURE 
 
Tissue culture plastic-wear, all from Appleton Woods Ltd. Birmingham, UK: 
75cm2 Corning tissue culture flasks 
6 and 24-well plates  
 
Media and solutions: 
Dulbecco’s Modified Eagles Medium (DMEM) containing 4500 mg/l glucose, L-
glutamine and sodium pyruvate (Sigma-Aldrich, Poole, Dorset, UK) 
 
Antibiotic – antimycotic solution, containing / ml, in 0.85 saline: 10,000 units of 
penicillin, 10,000 µg streptomycin, 25 µg amphotericin (Invitrogen Ltd., Paisley, UK) 
 
DMEM+ab: DMEM containing antibiotic –antimycotic solution 
 
DMEM wash: DMEM containing 4.6 g/l HEPES 
 
DMEM diluent: DMEM containing 4.6 g/l HEPES and 1 % BSA 
 
Poly-L lysine (Sigma-Aldrich)  
Poly-L lysine solution: 1 ml poly-lysine 
    100 ml PBS 
 
Trypsin-EDTA solution (Invitrogen) 
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Harvesting and counting of HEK cells 
 
1. Aspirate off medium 
2. Wash cells with 5 ml PBS and aspirate off 
3. Detach cells by adding 1-2 ml of trypsin and incubating at 37 ºC for 1 min 
4. Resuspend cells in 10 ml of DMEM+ab  
5. Transfer to 50 ml Universal tube and take off 10 µl to count using a 
haemocytometer 
6. Centrifuge for 6 min at 1000 rpm 
 
Seeding of HEK cells 
 
1. In a flow cabinet, place 3 coverslips / well into a six well tray 
2. Add 2 ml of poly-L lysine solution into each well 
3. Leave for 20 min 
4. Aspirate off poly-L lysine solution and allow to dry for 2 h 
5. Make a 12 ml cell suspension with DMEM+ab+FCS containing 1.8 x 106 cells 
6. Add 2 ml of cell suspension to each well and incubate overnight 
7. Transfect the following day 
 
HEK cell transfection 
 
1. Make up transfection solution according to number of wells: 
 
Mix in two separate tubes (per well):  
4 µg DNA 
250 – (x µl DNA) ab-free DMEM: incubate for 5 min 
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10 µl lipofectamine  
240 µl ab-free DMEM 
 
2. Mix the contents of the two tubes and incubate for 15 min RT 
3. Change medium of wells to ab-free DMEM (2 ml / well) and add 500 µl of     
transfection solution to each well 
4. Incubate overnight at 37 ºC  
5. Change medium to ab+DMEM 
6. Incubate overnight at 37 ºC 
7. The following day cells are ready for immunostaining 
  
Immunofluorescent staining of transfected HEK cells 
 
1. Transfer coverslips to a mew 24 – well plate containing / well 250 µl PBS 
2. Wash with PBS x 2 aspirating each time  
3. Fix cells with 4 % formaldehyde for 10 min 
4. Aspirate off formaldehyde and wash with PBS x 3 
5. Permeabilise cells to be stained with anti-M2 antibody by adding 250 µl Triton X 
for 10 min 
6. Aspirate off Triton X and wash with DMEM wash x 3 
7. Dilute each serum sample, 1:20 in DMEM diluent 
8. Dilute anti- M2 primary antibody 1:200 in DMEM diluent 
9. Add 250 µl of serum or anti-M2 antibody solution / per well  
10. Incubate for 1 h at 37 ºC 
11. Remove by aspiration 
12. Wash coverslips with 250 µl DMEM wash x2, then PBS x1, pipetting and 
aspirating each time 
13. Aspirate off formaldehyde and wash 3 times with PBS 
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14. Permeabilise cells  
15. Add 250 µl of secondary, fluorescently conjugated anti-human antibody (Diluted 
1:700 in DMEM diluent) to each well and incubate for 45 min in the dark at RT 
16. Aspirate off secondary antibody and wash with DMEM wash x 3 and PBS x 2 
17. Transfer coverslips to microscope slides, mounting 3 – 4 per slide using 
fluorescent mounting medium containing DAPI, 1:1000 
18. Store at 4 ºC before reading 
 
5.0 IMMUNOHISTOCHEMISTRY 
 
5.1 SOLUTIONS AND REAGENTS 
All solution and reagents were supplied by VWR International, Lutterworth, 
Leicestershire, UK (not stated), Dako, Ely, Cambridgeshire, UK (Dako), Bio-Genex 
Laboratories, San Ramon, CA, USA (Bio-Genex), or Sigma Aldrich, Poole, Dorset, UK 
(Sigma). R.T.U Vectastain Universal Elite ABC kit was supplied by Vector Laboratories 
Inc., Burlingame, CA, USA (Vector) (Cat. No. PK-7200). 
IMS = 100% industrial methylated spirits. 
  
Endogenous peroxidase blocking  6ml H2O2 
solution    194ml dH2O 
 
Acid Alcohol    300ml dH2O 
     700ml IMS 
10ml conc. HCl 
(added to 990ml of the above) 
 
Gill’s Haematoxylin   1L dH2O 
     625ml ethylene glycol, 
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     10g haematoxylin 
     1g sodium iodate 
     176g aluminium sulphate 
     50ml glacial acetic acid 
     825ml dH2O 
1% Eosin    1g eosin Y 
 
     100ml dH2O 
Immunohistochemistry 
 
Endogenous peroxidase  3ml 30% H2O2 
block (3%)     97ml 100% methanol 
 
REAL™ Antibody diluent (DAKO)  
 
Wash buffer (DAKO)   0.05mol/L Tris HCl 
     0.15mol/L NaCl 
     0.05% Tween 20 
 
Vectastain ABC Elite reagent (Vector) 
 
Diaminobenzidine    1ml substrate buffer   
tetrachloride (DAB) solution   1 drop DAB chromagen   
(Bio-Genex) 
 
Phosphate buffered saline (PBS)  
 
Mounting medium for immunohistochemistry: Canada balsam  
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Fluorescence mounting medium (Dako)  
 
Antigen retrieval 
 
Citrate buffer solution (Vector) Citrate buffer stock 100ml  
dH2O 900ml 
 
5.2 FIXATION AND PROCESSING OF TISSUE  
 
1. Fix tissue for at least 24 h in formal saline and embed in paraffin wax. 
2. Cut 3 µm thick sections and float in a warm water bath 
3. Pick up sections on negatively charged microscope slides (VWR International, 
Leicestershire, UK) and allow water to drain off  
4. Dry sections overnight at 37 ºC      
 
5.3 HAEMATOXLYIN AND EOSIN STAINING 
 
1. Dewax sections in xylene (2x 2 min) 
2. Remove xylene with IMS (2x 2 min) 
3. Wash in running tap water 5 min 
4. Stain in Gill’s haematoxylin for 20 min 
5. Wash in running tap water 5 min 
6. Differentiate by dipping in 1 % acid alcohol 
7. Wash in running tap water 5 min 
8. Stain in eosin for 3 min 
9. Dip in tap water and blot 
10. Dehydrate rapidly in IMS (2x 2 min) 
11. Clear in xylene (2x 2 min) 
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12. Mount in Canada balsam  
 
5.4 INDIRECT-IMMUNOHISTOCHEMICAL STAINING PROTOCOL  
 
1. Dewax sections in xylene (2x 2 min) 
2. Remove xylene with IMS (2x 2 min) 
3. Wash in running tap water 5 min 
4. Antigen retrieval (see below) 
5. Wash in running tap water 5 min 
6. Incubate sections in endogenous peroxidase blocking solution for 15 min 
7. Wash in running tap water for 5 min 
8. Soak in wash buffer (WB) 2 min 
9. Dry carefully around sections and encircle with ImmEdge pen (Vector Labs)  
10. Apply blocking serum for 20min: 
25 % normal horse serum (in kit)  
11. Tip off blocking serum. 
12. Apply primary antibody at the appropriate dilution in antibody diluent for 60 min RT 
(antibody diluent only to negative control sections) 
13. Rinse sections with WB and soak in WB 2x 5 min 
14. Wipe around sections and apply biotinylated secondary antibody diluted 1:250 in 
wash buffer for 30 min at RT 
15. Apply Vectastain Elite ABC reagent (from kit) for 30 min RT 
16. Rinse sections with WB and soak in WB 2x 4 min 
17. Make up DAB solution and apply for 5 min (examine positive control slide for 
progress of development) 
18. Wash in running tap water for 5 min 
19. Counterstain in Gill’s Haematoxylin for 2 min 
20. Wash in running tap water for 5 min 
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21. Differentiate by dipping two to three times in 1% acid alcohol 
22. Wash in running tap water for 5 min 
23. Dehydrate in IMS 
24. Clear in xylene 
25. Mount in Canada balsam 
 
5.5 INDIRECT-IMMUNOFLUORESCENT STAINING PROTOCOL  
 
1. Dewax sections in xylene (2x 2 min) 
2. Rehydrate with IMS (2x 2 min) 
3. Wash in running tap water 5 min 
4. Antigen retrieval (see below) 
5. Wash in running tap water 5 min 
6. Soak in PBS 2x 5 min 
7. Dry carefully around sections and encircle with ImmEdge pen (Vector Labs)  
8. Apply serum-free protein-block for 10min: 
9. Tip off blocking serum. 
10. Apply both primary antibodies in single solution at the appropriate dilution in 
PBS for 60 min RT (antibody PBS only to negative control sections) 
11. Soak slides in PBS 2x 5 min 
12. Wipe around sections and apply Alexa-fluor™ secondary antibodies diluted in 
PBS (1:200), in a single dilution (finally 1:100) in PBS for 45 min at RT 
13. Soak slides in PBS 2x 5 min 
14. Mount in fluorescence mounting medium containing DAPI diluted 1:1000 
15. Store at 4ºC until viewing  
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Antigen retrieval 
 
1. Place sections into plastic staining rack leaving a gap between the slides 
2. Place rack into a large glass staining trough containing exactly 1000ml of the 
antigen retrieval buffer 
3. Cover the trough with cling film and make several holes in the cling film 
4. Place the trough in the microwave and run at full power for 25 minutes 
5. With care, remove trough from microwave 
6. Carefully remove cling film 
7. Leave sections to stand in the hot buffer for 5 minutes 
8. Return to original technique 
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